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ABSTRACT
Cellular invasion is facilitated by localisation and activation of the human
circulating zymogen plasminogen. Increased binding and activation of plasminogen at
the surface of invasive breast cancer cells has been linked to the inappropriate and
unregulated expression of the plasminogen activator, uPA. To investigate the
mechanistic link between uPA and plasminogen binding, cell-surface uPA levels were
enhanced on the usually low uPA-expressing MCF-7 cell line. Enhancement of cellsurface uPA resulted in a significant increase to the cell-surface, lysine-dependent
plasminogen binding capacity of these cells (increase of 37%). This increase was
entirely uPA activity-dependent and was accompanied by an increase in plasminogen
activation potential. Analysis in the presence of the plasmin inhibitor, aprotinin, showed
that a large proportion of plasminogen binding was also plasmin-dependent (70-80%).
Similar analyses indicated that this was also the case on MDA-MB-231 cells, which
have naturally high levels of cell-surface uPA.
Investigation into the identity of potential cell-surface plasminogen receptors
showed that a proportion of cell-surface, lysine-dependent plasminogen binding to
MDA-MB-231 cells was mediated via a direct interaction with the A-chain of uPA.
Furthermore, fluorescent confocal microscopy experiments indicated that plasminprocessed annexin II may act as a plasminogen receptor on uPA-enhanced MCF-7.
Together with the results above, these data suggest a mechanism whereby a low level of
plasminogen may initially localise to receptors with pre-existing C-terminal lysines and,
on cells with high cell-surface uPA, a feed-forward activation loop proceeds. This
activation loop leads to generation of plasmin and subsequent plasmin-processing of

xii

cell-surface proteins, thereby generating new C-terminal lysines that facilitate further
lysine-dependent plasminogen binding and activation.
Primary tumour expression of uPA and its inhibitor, PAI-1, is a strong
prognostic indicator of adverse patient outcome in breast cancer, and uPA expression is
also associated with malignant disease in other cancers. Radiolabelled PAI-2 (α-PAI-2)
is a promising therapeutic which specifically targets uPA-expressing cells, however,
pre-clinical evaluation of α-PAI-2 toxicity and efficacy requires an appropriate mouse
model of breast cancer. To this end, immunocompromised mice bearing orthotopic
MDA-MB-231 xenografts were assessed as a suitable model for invasive breast cancer.
The model was characterised for tumour induction and growth rate, necrosis, local
invasion into surrounding tissue, and metastases to axillary lymph nodes and major
organs. Tumours were also characterised for uPA expression (using an ELISA
developed as part of this thesis), uPA activity and plasminogen activation capacity, both
with and without α-PAI-2 treatment.

These analyses indicated that the orthotopic

murine xenograft model was appropriate for assessing α-PAI-2 efficacy, as the
xenogenic tumours maintained the characteristics of the implanted cell line and
mimicked the development and histology of human breast tumours, including uPA
expression by tumour stromal cells.
The plasminogen binding model described in this thesis provides a plausible
explanation for the increased plasminogen binding capacity of cells with high cellsurface uPA expression and furthers understanding of the link between increased uPA
expression and increased tumour cell invasiveness. Furthermore, the characterisation of
the xenograft mouse model highlights the suitability of this model for the pre-clinical
investigation of potential uPA-targeted therapeutics for invasive breast cancer.
xiii
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Chapter 1
The Urokinase Plasminogen Activation System: A
Functionally and Clinically Relevant Pathway in Breast
Cancer Metastasis

Chapter 1: Literature Review

1 CHAPTER 1: THE UROKINASE PLASMINOGEN ACTIVATION SYSTEM:
A FUNCTIONALLY AND CLINICALLY RELEVANT PATHWAY IN BREAST
CANCER METASTASIS
1.1

An Introduction to Breast Cancer

Breast cancer is the leading form of cancer-related death in Australian women, with
2,641 women dying from the disease in 2004 alone (National Breast Cancer Foundation
Factsheet, 2006). Breast cancer is also the second most common form of cancer in
Australian women following non-melanoma skin cancer, with 1 in 11 women under the
age of 75 diagnosed with the disease each year (National Breast Cancer Foundation
Factsheet, 2006). At a biological level, cancer presents as a mass of cells that display
multiple genetic abnormalities and feature all or most of the following: limitless
replicative potential, unregulated cell growth through the production of autocrine
growth signals or resistance to paracrine anti-growth signals, the ability to evade
apoptosis, the ability to initiate and sustain angiogenesis and the ability to invade local
tissues and metastasise (Hanahan and Weinberg, 2000). It is the last process that forms
the focus of this review and subsequent research as it is the underlying cause in
approximately 80% of breast cancer mortalities (National Breast Cancer Foundation
Factsheet, 2006). Metastatic/invasive tumours rarely have a complete capsule,
frequently invade local tissue and may spread to remote sites within the body, via blood
and lymph vessels or via access to body cavities, to form new tumour cell colonies. This
latter process is known as metastasis and, as with invasion, requires the ability of the
tumour cells to degrade and migrate across anatomical boundaries (Fig. 1.1).
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PIaure 1.1. Cellular invasion

and metastasis in cancer. The complex process of metastasis involves
detachment of tumour cells from the primary tumour, invasion into blood and/or lymph vessels
(intravasation), invasion out of the vessels and into surrounding healthy tissue (extravasation) and
:,,~lOnization of that tissue to form a secondary tumour mass. During this process, degradation of the
e.fniceilular matrix (ECM) is essential, allowing tumour cells to breach into and out of vessels and tissues.
Ir mal cells also play an important part in metastasis, secreting factors which stimulate primary and
. ndary tumour growth, ECM degradation, migration and recruitment of new vasculature (angiogenesis).
h matic from Steeg (2006).
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1.1.1

The Barrier to Invasion: Extracellular Matrix

Extracellular matrix (ECM) is the term given to the physical barrier between
histologically distinct tissues. The basement membrane is the layer of ECM surrounding
epithelial cells and may be broadly divided into the basal lamina, which is secreted by
the epithelial cells, and the reticula lamina, which is secreted by stromal cells. The
basement membrane is dynamic (Miosge, 2001) but is typically composed of collagens,
glycoproteins (e.g. laminin, fibronectin, entactin and nidogen), proteoglycans,
glycosaminoglycans (e.g. hyaluronic acid, chondroitin and dermatan sulfate, heparan
sulfate, heparin, and keratan sulfate), which are often linked to proteins to form
proteoglycans, and in some tissues elastin (reviewed in Bosman and Stamenkovic,
2003). The ECM is also interspersed with various growth factors (e.g. fibroblast growth
factor), which may be released as a result of ECM dissolution (reviewed in Bosman and
Stamenkovic, 2003; Mignatti and Rifkin, 1993; Stamenkovic, 2003). ECM proteolysis
causes the usually cell-impermeable basement membrane to become locally permeable
to cells, a process that has been used to mark the passage of tumour cells from a
non-invasive to an invasive phenotype (Bosman, 1994). A number of proteases are
responsible for this process and include serine proteases, matrix metalloproteinases
(MMPs) and glycosidases, which degrade different components of the ECM (Andreasen
et al., 1997). The serine proteases (e.g. plasmin, elastase, cathepsin G) degrade
glycoproteins, elastin, some collagens and the protein core of the proteoglycan
components. The MMPs (e.g. collagenases and stromelysins) are capable of degrading
collagen, glycoprotein and the protein core of the proteoglycan components, while the
glycosidases

(e.g.

β-N-acetylglucosaminidase)

degrade

the

glycosaminoglycan

component (Andreasen et al., 1997). Although these proteases may be expressed by a
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number of cell types to facilitate invasion and migration during physiological processes,
it is their inappropriate expression by tumour cells which is associated with the
metastatic phenotype.

1.1.2

The Metastatic Phenotype

In addition to oncogenic transformation, invasive/metastatic tumour cells display further
genetic mutations or abnormal gene expression patterns, which result in changed
expression to a number of proteins that facilitate cellular invasion. These molecular and
phenotypic changes are often described in terms of Epithelial-Mesenchymal Transition
(EMT) (Vernon and LaBonne, 2004). Similar to the progression of cells from an
epithelial to a mesenchymal phenotype during normal developmental processes,
invasive/metastatic tumour cells are characterised by a loss of cell adhesion and
increased cell mobility (Thiery, 2003). Mutations or decreased expression of cell
adhesion molecules (e.g. E-cadherin) by cancer cells promotes their detachment from
one another and/or the surrounding ECM, thereby facilitating migration (Okegawa et
al., 2004). The deregulated expression of a number of proteases, protease activators or
protease receptors also facilitates invasion through proteolysis of ECM components and
also cell-cell and cell-ECM contacts, allowing cells to detach and invade into
surrounding tissues and vessels (Hunter, 2006; Steeg, 2006). Furthermore, proteolysis
of cell-surface proteins and ECM components can stimulate pro-invasive intracellular
signalling through the release of growth, survival and motility factors, proteolytic
activation of cell-surface transducers or removal of anti-invasive intracellular
transducers through cleavage of these molecules (Fowlkes and Winkler, 2002; Overall
and Blobel, 2007). Proteases which participate in these processes typically belong to the
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urokinase plasminogen activator system (PAS), the matrix metalloproteinase (MMP)
family or the cysteine proteinase family (reviewed in Ala-aho and Kahari, 2005; Dano
et al., 2005; Folgueras et al., 2004; Gocheva and Joyce, 2007). Members of these
families display some functional overlap and “cross-talk”, creating a complex network
of proteolytic activity at the cell surface e.g. the cysteine proteinases cathepsin B and L
can activate pro-urokinase (Goretzki et al., 1992; Kobayashi et al., 1993) and the active
form of plasminogen (plasmin) is a potent activator of pro-MMP-3 (stromelysin-1)
(Ramos-DeSimone et al., 1999). It is the inappropriate (i.e. unregulated) expression of
some or several of the proteases from these families which distinguishes cellular
invasion and migration in cancer from that which occurs during physiological and
pathophysiological processes such as wound healing, inflammation, embryonal
development and angiogenesis (Andreasen et al., 1997; Mignatti and Rifkin, 1993). Of
these ECM-degrading enzymes, plasmin (the active form of the zymogen plasminogen)
has been shown to have an important role in invasive processes and much clinical and
experimental evidence exists linking inappropriate plasminogen activation and tumour
cell invasion and metastasis (reviewed herein and Andreasen et al., 2000; Ranson and
Andronicos, 2003; Schmitt et al., 2000).

1.2

The Plasminogen Activation System (PAS)

The PAS is a proteolytic cascade regulated by numerous activators, inhibitors and
receptors, which culminates in the activation of plasminogen (plg) to plasmin (Fig. 1.2).
The PAS participates in a number of physiological and pathophysiological processes
including embryogenesis, development, tissue remodelling, inflammation and
angiogenesis (Andreasen et al., 1997). For example, the PAS is utilised by migrating
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endothelial cells during angiogenesis and is also involved in macrophage/monocyte
recruitment during inflammatory processes (Rakic et al., 2003; Syrovets and Simmet,
2004). The PAS has also been implicated in pathological processes such as bacterial
invasion and tumour cell invasion and metastasis (Andreasen et al., 2000; Lahteenmaki
et al., 2005) . Spatial and temporal regulation of the PAS components is essential to
prevent widespread and unregulated extracellular proteolysis by plasmin and untimely
invasion by host cells. Indeed, deregulation of components of the PAS is one
characteristic which facilitates tumour cell invasion and metastasis, and is thus an
important area of cancer research (Andreasen et al., 2000).

PA
INHIBITORS

PA
ACTIVATORS

HORMONES
GROWTH
FACTORS

uPA
tPA

ProPro-uPA
ProPro-tPA

uPA
tPA

ProPro-uPA
ProPro-tPA

TUMOUR
PROMOTERS
Plasminogen

Plasmin

Plasminogen

ECM DEGRADATION
MMP ACTIVATION
RELEASE OF GROWTH FACTORS
SIGNALLING EVENTS

Plasmin

PLASMIN
INHIBITORS

ECM DEGRADATION
MMP ACTIVATION
RELEASE OF GROWTH FACTORS
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Figure 1.2. A simplified schematic of the plasminogen activation cascade. Activation of plasminogen to
plasmin is controlled at many levels in the activation cascade thereby regulating cellular invasion. Synthesis
of the activators of plasminogen (PAs) and also plasmin inhibitors control the levels of active plasmin.
Expression of the inactive forms of the PAs are controlled by hormones, growth factors and tumour
promoters, while activators of the PAs themselves form another level of control. Inhibitors of the PAs
ultimately control the amount of plasmin-mediated pericellular ECM degradation whereas the plasmin
inhibitors directly inhibit this process. Adapted from Danø et al. (1985).
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1.2.1

Plasminogen/Plasmin

Plasmin is a broad-spectrum serine protease which hydrolyses fibrin and most
extracellular glycoproteins and peptides (including plg) C-terminal to lysine and
arginine residues. Plg is synthesized in the liver and is abundant in most mammalian
body fluids including bovine follicular fluid, porcine and human uterine fluid, saliva,
human plasma (2 μM) and central nervous system tissues (Basham and Seeds, 2001;
Dano et al., 1985). The classical function of plasmin is the degradation of the fibrin
component of blood clots during fibrinolysis (Cesarman-Maus and Hajjar, 2005 and
section 1.3.2). This process is primarily mediated via tissue-type plasminogen activator
(tPA), which has a relatively high affinity for fibrin, as does plg. Efficient, localised
activation of plg to plasmin occurs in the presence of tPA, leading to local degradation
of fibrin clots (Pennica et al., 1983; Voskuilen et al., 1987). Other functions of plasmin
pertain to cellular invasion, where plasmin facilitates migration and invasion via the
proteolytic degradation of focal contacts and the proteolytic breakdown of the laminin
and fibronectin component of the ECM (Andreasen et al., 2000). Plasmin also functions
in the activation of other proteases, such as the pro-enzyme form of MMP-3, which
leads to activation of MMP-9, a protease that can degrade the collagen component of
the ECM (Ramos-DeSimone et al., 1999; Stamenkovic, 2003). MMPs are in turn
regulated by tissue inhibitors of metalloproteinases (TIMPs) while plasmin activity is
regulated by both specific plasmin inhibitors and also inhibitors of its activators (see
section 1.3).
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1.2.1.1 Biochemical properties of plasminogen
Native plg is secreted as a single chain zymogen with an apparent molecular weight of
92,000 Da and occurs as two glycoforms (type I and II), which exhibit slightly different
electrophoretic mobility (2 – 4 kDa variation) but have identical amino acid sequences
(Brockway and Castellino, 1972). The molecular weight difference in the glycoforms
arises as a result of the presence (plg I) or absence (plg II) of an N-linked carbohydrate
chain at Asn289 (Brockway and Castellino, 1972; Hayes and Castellino, 1979). A further
six glycoforms of plg II (i.e. α, β, γ, δ and φ), which vary in their sialic acid content,
have since been identified (Pirie-Shepherd et al., 1995). The glycoforms of plg II
display micro-heterogeneity in their efficiency of activation by several plg activators
(Pirie-Shepherd et al., 1996).

Plg exists in two activatable forms, native Glu-plg, which has an N-terminal glutamate
residue and the more readily activatable Lys-plg, which has an N-terminal lysine
residue. Lys-plg is generated through limited proteolysis of Glu-plg at residues Arg68,
Lys77 or Lys78 by endogenous plasmin (Fig. 1.3A) (Zhang et al., 2003). The N-terminal
protease (NTP) domain (Glu1-Lys77 or Glu1-Lys78) of Glu-plg or Glu-plasmin can be
hydrolysed by plasmin in vitro to form Lys-plg or Lys-plasmin, respectively (Violand
and Castellino, 1976; Zhang et al., 2003) (Fig. 1.3B). Lys-plg is the preferred substrate
of the urokinase-type and tissue-type plasminogen activators (uPA and tPA,
respectively) due to its more open conformation (Lucas et al., 1983 and section
1.2.1.2). The conversion of Glu-plg to Lys-plg is enhanced by cell surface binding,
however, enhanced plg activation in the presence of cells is only observed for Glu-plg
but not Lys-plg (Gong et al., 2001; Hoylaerts et al., 1982; Lucas et al., 1983; Markus et
al., 1978b; Markus et al., 1979). This suggests a likely scenario where circulating
9
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Figure 1.3. Domain structure and activation states of human plasminogen. (A) Schematic showing
the domain structure of human Glu-plasminogen. K1-K5 – kringle domains; NTP – N-terminal protease
domain; PA – plasminogen activator. (B) Schematic showing the pathways of plasmin formation by
cleavage events involving plasmin and the PAs. Disulfide bonds are represented by –. Schematics are
not to scale. Adapted from Danø et. al. (1985).
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Glu-plg first binds to the cell surface and is then converted to Lys-plg, which is in turn
activated to plasmin (Gong et al., 2001).

Glu-plg is cleaved at the Arg561-Val562 peptide bond by plg activators to produce
proteolytically active two-chain plasmin. Inter-chain disulfide bonds connect the heavy
(63 kDa) and light (25 kDa) chains of active plasmin. The active site catalytic triad of
plasmin (His617, Asp646, Ser739) is contained within the protease domain of the light (B)
chain (Fig. 1.3A) and has amino acid sequence homology to other serine proteases such
as chymotrypsin and trypsin (Danø et al., 1985). The heavy (A) chain of plasmin
contains the NTP and five kringle domains (K1-K5) (Fig. 1.3A). The kringle domains
are homologous peptide regions each containing three disulfide bonds and occur at
Cys84-Cys162 (K1), Cys166-Cys243 (K2), Cys256-Cys333 (K3), Cys358-Cys435 (K4) and
Cys462-Cys541 (K5) (Sottrup-Jensen et al., 1978). K1, K2, K4 and K5 each contain a
lysine-binding site (LBS) motif, which mediates lysine-dependent binding of plg to
fibrin/fibrinogen, antiplasmin, ECM components, mammalian and bacterial cells and
small lysine analogues (Ranson and Andronicos, 2003). K2 displays a similar affinity
for internal lysine residues as K1, K4 and K5, as evidenced by 1H-NMR spectroscopy
studies with small aliphatic and aromatic ionic ligands, but has a relatively weak
affinity for C-terminal lysine residues compared to these other kringles (Marti et al.,
1997). However, K2 has recently been demonstrated to contain a pseudo-LBS with
high affinity for Arg/His residues in the Group A streptococcal protein, PAM
(Sanderson-Smith et al., 2006), which are presented in a lysine-like manner in the intact
PAM molecule (Rios-Steiner et al., 2001). K5-LBS is of low affinity and is often
termed the aminohexyl- or AH-site due to the fact that it binds to the aminohexyl and
not the carboxylate moiety of lysine, which represents internal lysine residues
11
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(Christensen, 1984; Lerch et al., 1980; Llinas et al., 1983; Thewes et al., 1990; Vali
and Patthy, 1982). The affinity of K5 is too low to be responsible for initial plg binding
or anchoring to fibrin or the cell surface (Ho-Tin-Noe et al., 2005; Thewes et al., 1990)
but it is likely involved in maintaining the conformation of native Glu-plg (see section
1.2.1.2). Conversely, K1-LBS and K4-LBS both have a comparatively high affinity for
C-terminal lysines, however, K4-LBS is “buried” internally within the Glu-plg
molecule in its native conformation (Banyai and Patthy, 1984). Therefore, Ho-Tin-Noe
et al. suggest that K1-LBS is responsible for initial binding to fibrin, ECM and cells
while K4-LBS appears to be responsible for anchoring plasmin and maintaining the
open conformation of plg following initial conformational changes (Ho-Tin-Noe et al.,
2005). While the binding of ligands to the high affinity K1-LBS does not result in a
detectable conformational change in plg, this LBS may mediate the binding of α2antiplasmin and is necessary for Glu-plg binding to cells and fibrin and its subsequent
activation (Ho-Tin-Noe et al., 2005).

1.2.1.2 Plasminogen conformation, activation and the importance of ligand binding
Small lysine analogues including ε-ACA, 6-aminohexanoic acid, benzamidine,
tranexamic acid and proteins such as α-enolase, have been shown to induce
conformational changes within Glu-plg and enhance activation in the presence of plg
activators (Andronicos et al., 2000; Christensen and Molgaard, 1991; Christensen and
Molgaard, 1992; Higazi et al., 1992; Markus et al., 1978a; Markus et al., 1979;
Marshall et al., 1994; Peltz et al., 1982). At least three conformational forms of plg
appear to exist - the closed (α) activation-resistant form, the intermediate (β) form and
the open, activation-susceptible (γ) form, which are mediated by intramolecular
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interactions involving the kringle domains (Andronicos et al., 2000; Christensen and
Molgaard, 1991; Christensen and Molgaard, 1992; Cockell et al., 1998; Marshall et al.,
1994; Ponting et al., 1992).

Native Glu-plg circulates in the blood in the closed α-conformation. This closed
conformation is maintained by Cl- ions (Urano et al., 1987) and is likely to be mediated
by intramolecular interactions between the NTP and K5 as the conversion of Glu-plg to
the more open β-conformation is induced by all of the following: 1) removal of the NTP
to form Lys-plg; 2) the addition of benzamidine, a small molecule inhibitor with known
specificity for K5; and 3) site-directed mutagenesis of the NTP and K5 (Cockell et al.,
1998; Marshall et al., 1994; Sjoholm, 1973; Thewes et al., 1990; Varadi and Patthy,
1981). Using site-directed mutagenesis, Cockell et al. (1998) have localised the residues
participating in this interaction to Asp516 and Asp518 of K5-LBS and Lys50 and/or
possibly Lys62 of the NTP. The importance of Lys50 to the maintenance of the αconformation has also been demonstrated by peptide inhibition studies (Takada et al.,
1993; Urano et al., 1991). Ligand-binding at the K5-LBS disrupts the K5-NTP
interaction and induces transformation to the partially open β-conformation (Fig. 1.4).

The β-conformation is most likely maintained between the K4-LBS and a Lys residue in
K3 (Ho-Tin-Noe et al., 2005; Marshall et al., 1994). In the β-conformation the K4-LBS,
which is masked in the α-conformation, is exposed and forms a second weak affinity
ligand-binding site. Ligand binding at K4-LBS disrupts the K4-LBS/K3 interaction,
inducing and stabilising the fully open γ-conformation (Marshall et al., 1994; Peltz et
al., 1982) (Fig. 1.4). In the γ-conformation, the scissile bond of plg is exposed to
cleavage by plg activators, thus the lysine-dependent binding of plg to fibrin, ECM
13
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Figure 1.4. Conformation states of Glu-plasminogen during fibrin or receptor binding. Schematic
showing the proposed role of the kringles in maintaining the three conformational states of human Gluplasminogen. The lysine binding sites (LBS) present in the kringles of plasminogen (K1, K2, K4 and K5)
mediate these interactions. Binding of plasminogen to lysine residues (shown in red) in fibrin or a plg
receptor induces a conformational change in plasminogen, transitioning from the activation resistant αconformation to the more activation-susceptible γ-conformation. In the presence of a plasminogen activator
(PA), the γ-conformation is then readily activated to plasmin. These conformational changes have been
observed in the presence of small lysine analogues including ε-ACA, 6-AHA, benzamidine and tranexamic
acid (Christensen and Molgaard, 1991; Christensen and Molgaard, 1992; Markus et al., 1978a; Markus et
al., 1979; Marshall et al., 1994; Marti et al., 1997). Schematic based on data presented in Andronicos et al.
(2000) and Marshall et al. (1994).
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components and the cell surface facilitates the activation of plg to plasmin and the rate
of plg activation is dependent on its conformational state (Markus, 1996). Positive
co-operative ligand binding at two sites in plg affords a level of control of plg activation
that is sensitive to small changes in the level of ligand and is important for the tight
regulation of plasmin activity during physiological and pathophysiological processes
(Christensen and Molgaard, 1992), such as the regulation of plasmin-dependent
leukocyte recruitment during the inflammatory response (Herren et al., 2001).

1.2.2

Plasminogen Activation

Conversion of plg to its active form, plasmin, is catalysed by plg activators.
Mammalian plg activators include kallikrein, blood coagulation factors XI and XII,
uPA and tPA (reviewed in Myohanen and Vaheri, 2004). Of these proteases, uPA and
tPA are considered to be the only physiologically significant plg activators as they have
plg activation rates around 100,000 times greater than that of kallikrein and the blood
coagulation factors (Miles et al., 1983). It should be noted, however, that new
information regarding the physiological role of kallikrein in plg activation has been
generated. For example, plasma kallikrein has recently been shown to play a role in plg
activation during wound healing in uPA (-/-), tPA (-/-) gene deficient mice (Lund et al.,
2006) and human kallikrein 6 (neurosin) may also be involved in the generation of a
truncated form of plg (angiostatin) through cleavage at Ser460-Val461 (Bayes et al.,
2004). uPA and tPA are structurally similar, but functionally and immunologically
distinct (Saksela and Rifkin, 1988). uPA is primarily associated with plg activation in
cell migration and tissue remodelling processes, while tPA is primarily involved in the
activation of plg during fibrin degradation (Syrovets and Simmet, 2004). Though a

15

Chapter 1: Literature Review

functional divide exists between uPA and tPA, in vivo studies have suggested that the
absence of tPA may be compensated for by uPA in the activation of plg during the
dissolution of fibrin clots (Carmeliet et al., 1994), even though uPA has a relatively low
affinity for fibrin (Husain, 1993). TPA is synthesised by endothelial cells and binds to
fibrin and mammalian cell-surface receptors (e.g. annexin II) that are also co-receptors
for plg (see section 1.3.3). The function of tPA-mediated plg activation is primarily to
support vascular rather than pericellular proteolysis (Andreasen et al., 1997; Chapman,
1997), with additional roles in neurobiology (East et al., 2005; Teesalu et al., 2002).
For these reasons, tPA-mediated plg activation does not form the focus of this thesis
and therefore will not be further discussed, with the focus therefore remaining on
uPA-mediated plg activation.

1.2.2.1 Urokinase-type plasminogen activator (uPA)
uPA was first discovered in high concentrations in human urine (Williams, 1951) and
has since been found in other bodily fluids including semen, blood plasma (at 20 pM)
and uterine fluid (Dano et al., 1985). uPA is also expressed by endothelial cells during
angiogenesis (Menashi et al., 1993), by macrophages (Nathan, 1987), migrating
keratinocytes (Kirfel and Herzog, 2004), infiltrating leukocytes (Heymans et al., 1999),
inflamed and healing gingival tissue (Kinnby et al., 1999; Xiao et al., 2001), and in
normal kidney tubular epithelium (Wagner et al., 1996). The expression of uPA is
upregulated in a number of cancers including breast, cervical, colon, lung, oral, brain
and bone cancers (reviewed in Andreasen et al., 1997; Konecny et al., 2001; Riethdorf
et al., 1999) and also in other pathological conditions including HPV infection
(Riethdorf et al., 1999; Turner and Palefsky, 1995), atherosclerosis (Garcia-Touchard et
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al., 2005) and rheumatoid arthritis (Busso et al., 1997). The human uPA gene is located
on chromosome 10 and the uPA protein is secreted by cells as an approximately 55 kDa
single-chain glycosylated pro-enzyme (pro-uPA) (Fig. 1.5A) with a pI between 8.4 and
9.7 (species-dependent) (Danø et al., 1985; Rajput et al., 1985). Pro-uPA is activated to
its two-chain form, uPA, by limited proteolysis of the Lys158-Ile159 bond by plasmin,
kallikrein, cathepsin B/L, thermolysin, tryptase, nerve growth factor-β/γ (reviewed in
Andreasen et al., 1997), matriptase (Uhland, 2006) and hepsin (Moran et al., 2006).
Until recently, only plasmin was considered as having activating ability large enough to
be considered physiologically significant (Andreasen et al., 1997), however, Moran et
al. (2006) have now demonstrated that hepsin, a serine protease upregulated on prostate
cancer cells, activates pro-uPA with a similar catalytic efficiency to plasmin (kcat/Km
4.8 x 105 M-1 s-1 [hepsin] vs kcat/Km 4.5 x 105 M-1 s-1 [plasmin]).

The N-terminal light (A) chain (~25 kDa) and C-terminal heavy (B) chain (~30 kDa) of
activated uPA are held together by one interchain disulfide bond between Cys148
(A chain) and Cys279 (B chain) (Danø et al., 1985). The B-chain contains the active site
catalytic triad common to most serine proteases (His204, Asp255, Ser356) and displays
30-40% amino acid sequence homology to other human serine proteases e.g. plasmin,
chymotrypsin and trypsin (Steffens et al., 1982; Strassburger et al., 1983). The A-chain
varies between species but contains a kringle domain (residues Cys50 - Cys131) and an
N-terminal Epidermal Growth Factor-like (EGF-like) domain (residues Ser1- Lys46;
Fig. 1.5A), which mediates binding to the uPA-specific receptor, uPAR (Fig. 1.5A)
(Dano et al., 1985; Mignatti and Rifkin, 1993). The A-chain also contains a putative
plg-binding site (residues Cys148 - Lys158) (Ellis et al., 1999). Urine-derived uPA differs
from cell-secreted uPA in vitro in that the C-terminal residue of the A-chain is a Phe
17
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and not a Lys residue respectively, owing to a differential activation cleavage site at
Phe157-Lys158 (Lenich et al., 1991). A fully activatable but truncated 33 kDa species of
pro-uPA also exists, termed low molecular weight uPA (LMW-uPA; Fig. 1.5B) (Stump
et al., 1986). This form of pro-uPA is generated through cleavage of pro-uPA at Lys135Lys136 to release the amino terminal fragment (ATF; Ser1-Lys135). Because the EGFlike region is contained within the ATF, LMW-uPA cannot bind to uPAR (Gunzler et
al., 1982).

UPA is considered one of the most potent activators of plg (Miles et al., 1983). The
positive feedback between the activation of plg by uPA and the activation of pro-uPA
by plasmin facilitates the generation of large amounts of cell-surface plasmin by cells
with uPA localised at the cell-surface via uPAR. It is possible that pro-uPA initiates
this feedback loop as Ellis et al. (1987) have demonstrated that pro-uPA has some
intrinsic plg activating activity, albeit many times lower than that of active uPA.

1.2.2.2

Urokinase-type plasminogen activator receptor (uPAR)

uPAR (CD87) is a 45 – 55 kDa cysteine-rich glycoprotein receptor, which is attached
to the outer plasma membrane of the cell via covalent linkage of its carboxyl terminal
Gly283 residue to a glycosylphosphatidylinositol (GPI) anchor (Moller, 1993). Soluble
forms of uPAR which lack the GPI moiety (suPAR) have also been identified (Ploug et
al., 1992; Ronne et al., 1995). UPAR is comprised of three domains: DI (Leu1-Asn77),
DII (Leu93-Asn177) and DIII (Gln193-Asn272) (Casey et al., 1994). Pro-uPA and uPA
bind to cell-associated uPAR with equal affinity (KD ~0.1-0.5 nM) (reviewed in
Andreasen et al., 1997) via a high affinity interaction involving the EGF-like domain of
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uPA (Cys19-Cys31) and DI of uPAR (Appella and Blasi, 1987; Behrendt et al., 1991;
Magdolen et al., 1996; Ronne et al., 1991). It is likely that the tertiary structure of
uPAR also is necessary for this interaction as both isolated DI and isolated DI+DII
fragment display a much reduced affinity for uPA (Behrendt et al., 1996; Ploug et al.,
1994). A 3-dimensional uPAR structure has been proposed where the three domains of
uPAR form a globular structure with a uPA-binding cavity, while the external surfaces
of the domains remain available for interaction with other molecules (reviewed in
Ploug, 2003). UPA is capable of cleaving GPI-uPAR in the linker region between DI
and DII at Arg83-Ala84 and Arg89-Ser90, releasing DI and leaving DII+III attached at the
cell-surface via the GPI anchor (Hoyer-Hansen et al., 1997; Hoyer-Hansen et al.,
1992). This cleavage variant is termed uPAR (II+III) or c-uPAR, and has been detected
in extracts of mouse xenograft tumours (Solberg et al., 1994). UPAR is also susceptible
to cleavage in the DI-DII linker region by plasmin (Hoyer-Hansen et al., 2001),
cathepsin G (Beaufort et al., 2004), elastase (Beaufort et al., 2004), MMP-12 (Andolfo
et al., 2002; Koolwijk et al., 2001) and chymotrypsin (Resnati et al., 1996) in vitro.
GPI-uPAR is more susceptible to uPA-cleavage than suPAR (Hoyer-Hansen et al.,
2001), even though GPI-uPAR and suPAR display no difference in affinity for uPA
(Ploug et al., 1991). The difference in uPA-cleavage susceptibility is most likely due to
differences in structural conformation or flexibility in the linker region (Hoyer-Hansen
et al., 2001). Though the functional consequence of the cleavage variant remains to be
defined, it has been suggested that cleaved suPAR DII+DIII (c-suPAR) may function in
the regulation of chemotaxis through binding to receptors of the chemotaxis stimulator,
fMLP (reviewed in Ragno, 2006).
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Unlike the specificity of uPA for uPAR, uPAR also has other high affinity ligands and
their interaction with uPAR facilitates cellular adhesion and migration. The interaction
of uPAR with vitronectin, integrins (including β1-, β2-, β3-, β5, β5, β6-integrins) and
other cell-surface adhesion molecules mediate the non-proteolytic functions of the
uPA/uPAR complex (e.g. intracellular signalling), which also promotes cancer
progression (Andreasen et al., 2000; Blasi and Carmeliet, 2002; Dano et al., 2005;
Kjoller, 2002; Myohanen and Vaheri, 2004; Ossowski and Aguirre-Ghiso, 2000;
Ragno, 2006; Saldanha et al., 2007; Schmitt et al., 2000; Sidenius and Blasi, 2003).

1.3

Regulation of Plasminogen Activation

1.3.1

Inhibition of the PAS

A key level of control in the regulation of plasmin activity arises from the action of
inhibitors. These inhibitors regulate plasmin proteolytic activity either through the direct
inhibition of plasmin (e.g. via α2-antiplasmin) or through inhibition of the plg
activators, uPA and tPA (e.g. via plasminogen activator inhibitor type-1 [PAI-1] and
type-2 [PAI-2]). The three main inhibitors of the PAS, namely α2-antiplasmin (section
1.2.3.2), PAI-1 and PAI-2 (section 1.2.3.3), all belong to the serpin (serine proteinase
inhibitor) family. Serpins share a common mechanism of inhibition with varied
specificity toward the diverse range of target serine proteinases. Reviewed below is the
general mechanism of inhibition shared by the major inhibitors of the PAS and a brief
overview of each these inhibitors.
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1.3.1.1 Serpins: a family of proteinase inhibitors
Serpins are a family of proteinase inhibitors which display wide sequence variation but
share a highly conserved tertiary structure (Silverman et al., 2001). The mechanism of
inhibition of serine proteinases by inhibitory serpins is mediated by the exposed reactive
centre loop (RCL). This region of inhibitory serpins, unlike the rest of the conserved
structure, is highly flexible (van Gent et al., 2003) and contains a reactive or scissile
peptide bond (P1-P1’) which mimics the substrate of the target proteinase (Loebermann
et al., 1984). Cleavage of the reactive peptide bond by the proteinase is followed by
formation of an acyl-enzyme complex, which is stabilised by the formation of an ester
bond between the carboxyl terminus of the P1 residue 1 of the serpin and the active site
serine residue of the target proteinase (Bode and Huber, 1994; Lawrence et al., 1995).
This interaction is coupled with a conformational change in the serpin that involves
insertion of the RCL into the centre of the five-stranded β-sheet A, a prominent serpin
feature, to form a six-stranded anti-parallel β-sheet (reviewed in Huntington, 2006). The
conformational change in the serpin:proteinase complex distorts the active site of the
proteinase thus rendering it inactive and results in a covalently linked, SDS-stable 1:1
stoichiometric complex between the serpin and the proteinase (Huntington et al., 2000).

1.3.1.2 Plasmin Inhibition: α2-Antiplasmin and α2-Macrogloubulin
The

two

major

circulating

inhibitors

of

plasmin

are

α2-antiplasmin

and

α2-macroglobulin (Collen, 1976). Human α2-antiplasmin is a single-chain glycoprotein
serpin with an apparent molecular weight of approximately 70 kDa (Moroi and Aoki,
1976; Wiman and Collen, 1977). α2-antiplasmin circulates in human plasma at a
1

The amino acid residue on the amino-terminal side of the reactive centre bond.
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concentration of approximately 1 μM and is the primary inhibitor of plasmin in human
plasma (Moroi and Aoki, 1976; Mullertz and Clemmensen, 1976; Wiman and Collen,
1977). α2-antiplasmin displays rapid inhibition of solution-phase plasmin by the
formation of a 1:1 stoichiometric complex in both purified systems and in plasma
(Collen, 1976; Moroi and Aoki, 1976; Mullertz and Clemmensen, 1976; Wiman and
Collen, 1977). Critically, cell-surface bound plasmin is protected from inhibition by
both α2-antiplasmin and α2-macroglobulin (Ellis et al., 1991; Hall et al., 1991; Plow et
al., 1986). Inhibition of plasmin in solution by α2-antiplasmin is rapid, irreversible and
occurs via a two-stage reaction with a second order rate constant of 2 - 4 x 107 M-1 s-1
(Christensen and Clemmensen, 1977; Wiman and Collen, 1978). The first stage of the
plasmin:antiplasmin interaction is mediated by a reversible, lysine-dependent
interaction between K1-3 of plasmin and the lysine residues of α2-antiplasmin, and
requires a free active site in the plasmin B-chain (Christensen and Clemmensen, 1977;
Nilsson et al., 1982; Wiman et al., 1978; Wiman and Collen, 1978). Recent studies have
shown that the internal lysine residue (Lys436) and not the C-terminal lysine residue
(Lys452) of α2-antiplasmin is important for the initial lysine-dependent interaction with
plasmin (Wang et al., 2006b; Wang et al., 2003). During the inhibition reaction,
plasmin cleaves bound antiplasmin at the C-terminal end to release an approximately
8 kDa fragment. Release of this C-terminal fragment induces formation of an
irreversible covalent linkage between the resultant C-terminal leucyl residue and the
serine residue in the active site of plasmin, which is coupled with a conformational
change in α2-antiplasmin (Wiman and Collen, 1979). Circulating plasmin:antiplasmin
complex in the plasma of healthy patients has a half-life of approximately 2.6 days
(Collen and Wiman, 1979).
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Circulating plasmin may also be inhibited by α2-macroglobulin, a 725 kDa broadspectrum, non-serpin inhibitor which itself circulates at approximately 2.5 mg/mL in
human plasma (Dano et al., 1985). α2-macroglobulin reacts more slowly with plasmin
than α2-antiplasmin (Collen, 1976) and is likely to function when there is deficit of
α2-antiplasmin or the concentration of plasmin exceeds the ability of α2-antiplasmin to
inhibit it (Mullertz and Clemmensen, 1976). In contrast to α2-antiplasmin,
α2-macroglobulin inhibits plasmin by formation of a dissociable, non-covalent complex
(Aoki et al., 1978).

1.3.1.3 Plasminogen Activator Inhibitors (PAIs)
Indirect regulation of plasmin generation from plg is exerted through inhibition of the
plg activators, uPA and tPA. PAI-1 and PAI-2 are two Arg-serpins that represent an
important level of control of pericellular proteolysis through specific inhibition of the
plg activators. Human PAI-1 (54 kDa) is a single-chain glycoprotein, which under
physiological conditions is secreted by smooth muscle cells, liver cells, adipocytes and
platelets, and is also found in the plasma of healthy individuals ranging in concentration
from 5-20 ng/mL (Pihusch et al., 2005). PAI-1 is also secreted by various cancer cell
lines and endothelial cells under pathophysiological conditions (Binder et al., 2002).
PAI-2 is expressed by some keratinocytes (Chen et al., 1993), fibroblasts (Kruithof et
al., 1995), and cultured macrophages (Belin, 1993) and has also been detected in
gingival crevicular fluid and saliva (Kruithof et al., 1995). PAI-2 is found as a 47 kDa
intracellular form and a secreted, glycosylated 60 kDa form. PAI-2 is not normally
detectable in plasma except during pregnancy (Astedt et al., 1998) where it is possibly
secreted by placental trophoblasts (Feinberg et al., 1989).
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The different physiological roles of uPA and tPA are further emphasised by their
differential interactions with PAI-1 and PAI-2. PAI-2 effectively inhibits both soluble
and receptor-bound uPA and tPA, but is a slower inhibitor of tPA than of uPA and is
also a slower inhibitor of both these activators than PAI-1 (Table 1.1). PAI-2 is also a
poor inhibitor of pro-tPA compared to PAI-1. PAI-1 and PAI-2 inhibit uPA, pro-tPA
and tPA via a classic serpin mechanism through cleavage of the P1-P1’ peptide bond in
the RCL of the inhibitor and formation of an SDS-stable enzyme:inhibitor complex.
While PAI-1 and PAI-2 can form complexes with pro-uPA and inhibit its intrinsic
enzymatic activity, these interactions are reversible and not SDS-stable (Manchanda and
Schwartz, 1995; Schwartz, 1994). PAI-1 and PAI-2 therefore do not appear to inhibit
pro-uPA by a classic serpin mechanism (Huntington, 2006). It has been suggested that
this type of non-serpin interaction may also occur in the uPA:PAI interaction as an
initial reaction prior to the archetypal covalent interaction, but due to the fast reaction
time (approximately 1000 times faster than with pro-uPA) this initial reaction has a very
short lifetime (discussed in Behrendt et al., 2003).

Table 1.1. Inhibition kinetics of the plasminogen activator inhibitors.
-1 -1

Second order rate constant (M s )
PAI-1

PAI-2

PAI-3

7

1 x 10

6

2 x 10

7

2 x 10

5

3 x 10

6

1 x 10

3

2 x 10

4

1 x 10

2

1 x 10

uPA

2 x 10

tPA

2 x 10

Pro-tPA

5 x 10

Plasmin

9 x 10

References

5
4
3

(Eaton et al., 1984;
Kruithof et al., 1995;
Scott et al., 1985)

5
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In addition to the inhibition of plg activator activity through the formation of
enzyme:inhibitor complexes, the PAIs further regulate plg activation through several
other mechanisms. When complexed to uPA, both PAI-1 and PAI-2 undergo
uPAR-mediated endocytosis at the cell surface in a mechanism which also involves
low-density lipoprotein receptor-related protein (LRP) and very-low density lipoprotein
receptor (VLDLR) (Al-Ejeh et al., 2004; Andreasen et al., 1997; Croucher et al., 2006).
Whilst uPAR is recycled back to the cell surface, both uPA and the complexed inhibitor
are destroyed in the lysosomes (Al-Ejeh et al., 2004; Andreasen et al., 1997). Recently
PAI-2 was also demonstrated to display a differential ability to initiate
uPA/uPAR-dependent signalling pathways compared with PAI-1 due to the absence of
a high affinity LRP/VLDLR binding site in PAI-2, indicating that PAI-2 may not
participate in the same mitogenic pathways as PAI-1 (Croucher et al., 2007). In addition
to its direct interaction with uPA, PAI-1 (but not PAI-1:uPA complex) also interacts
with VN, which stabilises PAI-1 in the active form thereby promoting inhibition of
uPA. The interaction of PAI-1 with VN also inhibits cellular migration through
competition with integrins for binding to VN (reviewed in Andreasen et al., 1997).
Moreover, expression of PAI-1 and PAI-2 is upregulated by a wide range of agonists
such as tumour necrosis factor-α (PAI-1/PAI-2) and -β (PAI-1), interleukins
(PAI-1/PAI-2), transforming growth factor β (PAI-1/PAI-2), endotoxin, (PAI-2),
retinoic acid (PAI-2) and phorbol 12-myristate 13-acetate (PAI-1/PAI-2) (reviewed in
Medcalf and Stasinopoulos, 2005; Pihusch et al., 2005, see also Table 2.2 for PMA
effects on PAI expression). Given that high PAI-1 expression in tumours is associated
with a poor prognosis (possibly related to integrin and LRP/VLDLR signalling
functions), together this information suggests that PAI-2 may have a more dominant
role in the control of pericellular proteolysis than PAI-1.
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A third serpin, Protease Nexin 1 (PN-1, also known as PAI-3), has been identified and
only recently shown to have a role in cancer progression (Buchholz et al., 2003; Candia
et al., 2006), with the bulk of previous research carried out in the context of neural
development (reviewed in Festoff et al., 1996). PAI-3 (45 kDa) is synthesised by human
astrocytes, neuroglial and neuroblastoma cells (Stone et al., 1987; Vaughan and
Cunningham, 1993) as well as fibroblasts, kidney epithelial cells, heart muscle cells
and normal human mammary tissue (Candia et al., 2006; Saksela and Rifkin, 1988;
Sprengers and Kluft, 1987). Although PAI-3 exhibits a lower specificity toward uPA
and tPA than both PAI-1 and PAI-2 (Table 1.1), it has the ability to efficiently inhibit
uPA (albeit with a slower rate than PAI-1 or PAI-2), trypsin and plasmin (Crisp et al.,
2002; Eaton et al., 1984; Scott et al., 1985). Similarly to PAI-1 and PAI-2 complexes
with uPA, PAI-3:uPA complexes are internalised at the cell surface via an
LRP-mediated mechanism, with degradation of the complex occurring in the lysosomes
(Crisp et al., 2000). PAI-3, like PAI-1, is elevated in breast cancer tissue compared to
normal tissue and has been correlated with changes to the uPA PAS in breast cancer
(Candia et al., 2006; Castello et al.), however, it is not specific to the plg activators and
reacts more readily with thrombin and trypsin than with uPA and tPA (Scott et al.,
1985; Sprengers and Kluft, 1987), consequently PAI-3 is not usually considered a
physiologically significant uPA inhibitor.

1.3.2

Fibrin binding

Plasmin was first identified and characterised as the causative agent of fibrin
degradation during fibrinolysis (reviewed in Dano et al., 1985). Fibrin (and its
pre-cursor fibrinogen) binds both plg (via regions Aα148-160 and γ320-324) and tPA
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(via region γ312-324) and potentiates the activation of plg by tPA approximately
1000-fold (Mosesson, 2005; Ranby, 1982). The plasmin formed on the fibrin surface
can then cleave fibrin molecules to release fibrin degradation products and expose
C-terminal lysine residues, thereby generating new plg binding sites (Cesarman-Maus
and Hajjar, 2005). Like the activation of plg on cells by uPA (see section 1.3.3), fibrinbound plasmin generation is controlled through inhibition of tPA by PAI-1. While
degradation of the fibrin clot by solution-phase plasmin is efficiently and rapidly
inhibited by α2-antiplasmin (Aoki et al., 1978), fibrin-bound plasmin bound is protected
from inhibition by α2-antiplasmin (Ponting et al., 1992). The thrombin-activatable
fibrinolysis inhibitor (TAFI) also inhibits this process by blocking plg binding via
removal of the C-terminal lysine residues of fibrin and hence stabilises the fibrin clot
(Cesarman-Maus and Hajjar, 2005). Since TAFI is activated during coagulation, this
molecule provides a regulatory link between coagulation and fibrinolysis (discussed in
Marx, 2004). As many of the components of the fibrinolytic pathway (e.g. plg, tPA,
PAI-1) also participate in pericellular proteolysis, a brief review of their role in
fibrinolysis has been presented, however, this physiological pathway is not the focus of
this review and as such will not be further discussed.

1.3.3

Plasminogen Receptors

Plg not only binds to fibrin but to the surface of cells, potentiating its activation to
plasmin by uPA and tPA (Duval-Jobe and Parmely, 1994; Ellis et al., 1991; Felez et al.,
1996; Hajjar et al., 1986; Hall et al., 1990; Hembrough et al., 1996b; Longstaff et al.,
1999; Loscalzo and Vaughan, 1987; Miles and Plow, 1985; Sinniger et al., 1999;
Stricker et al., 1986). Plg receptors facilitate plasmin generation by 1) inducing a
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lysine-dependent conformational change in Glu-plg that exposes the Arg360-Val361 bond
to cleavage by activators (see section 1.2.1.2), 2) localising plg in close proximity to a
plg activator, and 3) protecting the plasmin formed from inhibition by circulating
inhibitors such as α2-antiplasmin. The conformational change in plg is mediated by the
LBSs of K1, K2, K4 and K5 of plg (reviewed in Ranson and Andronicos, 2003 and
section 1.2.1.2), therefore lysine-dependent binding of plg to the cell surface is an
important determinant in the ability of cells to efficiently bind and activate plg.

Plg receptors have been identified on many mammalian, bacterial and yeast cells
(Crowe et al., 2003; Lahteenmaki et al., 2005; reviewed in Ranson and Andronicos,
2003; Walker et al., 2005), however, as this thesis is focussed on cancer only the
mammalian receptors will be discussed. Mammalian plg receptors are expressed on the
surfaces of tumour cells, endothelial cells, monocytes, keratinocytes, fibroblasts,
neutrophils, hepatocytes, platelets and neuronal cells (reveiwed in Ranson and
Andronicos, 2003). Plg binding to cells is generally saturable, of overall moderate
affinity (KD 0.1-2 μM) but high capacity (104-107 sites per cell) and is lysine-dependent
(reviewed in Felez, 1998; Ranson and Andronicos, 2003). To date, at least 15
heterologous proteins have been named as plg receptors (Table 1.2). It must be noted
however that many of the named receptors such as annexin II and α-enolase, also have
intracellular functions and the mechanism of cell-surface expression is unknown (see
Table 1.2). Importantly, no single cell-surface protein exists at high enough levels to
constitute an exclusive cell-surface plg receptor, therefore it is likely that multiple
proteins are responsible for total cell-surface plg binding capacity (Andronicos and
Ranson, 2001; Plow and Miles, 1990; Ranson and Andronicos, 2003). For example,
while the plg receptor α-enolase is highly expressed on U937 cells (1.8 x 106
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Table 1.2. Properties of some putative mammalian plasminogen receptors.
a
a
Plg binding
α-enolase
Annexin II
Actin
molecule

Annexin II
heterotetramer

Synonyms

2-phospho-Dglycerate
hydrolyase

β-actin

Lipocortin II,
Calpactin I
heavy chain, p36

AIIt, Annexin A2,
Calpactin I

Mr (kDa)

54

42

40

94

Description

Dimeric
cytoplasmic
enzyme

Globular protein

Ca2+ and
phospholipidbinding protein

Two subunits
annexin II + two
subunits S100A10

Classical function

Glycolytic/glucon
eogenic pathway

Cytoskeletal stress
fibre

DNA synthesis
(nucleus); Ca2+regulated
exocytosis and
endocytosis

Ca2+-regulated
exocytosis and
endocytosis; ion
channel regulation

KD

1.4 μM

0.14 μM

0.16 μM

0.11 μM
(S100A10: 1.81
μM)

Lysine dependent
interaction

9b

9b

9b

9c

Pre-existing
C-terminal lysine

9

8

8

9

Region/s
important for
binding

C-terminal lysine
residue

Gly55-Tyr69
(specifically Lys61
and Lys 68)

Lys307

C-terminal Lys
residues (Lys95Lys96) of S100A10
subunit

Enhances plg
activation

9

9

9

9

Activator of
bound plg

tPA

tPA
uPA

tPA

tPA

Co-receptor for
tPA (KD μM)

-

9(KD 0.55 μM)

9(KD 25 nM)

9

Cell type

Monocytes

Endothelial cells
Epithelial (prostate)

Endothelial
Epithelial
(kidney)

Embryonic
(kidney)

References

(Redlitz et al.,
1995a)

(Dudani and Ganz,
1996; Lind and
Smith, 1991; Lind
and Smith, 1993;
Wang et al., 2006a)

(Cesarman et
al., 1994; Hajjar
et al., 1994)

(MacLeod et al.,
2003)

(KD 0.68 μM;
S100A10:0.45μM)
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Table 1.2 continued.
Plg binding
molecule
Synonyms

Amphoterin

Cytokeratin 8

HMGB1

Keratin-8

Glycoprotein IIbIIIa complex
CD41 antigen

Mr (kDa)

30

59

115 (IIb)/97 (IIIa)

54

Description

Heparin- and
sulfoglycolipidbinding protein

Cytoplasmic
intermediate
filament protein
often associated
with cytokeratin 18

Integrin, present on
platelets

DNA Helicase

Classical function

Nervous system
related; DNA
transcription
regulation,
motility

Cell-cell adhesion,
cell-matrix
adhesion

Calcium-dependent
regulation of
platelet
aggregation and
endothelial
adherence

ATP-dependent
regulation of
unwinding of the
DNA double helix
preceding
replication and
transcription

KD

ND

0.5 μM
(partial protein)

ND

0.57 μM

Lysine dependent
interaction

9b

9b

9d

9b

Pre-existing
C-terminal lysine

ND

9

8

9

Region/s
important for
binding

ND

Gly471-Lys483

ND

ND

Enhances plg
activation

9

9

9

9

Activator of
bound plg

tPA

tPA

uPA

tPA

Co-receptor for
tPA (KD μM)

-

-

-

-

Cell type

ND but present
on cell surface
of breast tissue
(Salmivirta et
al., 1992)

Hepatocyte (rat)
Epithelial (breast)

Platelets
Synovial
fibroblasts
(Rheumatoid
arthritis)

Monocytes

References

(Parkkinen and
Rauvala, 1991)

(Hembrough et al.,
1995; Kralovich et
al., 1998)

(Gonzalez-Gronow
et al., 1994; Miles
et al., 1986)

(Hawley et al.,
2001)

e

TIP4a
RUVB-like
protein 1, nuclear
matrix protein
238, Pontin52
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Table 1.2 continued.
Plg binding
molecule

Glycoprotein 330

Tissue factor
apoprotein

Dipeptidyl peptidase
IV

uPA

Synonyms

GP330, Heymann
nephritis
autoantigen,
LRP2, Megalin

Coagulation factor
III, thromboplastin,
CD142 antigen

CD26, adenosine
deaminase
complexing protein 2

Urokinase

Mr (kDa)

600

45

120

55

Description

Transmembrane
glycoprotein

Transmembrane
glycoprotein

Serine protease
(glycoprotein)

Serine
protease

Classical function

Endocytic
receptor with
signalling
function

Coagulation
cascade: catalyses
conversion of factor
X to factor Xa
when complexed to
factor VIIa

Glucose metabolism;
modulates T-cell
activation

Plasminogen
activator

KD

~ 0.25 μM

0.017 μM (Plg I)

10.6 nM (Plg II γ)
13.6 nM (Plg II δ)
3.8 nM (Plg II ε)

50 nM

Lysine dependent
interaction

9f

9d

ND

9 d, g

Pre-existing
C-terminal lysine

8

8

8

9

Region/s
important for
binding

ND

Extracellular
domain of TF; K1K3 of plasminogen

ND

Gly149-Lys158

Enhances plg
activation

9

9

ND

9

Activator of
bound plg

uPA

uPA

ND

uPA

Co-receptor for
tPA (KD μM)

-

-

ND

-

Cell type

Epithelial
(glomerular)

Transfected CHO
cells
Epithelial (prostate)

Synovial fibroblasts
(Rheumatoid
arthritis) Epithelial
(prostate)

Monocytes

References

(Kanalas, 1992;
Kanalas and
Makker, 1991)

(Fan et al., 1998;
Gonzalez-Gronow
et al., 2002)

(Gonzalez-Gronow et
al., 1994; GonzalezGronow et al., 2001)

(Ellis et al.,
1999)

(on A-chain)
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Table 1.2 continued.
Plg binding
molecule
Synonyms

Integrin α5β1

Osteonectin

Tetranectin

CD49e,
CD29,VLA-5

SPARC, basementmembrane protein 40,
BM40

Plasminogen kringle 4 binding
protein

Mr (kDa)

265

32.7

~ 68

Description

Integrin

Glycoprotein
present in bone

Homotrimeric, C-type lectin,
circulates in plasma at 10mg/L,
also found in extracellular deposits

Classical function

Fibronectin
receptor; cell
adhesion

Tissue mineralisation

Plasminogen K4 binding protein;
Ca2+ and complex sulfated
polysaccharide binding protein;
biological function unknown

KD

ND

120 nM (platelet-derived)
47 nM (bone-derived)

0.5 μM

Lysine dependent
interaction

ND

9b

9b, h

Pre-existing
C-terminal lysine

-

8

8

Region/s
important for
binding

ND

ND

K4 of plasminogen; CRD calcium
site 2 (Glu150/Asp165) and Lys148 of
tetranectin

Enhances plg
activation

9i

9

9

Activator of
bound plg

tPA

tPA

tPA

Co-receptor for
tPA (KD μM)

-

-

9 (KD 0.28 μM)

Cell type

Monocytes
Embryonic
(kidney)

ND

ND

(Lishko et al.,
2004)

(Kelm et al., 1994)

(Clemmensen et al., 1986;
Graversen et al., 1998;
Westergaard et al., 2003)
Conflicting opinions exist regarding the ability of annexin II to bind plasminogen in the absence of
p11 (Waisman, 2005), therefore data for annexin II and annexin II heterotetramer (annexin II plus
p11 subunits) are presented.
Inhibited by ε-ACA
Determined by use of a C-terminal lysine deletion mutant
Inhibited by ω-ACAs
Not determined
Inhibited by benzamidine
Inhibited by a lysine derivative (N-α-acetyl-L-lysine methyl ester)
Plasminogen binding is also calcium-modulated
Plg activation was significantly reduced in the presence of antibodies directed against α5β1

References
a.
b.
c.
d.
e.
f.
g.
h.
i.
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molecules/cell), it only accounts for 10% of the total plg binding to these cells (Redlitz
et al., 1995a). Furthermore, gangliosides have also been observed to bind plg in a direct
and specific manner and can be incorporated into the plasma membrane, thus increasing
cell-surface plg binding (Miles et al., 1989), suggesting that not only the protein
component of the plasma membrane may be responsible for plg binding capacity.

Many plg receptors, in both soluble and cell-surface associated forms, bind plg via
C-terminal lysine residues as evidenced by a significant reduction in plg binding and
activation in the presence of carboxypeptidase B, an enzyme which cleaves C-terminal
basic amino acid residues e.g. lysine and arginine (Table 1.2) (Camacho et al., 1989;
Cesarman et al., 1994; Felez, 1998; Hawley et al., 2001; Kim et al., 1996; MacLeod et
al., 2003; Redlitz et al., 1995b). Many studies have indicated the importance of a
C-terminal lysine residue to plg binding, however, several plg receptors have been
identified that do not posses C-terminal lysines e.g. annexin II and actin (Fitzpatrick et
al., 2000; Lind and Smith, 1991). Increased plg/plasmin binding on cancer cells may
therefore be the result of the generation of C-terminal lysine residues on proteins
already existent on the cell surface (as opposed to alterations in the expression patterns
of cell surface proteins). For example, studies in human mammary and colon carcinoma
cells indicate that plg binding increases upon pre-incubation of the cells with plasmin or
trypsin, which cleave proteins C-terminal to Lys and Arg residues (Burtin et al., 1993;
Camacho et al., 1989), and pre-treatment of cells with cycloheximide, an inhibitor of de
novo protein synthesis, does not ablate increased plg/plasmin binding (Camacho et al.,
1989). These studies into the nature of plg binding suggest that plg can bind to not only
pre-formed receptors (i.e. receptors with C-terminal lysine residues in their native form)
but also to proteins that have had C-terminal lysine residues generated through limited
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proteolysis by plasmin or other proteinases. While both these mechanisms have been
proposed to occur at the surface of a number of cancer cells in vitro (reviewed in
Ranson and Andronicos, 2003), the exact mechanism of enhanced plg binding by cancer
cells remains unresolved.

1.3.4

Functional Consequences of Plasminogen Activation

The spatial and temporal regulation of the PAS (Fig. 1.6) is critical in order to prevent
widespread proteolysis by plasmin. However, cancer cells inappropriately express
components of this system thereby facilitating cancer cell invasion and metastasis
(Andreasen et al., 2000). The proteolytic activity of plasmin leads to ECM breakdown
and MMP activation, which is necessary for cellular invasion to occur. Plasmin and
MMP activity further regulate cellular growth and migration through cleavage of
extracellular components to release or activate chemokines, cytokines and growth
factors (e.g. HGF/SF, MSP, TGF-β and bFGF) (Stamenkovic, 2003) and even uPAR
has been suggested to act as a chemokine in its uPA-cleaved form (Blasi, 1999).
Pro-uPA may very well initiate the plg activation cascade on the cell surface as it has
been shown to possess minimal (if very low) intrinsic plg activating ability in vitro even
in the presence of PAI-1, however, the existence and significance of this activity is still
debated (Behrendt et al., 2003; Collen et al., 1986; Ellis et al., 1987; Manchanda and
Schwartz, 1991; Nielsen et al., 1982; Petersen et al., 1988). In addition, cell-surface
localisation of pro-uPA enhances its intrinsic proteolytic activity (Manchanda and
Schwartz, 1991). The physiological significance of pro-uPA activation of plg as a
cascade initiator is still unknown as a number of other proteases also activate pro-uPA
(see section 1.2.2.1) and may therefore initiate the cascade by activating uPA. There are
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Cell
PlgRlatent
uPAR

Extracellular space

ProPro-uPA

uPAR
uPA

PlgRinactive

PAIPAI-1
PAIPAI-2

PlgR

PlgR

Plg

Plasmin

CpB
Plasmin

Cathepsin B

α2-antiplasmin
α2-macroglobulin

Degradation of
ECM components
Invasion

Release of
growth factors
chemokines
cytokines

MMPs*
MMPs*

ProPro-MMPs

TIMPs

Extracellular matrix
Fig 1.6. Regulation of the plasminogen activation system at the cell surface. Activation events are represented by red arrows. Cleavage events are represented by blue
arrows. Inhibition of protease activity is represented by -|. Green circles represent lysine residues. Abbreviations: CpB – carboxypeptidase B; c-Plg-R – cryptic plasminogen
receptor; ECM – extracellular matrix; MMP – matrix metalloproteinase; PAI – plasminogen activator inhibitor; Plg – plasminogen; PlgR – plasminogen receptor; TIMP –
tissue inhibitor of matrix metalloproteinases; uPA – urokinase plasminogen activator; uPAR – urokinase plasminogen activator receptor. *MMPs may also be associated with
the cell surface via interaction with other cell surface molecules. Adapted from Ranson and Andronicos (2003).
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few studies demonstrating which mechanism may act in vivo (discussed in Behrendt et
al., 2003).

The timing of plg activator (i.e. uPA and tPA) expression forms another level of control
as their activity directly influences the level of plasmin generated at the cell-surface.
Physiologically, extracellular expression of uPA must be tightly regulated to prevent the
production of excessive plasmin generation at the cell surface via the uPA/plg positive
feedback loop (Behrendt et al., 2003; Petersen et al., 1988). Most cells secrete low
levels of uPA and uPAR, however, hormones, growth factors and tumour promoters,
which also affect cellular proliferation and differentiation, induce over-expression of
these components (Table 1.3) (reviewed in Myohanen and Vaheri, 2004). The activation
of pro-uPA to fully active uPA is mediated not only by plasmin activity, but also by
uPAR-binding where an increased efficiency of plasmin-catalysed pro-uPA activation is
observed when pro-uPA is bound to uPAR (Duval-Jobe and Parmely, 1994; Ellis and
Dano, 1993; Ellis et al., 1989; Stephens et al., 1989). suPAR has been excluded as a
stimulatory agent for pro-uPA/uPA activity and also pro-uPA activation (Behrendt et
al., 2003). A further level of regulatory control stems from the cleavage variants of
uPA, of which there are at least five, each being a different molecular weight species of
uPA (Stepanova and Tkachuk, 2002). Some of these species are without catalytic
activity (e.g. thrombin cleavage inactivates uPA) and so this mechanism has also been
suggested to function in the temporal regulation of plasmin activity (Braat et al., 1999;
Ichinose et al., 1986). PAI-1 and PAI-2 are also important regulators of soluble phase
and cell-surface uPA activity through the direct inhibition of uPA catalytic activity and
also through mediation of cell-surface uPA:uPAR:PAI-1 complex internalisation,
leading

to

degradation

of

uPA

and

recycling

of

uPAR

to

the
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Table 1.3. Intracellular and extracellular regulatory factors affecting uPA, uPAR, PAI-1 and PAI-2 expression.
Class

Regulator

Type of Regulation

Cell Line

Reference

Adhesion molecule

β3α-Integrin

Down-regulation of uPAR mRNA and
protein

Chinese hamster ovary cells
(CHO)

(Hapke et al., 2001)

Anti-angiogenic
factor

16K Prolactin (PRL)

Down-regulation of uPA activity via upregulation of PAI-1 mRNA and protein

Bovine capillary endothelial cells
(BBEC)

(Lee et al., 1998)

Antibody

Pemphigus IgG

Up-regulation of uPAR protein

Squamous cell carcinoma (DJM-1)

(Seishima et al., 1997)

Bacterial protein

Conditioned medium from
Borrelia burgdorferi strain N40

Up-regulation of uPAR mRNA and
membrane and cytosolic protein

Monocytic cells (U937), fresh human
peripheral blood monocytes (hPBM)

(Coleman et al., 2001)

Bacterial protein

Lipopolysaccharide (LPS;
Salmonella typhimurium)

Up-regulation of membrane uPAR protein,
PAI-2 mRNA expression and stability, and
PAI-2 protein; increases PAI-1 mRNA and
protein

hPBM, Human umbilical vein
endothelial cells (HUVEC)

(Coleman et al., 2001;
Schwartz and Bradshaw,
1992; Zhang et al., 1997)

Bacterial protein

Lipotechoic acid (LTA;
Streptococcus pyogenes)

Up-regulation of membrane uPAR protein

hPBM

(Coleman et al., 2001)

Bacterial protein

Outer surface protein A (OspA,
B. burgdorferi)

Up-regulation of membrane uPAR protein

hPBM

(Coleman et al., 2001)

Cytokine

INF-γ

Up-regulation of cell-surface uPAR protein

Human monocytes

(Kirchheimer et al., 1988)

Cytokine

Interlukin-1 (IL-1)

Up-regulation of PAI-1 and uPAR mRNA
and protein, increases PAI-2 protein

Cultured endometrial stromal cells,
monocytes, bone marrow stromal cells,
endothelial cells, synovial and foetal
fibroblasts

(Chung et al., 2001;
Kruithof et al., 1995)
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Table 1.3 continued
Class

Regulator

Type of Regulation

Cell Line

Reference

Cytokine

TNF-α

Up-regulation of cell-surface uPAR protein,
up-regulation of uPA and uPAR mRNA,
increased expression of PAI-2 protein

Human monocytes; colon cancer cell
lines (HCT116, KM12SM, LM1215),
FGF- or VEGF-stimulated human
microvascular endothelial cells
(hMVEC) in hypoxic conditions,
HUVEC, melanoma cells

(Kirchheimer et al., 1988;
Kroon et al., 2000;
Kruithof et al., 1995;
Wang et al., 1994)

Environmental
condition

Hypoxia

Up-regulation of uPAR mRNA, protein and
activity

Human melanoma xenograft (R18),
hMVECs

(Kroon et al., 2000;
Rofstad et al., 2002)

Environmental
condition

UVB

Up-regulation of uPA protein, uPAR mRNA
and uPAR protein

Epidermal keratinocytes
(A431)

(Marschall et al., 1999)

Growth Factors

Epidermal growth factor (EGF)

Up-regulation of uPA mRNA and protein
secretion

MDA-MB-231, mouse mammary
carcinoma (SP1)

(Korczak et al., 1991;
Long and Rose, 1996)

Growth Factors

Hepatocyte growth
factor/scatter factor (HGF/SF)

Up-regulation of uPAR mRNA and uPA
activity

c-Met positive human glioma cells

(Moriyama et al., 1999)

Growth Factors

Insulin-like growth factor
receptor (IGF-IR)

Antisense IGF-IR mRNA down-regulates
uPA and tPA mRNA

IGF-IR transfected murine mammary
carcinoma cells (EMT6)

(Chernicky et al., 2002)

Growth Factors

Transforming growth factor-β1
(TGF-β1)

Up-regulation of uPA mRNA, protein and
activity, up-regulation of PAI-1 mRNA and
protein, reduces PAI-2 protein basal
expression

MDA-MB-231, keratinocytes (PDV),
human hepatoma cells (Hep3B),
human monocytes

(Arnoletti et al., 1995;
Hamilton et al., 1993;
Keeton et al., 1991;
Santibanez et al., 2000)

Hormone

Dihydroxytestosterone
(DHT; an androgen)

Down-regulation of uPA mRNA and protein

Androgen responsive prostate cancer
cells (PC-3T)

(Xing and Rabbani, 1999)
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Table 1.3 continued
Class

Regulator

Type of Regulation

Cell Line

Reference

Hormone

Estrogen

Down-regulation of uPA mRNA

MDA-MB-231

(Long and Rose, 1996)

Hormone

Forskolin

Up-regulation of uPAR protein

HUVEC

(Langer et al., 1993)

Hormone

Gonadotropin

Up-regulation of uPA protein and activity,
up-regulation of tPA, uPA and uPAR
mRNA

Bovine pre-ovulatory follicles, new
corpora lutea

(Dow et al., 2002)

Hormone

Heregulin

Up-regulation of uPA and uPAR mRNA and
protein

Non-metastatic breast carcinoma
(MCF-7)

(Mazumdar et al., 2001)

Hormone

Progesterone

Up-regulation of PAI-1 mRNA and protein

Endometrial stromal cells

(Casslen et al., 1995)

Hormone

Thrombospondin

Up-regulation of uPA protein

Metastatic breast carcinoma
(MDA-MB-231)

(Arnoletti et al., 1995)

Kinase

MAP kinase

Stabilises uPAR mRNA

Pig epithelial (LLC-PK), HeLa, MDAMB-231

(Montero and Nagamine,
1999)

Oncogene

c-erbB2

Up-regulation of uPA protein, no effect on
uPA mRNA

Lung cancer (H460), chick embryo
fibroblasts (CEF)

(Bell et al., 1993; Gum et
al., 1995)

Oncogene

Src

Up-regulation of uPAR mRNA and protein

Colon adenocarcinoma
(SW480)

(Allgayer et al., 1999)

Oncogene

v-mos

Up-regulation of uPA protein

Squamous cell carcinoma
(NIH-3T3)

(Lengye et al., 1995)

Oncogene

v-ras

Up-regulation of uPA mRNA

CEF

(Bell et al., 1993)

Oncogene

v-src

Up-regulation of uPA mRNA

CEF

(Bell et al., 1990)
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Table 1.3 continued.
Class

Regulator

Type of Regulation

Cell Line

Reference

Oncogene

v-yes

Up-regulation of uPA mRNA

CEF

(Bell et al., 1993)

Protease

uPA (via EGF-like domain)

Up-regulation of cell-surface uPAR protein,
uPA mRNA and protein, and c-myc, c-jun
and c-fos mRNA

Thyroid carcinoma; melanoma,
Epidermal carcinoma; fibroblast,
human osteoblast (SaOS2), lungderived epithelial cells (Beas2B)

(Montuori et al., 2000;
Rabbani et al., 1997;
Shetty et al., 2002)

Pyrazine derivative

Amiloride

Down-regulation of uPAR mRNA

HCT116, KM12SM, LM1215

(Wang et al., 1994)

Transcription factor

cAMP

Up-regulation of uPAR mRNA

PL-21,
HUVEC

(Langer et al., 1993; Niiya
et al., 1998)

Transcription factor

E2F

Down-regulation of PAI-1 mRNA

Osteosarcoma cells
(U2OS)

(Koziczak et al., 2001)

Transcription factor

Krüppel-like factor Zf9

Up-regulation of uPA mRNA, protein and
activity

BAEC

`(Kojima et al., 2000)

Tumour promoter

PMA

Up-regulation of uPAR mRNA expression
and stability, uPA mRNA and protein, PAI-1
mRNA and PAI-2 protein

Human myeloid leukaemia (PL-21),
HUVEC, CEF, colon cancer; low grade
glioma; mouse skin (epithelial and
stromal cells), U937, HL-60, K562,
a
PL-21, MCF-7

Tumour Suppressor

Von-Hippel-Lindau gene
(VHL)

Up-regulation of uPA mRNA, and protein,
down-regulation of PAI-1 mRNA and
protein

Renal cell carcinoma
(789-O)

(Bell et al., 1990; Johnson
et al., 1999; Kruithof et
al., 1995; Lakka et al.,
2001; Langer et al., 1993;
Lund et al., 1996; Niiya et
al., 1998; Ree et al., 1998;
Wang et al., 1994)
(Los et al., 1999)

a

a. See also Table 2.2
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cell-surface (Al-Ejeh et al., 2004; Andreasen et al., 1997; Croucher et al., 2006). The
latter mechanism is particularly important for removing active uPA from the
cell-surface thus inhibiting the uPA/plg feedback loop.

In summary, perhaps one of the most important regulatory mechanisms of the PAS is
the binding of plg to the cell surface via plg receptors. The binding of plg in a lysinedependent manner induces conformational changes that increase the rate of activation of
plg (see section 1.2.1.2) (Ellis et al., 1991; Ponting et al., 1992). Plg receptors therefore
afford a level of control of plg activation at the cell-surface and are necessary to
1) increase the rate of cell-surface plg activation, 2) retain plasmin on the cell-surface to
maintain localised proteolysis only, 3) protect plasmin from inhibition by
α2-antiplasmin to maintain proteolytic activity and 4) to allow plasmin to more readily
activate cell-surface pro-uPA (Ranson and Andronicos, 2003). The functional relevance
of plg receptors is the co-localisation of plg in a readily activatable form with its
activator, without which plasminogen is not efficiently activated to plasmin.

1.4

The Urokinase Plasminogen Activation System as a Therapeutic

Target for Breast Cancer
Studies indicate that targeting the urokinase PAS may result in increased efficacy for
the treatment of metastatic breast cancer, with reduced toxicity compared to current
therapeutics

that

non-specifically

target

a

range

of

cells

and

tissues

(e.g. chemotherapies, radiotherapies and hormone-based therapies). Evidence
supporting this theory comes from studies which have shown that altered expression of
the various components of the uPA PAS (particularly uPA and PAI-1 expression) are
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linked to decreased survival and disease-free interval in breast cancer patients (Duffy
and Duggan, 2004; Harbeck et al., 2004a; Look et al., 2003; Look et al., 2002) and also
increased invasive capacity of tumour cells in vitro and in vivo (Andreasen et al., 2000).
In addition, gene disruption studies undertaken in mice have suggested that one of the
major physiological functions of uPA is in cell migration and invasion during the
inflammatory process but is not essential to development (reviewed in Andreasen et al.,
2000) and a recent study has shown that in the absence of uPA and tPA, in vivo wound
healing is impaired but still occurs (Lund et al., 2006). The uPA system therefore
represents an attractive target for the development of anti-invasive therapeutics for
cancer. A number of potential therapeutics already exist which target uPA and include
antisense uPA, antibodies directed against uPA/uPAR, uPA/uPAR analogues (e.g. ATF,
soluble uPAR), naturally occurring and synthetic uPA inhibitors (e.g. substituted
benzo[b]thiophen-2-carboxamidines) and toxins linked to uPA-targeted molecules
(e.g. PAI-1-A-chain cholera toxin) (Rakic et al., 2003; Schmitt et al., 2000). However,
to date only two of these, a uPAR antagonist (Å6) and a small molecule uPA inhibitor
(WX-UK1) have progressed to Phase I (both are currently in Phase II) clinical trials in
humans (Berkenblit et al., 2005; Ertongur et al., 2004; Setyono-Han et al., 2005).

Angiogenesis, while being an important physiological process, is also necessary for
continued tumour growth as the blood supply provides both oxygen and nutrients to the
growing tumour mass, therefore this process represents a new therapeutic target for
cancer treatment (Carmeliet, 2005; Ferrara and Kerbel, 2005). In addition to the lymph
system, the angiogenic process also facilitates metastasis by providing an “escape route”
through which detached tumour cells may disseminate throughout the body (see section

43

Chapter 1: Literature Review

1.1). The uPA PAS has been shown to not only participate in tumour cell invasion but
also in the angiogenic process, where the presence of uPA/PAI-1 in the conditioned
media of a highly invasive breast cancer cell line has been shown to induce angiogenic
effects in endothelial cells (Bajou et al., 2002). Studies in in vivo models using PAI-1
deletion mutants suggest that PAI-1 is necessary for angiogenesis, with the reduced
tumour invasion and vascularisation seen in these animals not observed in the absence
of uPA or tPA (reviewed in Rakic et al., 2003). The role of PAI-1 in facilitating
angiogenesis sheds some light on the paradoxical association of PAI-1 with poor
outcome in breast cancer given that PAI-1 is also an inhibitor of the proteolytic activity
of uPA. A recent study by Croucher et al. (2007) also suggests that the pro-metastatic
effects of PAI-1 may be related to PAI-1-mediated signalling events since these are not
observed in the presence of PAI-2. Increased PAI-2 levels have been associated with a
favourable outcome in breast cancer patients (Duffy, 2004). The best known antiangiogenic therapeutics are the anti-VEGF (vascular endothelial growth factor)
inhibitors which block the action of VEGF and arrest endothelial cell proliferation and
therefore new vessel growth, as well as causing existing endothelial cell death (Ferrara,
2005; Ferrara and Kerbel, 2005). The uPA system has also evolved as a target for
potential anti-angiogenic therapies, with uPA, uPAR and PAI-1 having shown a role in
endothelial cell migration, and experimental therapeutics targeting these molecules have
shown some success in animal models (reviewed in Rakic et al., 2003). However, the
intricacies of tumour therapy are complicated and halting angiogenesis may also prove
counterproductive as these vessels represent an effective route for drug delivery and
perfusion into the tumour mass (Carmeliet, 2005).
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Though the uPA PAS represents an important prognostic determinant for the outcome
of breast cancer, reliable assays for the measurement of these components are yet to be
used in routine clinical practice (Benraad et al., 1996; Grebenchtchikov et al., 2005).
Nevertheless, uPA/PAI-1 status has been validated as a prognostic indicator for breast
cancer outcome in two Level 1 Evidence2 studies (Duffy, 2004; Janicke et al., 2001;
Look et al., 2002). The status of uPA/PAI-1 is particularly important in node-negative
breast cancer, where invasion to the lymph nodes is not detected at diagnosis. It is
estimated that 55-70% of node-negative patients that would be candidates for adjuvant
therapy when assessed using traditional histomorphologic and clinical parameters such
as tumour size, grade, age, steroid hormone receptor status (ER and PR) and
menopausal status, could be spared adjuvant chemotherapy using uPA/PAI-1 as
predictive tools (Janicke et al., 2001). These prognostic indicators are increasingly
important as earlier diagnosis means that the proportion of patients without lymph node
involvement is increasing (Janicke et al., 2001). The uPA/PAI-1 status of the primary
tumour has yet to be recommended as a prognostic indicator for node-negative breast
cancer by the current National Health and Medical Research Council’s Clinical Practice
Guidelines for the Management of Early Breast Cancer (National Health and Medical
Research Council, 2001), and is not yet widely used in clinical practice (Weigelt et al.,
2005). However, a clinical test does exist and can be requested by breast cancer patients
(breastcancer.orgTM website, 2006).

Several experimental uPA/uPAR-targeted therapies appear promising (Duffy, 2004;
Rakic et al., 2003; Schmitt et al., 2000), including PrAg-U2 (a modified anthrax toxin

2

Definitive evidence obtained from a single, high-powered, prospective, randomised, controlled trial or
from a meta-analysis or overview of multiple, well-designed studies (Hayes et al. 1996).
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where the furin cleavage site has been replaced by the uPA substrate sequence,
SGRSA), which is targeted to cells that overexpress uPAR/uPA (Liu et al., 2003; Liu et
al., 2001). On cleavage of the PrAg-U2 molecule by uPA, the chimeric anthrax toxin is
internalised into cells expressing both the PrAg receptor and uPA at the surface, thus
selectively targeting uPA-overexpressing tumour cells. This chimeric toxin has been
demonstrated to be effective both in vitro and in vivo against a range of cancer cell lines
(Abi-Habib et al., 2006; Rono et al., 2006). Despite the obvious importance of the uPA
PAS to more advanced breast cancer and the considerable volume of research currently
being performed, a uPA-targeted therapy is yet to be used in clinical practice.
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1.5

Rationale and Aims

The uPA PAS is functionally important in cellular invasion and metastasis, as indicated
by numerous in vitro and in vivo studies (Andreasen et al., 2000). Although increased
expression of uPA by breast cancer cells has been correlated to increased plg binding
and activation and also invasion (Holst-Hansen et al., 1996; Ranson et al., 1998), the
mechanistic link between increased cell-surface uPA and increased plg binding capacity
remains largely unresolved. Multiple proteins may be responsible for the total plg
binding capacity of a cell (see section 1.3.3 and Ranson et al., 1998) and plasmin itself
could potentially have a role in the generation of plg binding sites through limited
proteolysis of cell-surface proteins (Camacho et al., 1989; Gonzalez-Gronow et al.,
1991; Herren et al., 2001). Such a feed-forward mechanism of plg binding, which
requires increased levels of uPA to negate the inhibitory effects of PAI-1, has
previously been proposed for monocytic cells (Behrendt et al., 2003). It is plausible that
this plg binding mechanism may also function on breast cancer cells and may provide
an explanation for the increased plg binding capacity that is associated with increased
cell-surface uPA expression. Therefore, the aim of Chapter 2 was to determine a
physiologically relevant mechanism by which invasive breast cancer cells with
increased cell-surface uPA bind increased amounts of plg using a cell-based model, and
to identify candidate plg receptors that may also function in this capacity.

Increased expression of uPA and PAI-1 in the primary tumour has been correlated to
poor disease outcome in breast cancer patients and is the first biological marker to be
validated as a prognostic indicator for breast cancer in two Level 1 Evidence studies
(Duffy, 2004). PAI-2 represents an attractive targeting molecule on which to base a
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uPA-targeted therapeutic modality as it is an efficient, rapid, irreversible inhibitor of
uPA (Ellis et al., 1990), is not present at detectable levels in serum under physiological
conditions except during pregnancy (Astedt et al., 1998) and uPA:PAI-2 complexes are
rapidly internalised into cells expressing uPA at the cell surface (Al-Ejeh et al., 2004).
PAI-2 labelled with the alpha-emitting radionuclide

213

Bi (α-PAI-2), has previously

been demonstrated to have anti-metastatic potential with little associated toxicity in a
2-day post-inoculation in vivo model of breast cancer (Allen et al., 2003). Additional
characterisation of this xenogenic mouse model of breast carcinoma is required,
particularly with respect to uPA expression, to facilitate further study of the biological
effects of α-PAI-2. The aim of Chapter 4 was therefore to present a characterisation of
an orthotopic murine xenogenic model of breast carcinoma, with a focus on uPA
expression, as well as an evaluation of various parameters for the purpose of
investigating the biological effects of a uPA-targeted therapy, such as α-PAI-2.

Characterisation of the biological effects of α-PAI-2 treatment on uPA-expressing
xenogenic primary tumours in a mouse model of breast carcinoma (Chapter 4) requires
the quantification and comparison of uPA levels in detergent extracts of the tumours,
both in the absence of and following treatment. However, analysis of the biological
effects of a uPA-targeted therapy can be costly, with a commercial ELISA-based system
for the quantification of uPA in tumour homogenates costing upwards of US$390 per
assay plate. Chapter 3 describes the development of a cost-effective yet reliable ELISAbased assay to quantify uPA levels in detergent extracts of murine tumours (at reduced
cost of commercial kits), which was subsequently used to characterise the uPA levels in
a mouse model of breast carcinoma (Chapter 4).
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The overall aim of this thesis was to provide a plausible model for the link between
increased cell-surface uPA expression, increased plg binding capacity and increased
tumour cell invasiveness and to characterise a xenograft mouse model to determine its
suitability for the use in pre-clinical investigations of potential breast cancer
therapeutics that target the uPA system.
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Chapter 2: Plasminogen binding to breast cancer cells

2 CHAPTER 2: A POSSIBLE MECHANISM FOR ENHANCED PLASMINOGEN
BINDING TO THE SURFACE OF UPA-OVEREXPRESSING BREAST CANCER
CELLS

2.1

Introduction

Metastasis remains the most lethal aspect of breast cancer (Hedley et al., 2004) and the
mechanisms which facilitate this process are still poorly understood. However,
deregulation of the uPA PAS on cancer cells has been linked to this process, functioning
in both the proteolytic (e.g. ECM degradation) and non-proteolytic (e.g. intracellular
signalling) pathways that facilitate invasion and metastasis (Andreasen et al., 2000; Han
et al., 2005; Ranson and Andronicos, 2003).

The importance of uPA as a regulator of cellular plg activation is highlighted by the fact
that a) significantly higher levels of uPA/uPAR are expressed at the cell surface of
metastatic breast cancer cells in vitro, b) these cells are capable of binding larger
amounts of Glu-plg at the cell surface than non-metastatic cells (Holst-Hansen et al.,
1996; Ranson et al., 1998), and c) the combination of increased uPAR/uPA/PAI-1 is
associated with invasive breast cancer in vivo (Costantini et al., 1996). Moreover, whilst
plg displays widespread cell surface binding to a range of putative receptors (see section
1.3.3 and Ranson and Andronicos, 2003), it is the uPA co-localised fraction of plg that
is readily activated to plasmin (Andronicos and Ranson, 2001). Furthermore, a direct,
non-active site interaction between the uPA A-chain and plg has been shown to exist at
the surface of the monocytic cell line, U937 (Ellis et al., 1999) and the ATF of uPA
(Ser1-Lys135, specifically the Lys135 residue) has been shown to mediate the activation of
plg by uPA and the reciprocal activation of pro-uPA by plasmin (Sun et al., 2002).
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Accrual of active uPA may therefore be a key step in tumour invasion and metastasis by
not only controlling the levels of plg activated at the cell surface, but also by influencing
the amount of plg bound at the cell surface. This latter mechanism has not been hitherto
investigated on breast cancer cells.

The aim of this study was to investigate the plg binding mechanisms of breast cancer
cells in vitro in order to better understand the association between increased uPA
expression and increased plg binding in invasive disease. In this study, two breast
cancer cell lines were selected to characterise plg binding and activation: the “luminal
epithelial-like” MCF-7 cell line (non-invasive) and the more “mesenchymal-like”
MDA-MB-231 cell line (invasive) (Lacroix and Leclercq, 2004; Ranson et al., 1998).
Though both of epithelial origin, these cell lines represent different ends of the spectrum
with respect to expression of PAS components and invasive capacity (Table 2.1) and are
therefore good models for comparing the relative contribution of these components to
tumour progression in vitro. In direct contrast to MDA-MB-231 cells, MCF-7 cells have
typically low expression of uPA and uPAR at cell surface, display relatively little plg
binding and activation capacity and have minimal invasive activity in vitro (Andronicos
and Ranson, 2001; Holst-Hansen et al., 1996; Ranson et al., 1998). Therefore, to
directly assess the effect of increased cell surface uPA on plg binding capacity, uPA
expression on MCF-7 cells was modulated to mimic that of the invasive cell line,
MDA-MB-231. This was achieved via transient up-regulation of uPAR, which has
previously been achieved with phorbol ester treatment of this cell line (Johnson et al.,
1999; Ree et al., 1998).
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Table 2.1. Comparison of the MDA-MB-231 and MCF-7 breast cancer cell lines. Adapted from
Ranson et. al (1998) and the American Tissue Culture Collection website (www.atcc.org). Values shown
are means ± SD (n=3).
MCF-7

MDA-MB-231

Epithelial

Epithelial

Origin

Mammary gland

Mammary gland

Source

Adenocarcinoma

Adenocarcinoma

Most characteristics of a
differentiated cell

Poorly differentiated

Estrogen sensitive
(ER+)

Estrogen insensitive
(ER-)

Weakly invasive

Invasive

Cuboidal, can form domes in
a
culture

Fibroblast-like, grows in
monolayer

Low
b
10 ± 3 MFI

High
63 ± 7 MFI

Low
59 ± 8 mIU/mg

High
273 ± 14 mIU/mg

Low
8 ± 0.8 MFI

High
21.2 ± 3.6 MFI

Cell lineage

Differentiation status

Hormone receptor status
Invasive capacity (in vitro)
Structural morphology

uPAR expression
(Flow cytometry)
uPA activity assay
(Coleman and Green assay)
Lysine-dependent plasminogen
binding
(Flow cytometry)
Plasmin generation - plasmin specific
activity
(Chromogenic activity assay)

ND

c

High
110 pmol/min/mg

a. A feature of more differentiated cells.
b. Mean fluorescence intensity.
c. ND – not detectable.

Phorbols are a group of natural, plant-derived organic compounds, the esters of which
are analogues of diacylglycerol and known for their tumour promoting capabilities
(Azzi et al., 1992; Furstenberger et al., 1981; O'Neil et al., 2006). One of the most
common tumour-promoting phorbol esters used in both in vitro and in vivo studies is
phorbol-12-myristate-13-acetate (PMA, 12-O-tetradecanoylphorbol-13-acetate or TPA).
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PMA acts to increase protein kinase C (PKC) activity in the cytosol (Issandou et al.,
1986) thereby modulating the expression of a number of proteins that are regulated by
this pathway (Fig 2.1). PMA has long been used in this way in a variety of cell lines to
characterise the involvement of the PAS in processes such as cell growth, adhesion,
motility, invasion and metastasis (Table 2.2).

Evidence suggests that a positive feedback loop exists between uPA and plg activation
(Behrendt et al., 2003; Petersen et al., 1988) and that resultant plasmin activity may
facilitate increased plg binding (Camacho et al., 1989; Gonzalez-Gronow et al., 1991;
Herren et al., 2001). Pro-uPA has some minor intrinsic plg-activating activity indicating
that it may initiate this process (Behrendt et al., 2003), while pre-treatment of cells with
plasmin has been shown to increase plg binding, thus indicating a role for plasmin
proteolysis in enhancing cell-surface plg binding (Camacho et al., 1989; GonzalezGronow et al., 1991; Herren et al., 2001). Although evidence for this mechanism has
been collected using isolated neutrophils, monocytic cells and colon cancer cells and
has also been proposed to occur on other cancer cell types, it has not been demonstrated
to occur on breast cancer cells. The results within this chapter indicate that enhanced
uPA on breast cancer cell may increase cell-surface plg binding through 1) direct,
lysine-dependent plg binding via a region in the uPA A-chain and 2) enhancing plg
activation which in turn increases plasmin-dependent plg binding.
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Figure 2.1. Simplified schematic of the protein kinase C (PKC) intracellular signalling pathway.
Phorbol-12-myristate-13-acetate acts to increase PKC translocation (indicated by black arrows) in the
intracellular space thereby resulting in enhanced activation of the PKC/Raf/MEK/ERK pathway.
Green arrows indicate an activation event. Red arrows indicate a downstream effect.
ER – endoplasmic reticulum. Schematic adapted from Calbiochem PKC pathway interactive diagram
(www.calbiochem.com).
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Table 2.2. Examples of studies using PMA to modulate expression of plasminogen activation system components in human cells and cell lines.
Effect of PMA on PAS component/s
PAS Component

uPA

Experimental conditions

Cell line/s

Cell type

Reference

30 min

-

Neutrophils Polymorphonuclear
leukocytes

(Pluskota et al., 2004)

160 nM

24 h

T-47D
LLC-PK1

Epithelial (breast cancer)
Epithelial (Kidney)

(Jans et al., 1987)

Induction of mRNA

1-1000 nM
(maximal at 100 nM)

24 h

MCF-7

Epithelial (Breast cancer)

(Johnson et al., 1999)

Increased secretion

2-200 nM

4h

HUVEC

Endothelial

(Niedbala and SteinPicarella, 1993)

Increased secretion

1.6-52 nM

24-48 h

U937

Myeloid

(Genton et al., 1987)

Increased mRNA stability
and protein expression

150 nM

24 h

Beas2B

Epithelial (Lung)

(Shetty and Idell, 2004)

Induction of mRNA

1-1000 nM
(maximal at 100 nM)

24h

MCF-7

Epithelial (Breast cancer)

(Johnson et al., 1999)

Induction of mRNA

100 nM

6 or 12 h

MCF-7

Epithelial (Breast cancer)

(Ree et al., 1998)

Induction of mRNA and
protein expression

10-300 nM
(maximal at 100 nM)

1-12 h
(maximal at 12 h)

HRA

Epithelial (Ovarian cancer)

(Kobayashi et al., 2002)

Effect

PMA Concentration

Treatment Time

Increased secretion

20 nM

Increased secretion
a

uPAR
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Table 2.2. Examples of studies using PMA to modulate expression of plasminogen activation system components in human cells and cell lines continued.
Effect of PMA on PAS component/s
PAS Component

uPAR (cont.)

PAI-1

Experimental conditions

Cell line/s

Cell type

Reference

24 h

HT-1080

Fibroblast

(Dear et al., 1997)

150 nM

24-72 h

U937

Myeloid

(Picone et al., 1989)

Increased protein
expression

8.1 μM

6 or 15 min

-

Neutrophil

(Plesner et al., 1994)

Induction of mRNA

100 nM

12 h

MCF-7

Epithelial (Breast cancer)

(Ree et al., 1998)

b

100 nM

24 h

MCF-7

Epithelial (Breast cancer)

(Knudsen et al., 1994)

Induction of secretion

b

2-200 nM

4h

HUVEC

Endothelial

(Niedbala and SteinPicarella, 1993)

Induction of mRNA

100 nM

24 h

HT-1080

Fibroblast

(Dear et al., 1997)

Increased mRNA and
protein synthesis

1.6-52 nM

24-48 h

U937

Myeloid

(Genton et al., 1987)

Effect

PMA Concentration

Treatment Time

Induction of mRNA

100 nM

Increased mRNA and
protein expression

Induction of secretion

PAI-2

a. according to Ree et al. (1998), uPA mRNA was unresponsive to treatment with 100 nM PMA for 6 or 12 h.
b. according to Ree et al. (1998), PAI-1 secretion was low (< 2 ng/106 cells) and unresponsive to treatment with 100 nM PMA for 24 h.
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2.2

Materials and Methods

2.2.1

BioRad Dc Protein Assay

Samples (0 – 1:10 dilution) and BSA standards (0-2 mg/mL) (5 μL) were incubated in
duplicate in a 96-well microtitre plate with 25 μL per well Dc Protein Reagent A
(BioRad, Australia) followed by Dc Protein Reagent B (200 μL per well) for 10 min at
RT. Absorbances were recorded at 655 nm on a Spectramax 250 plate reader. Protein
concentration was determined by interpolation of the BSA standard curve using
SoftMax Pro software V4.0 (Molecular Devices, USA).

2.2.2

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)

SDS-PAGE gels were cast and run using the BioRad Mini-PROTEAN III
electrophoresis system as per the manufacturers instructions (BioRad, Australia).
Briefly, a 12% separating gel (Appendix 1) was cast in a BioRad SDS-PAGE casting
system (BioRad, Australia) and allowed to polymerise for 45 min. A 4% stacking gel
(Appendix 1) was then cast on top of the stacking gel and allowed to polymerise for
45 min. The gel was then placed into the BioRad Electrophoresis Apparatus (BioRad,
Australia) containing enough 1X SDS-PAGE Running Buffer (Appendix 1) to cover the
gel. Samples (2-10 μg) were mixed with non-reducing or reducing sample buffer
(Appendix 1), made up to a total of 25 μl in dH2O and boiled for 5 min. Boiled samples
(25 μl) and Precision Plus unstained broad range protein standard (BioRad, Australia) or
Benchmark unstained protein standard (Invitrogen, USA) (10 μl) were applied to the gel
and electrophoresed at 200 V for approximately 45 min. Following electrophoresis, the
4% stacking gel removed and discarded. To visualise proteins, gels were microwaved in
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Coomassie Blue Staining Solution (Appendix 1) for 1 min and then incubated at RT for
5 min in the hot staining solution. Staining solution was then removed and gels were
microwaved in Rapid Destain Solution (Appendix 1) for 1 min and incubated for a
further 5 min at RT. Finally, gels were incubated overnight at RT in Final Destain
Solution (Appendix 1) with rocking motion. Gels were photographed using the
Novaline Gel Documentation System (Novex, Australia) or scanned directly using a HP
Scanjet 2400 flatbed scanner and HP PrecisionScan Pro software V5.0.8 (HewlettPackard, USA).

2.2.3

Purification and Characterisation of Human Glu-Plasminogen

Fresh frozen human plasma was obtained from the Australian Red Cross Blood Service
(Sydney, Australia) under agreement numbers 02-10-008 and 04-10NSW-15 and stored
at -20oC until use. Plg was purified essentially as previously described (Deutsch and
Mertz, 1970). Lysine sepharose® 4B (GE Healthcare, UK) was re-hydrated and washed
as per the manufacturer’s instructions. Plasma was defrosted in ice-cold water and
diluted 1:2 in ice-cold dH20 containing phenylmethylsulfonyl fluoride (PMSF) and
EDTA (final concentrations: 1 mM and 5 mM respectively). PMSF was dissolved in
100% (v/v) isopropanol prior to use and the final concentration of isopropanol in the
diluted plasma was 2% (v/v). Diluted plasma was incubated on ice for 30 min to allow
precipitation of fibrinogen and other plasma components. Diluted plasma was separated
from the precipitate and incubated for 1.5 h on ice with Lysine sepharose® 4B at a ratio
of 5 mL sepharose to 45 mL diluted plasma, with gentle agitation. Lysine sepharose was
then centrifuged at 200 x g at 4oC for 2-5 min and the supernatant collected as
plg-depleted plasma. The sepharose was then resuspended in a 0.1 volume of PBS
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pH 7.4 and loaded into a 200 mL chromatography column. Chromatography was
performed at 4oC using a peristaltic pump and flow rate monitor (Econo Pump; BioRad,
Australia). The column was washed with ice-cold PBS containing 1 mM PMSF and 5
mM EDTA. Fractions (13 mL) were collected at 4oC at the rate of 0.5 mL/min and
assayed for protein content (Section 2.2.1). Washing was continued until baseline was
reached (i.e. when the protein content of the fractions was equal to that of the buffer –
typically 16 h). Proteins and DNA that were non-specifically bound to the sepharose
were removed by washing the column with ice-cold high salt buffer [0.05 M Na2HPO4,
0.5 M NaCl (pH 7.4) containing 1 mM PMSF and 5 mM EDTA]. Further 13 mL
fractions were collected at the rate of 0.5 mL/min and assayed for protein content as
above. Washing was continued until protein content again reached baseline. Plg/plasmin
was eluted by washing the column with ice-cold PBS containing 200 mM epsilon amino
caproic acid (ε-ACA) to compete lysine-dependent binding of plg/plasmin to the
column. Fractions (2.5 mL) were collected at 4oC at the rate of 0.5 mL/min and assayed
for protein content as above until baseline was reached. The lysine sepharose column
was then washed overnight with ice-cold PBS pH 7.4 to remove ε-ACA and stored at
4oC in dH2O containing 20% ethanol as a preservative.

On analysis of the protein trace, the leading peak was recovered as Glu-plg. This
fraction was dialysed against 2 x 5L PBS pH 7.4 at 4oC over 48 h to remove ε-ACA and
exchange into PBS pH 7.4 buffer. Glu-plg was then concentrated at 4oC at 2000 x g
using a Centricon® centrifugal filter unit with 50 kDa cut-off (YM-10 membrane;
Millipore, MA, USA), until the protein concentration reached 1-2 mg/mL. The
centrifugal filter unit was equilibrated with ice-cold PBS pH 7.4 prior to use. Glu-plg
was aliquoted and stored at -80oC until use.
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Purified Glu-plg was verified as relatively free from plasmin by SDS-PAGE (Section
2.2.2). To determine that the Glu-plg preparation contained negligible plasmin and was
fully activatable, samples of Glu-plg (3.3 μg) were incubated in triplicate at 37oC for 30
min in assay buffer [50 mM Tris pH 7.4 buffer containing 0.01% Tween-80 and 5 mM
tranexamic acid] containing the chromogenic plasmin substrate Spectrozyme® PL
(0.4 mM), in the absence and presence of 6.6 IU human uPA (Chemicon International,
USA). Human plasmin (0.33 IU; Roche, Switzerland) was used as a positive control and
human uPA without added plg was used as a negative control.

2.2.4

Modification of Glu-Plasminogen

2.2.4.1 FITC-labelling
Glu-plg was labelled with FITC for use in immunofluorescence assays essentially as
previously described (Goding, 1976). Briefly, purified Glu-plg in PBS pH 7.4 (Section
2.2.3) was defrosted on ice. The pH of the solution was raised to pH 9.0 to enhance
labelling efficiency by the addition of a 0.1 volume of 1 M NaHCO3 pH 9.0. Glu-plg
was incubated for 16 h at 4oC in the absence of light with a 40-molar excess of FITC
(Sigma Aldrich, USA) dissolved in dimethyl sulfoxide (DMSO) just prior to use (final
concentration of DMSO: 1-2% (v/v)). Following the labelling reaction, unbound FITC
was removed by gel filtration using a PD-10 de-salting column (Amersham Biosciences,
USA) equilibrated with ice-cold PBS pH 7.4 prior to use. FITC-plg was eluted with
ice-cold PBS while collecting 500 μL fractions. The protein content of the fractions was
determined as per Section 2.2.1. The fractions with the highest protein content were
pooled and the protein content of the pooled sample was determined as above. FITC-plg
was aliquoted and stored at -20oC in the dark until use. The absence of FITC-plasmin in
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was verified by SDS-PAGE under reducing and non-reducing conditions as per Section
2.2.2. The gel was visualized under UV light prior to Coomassie staining to determine
the success of FITC labelling.

2.2.4.2 Cy5-labelling
Human Glu-plg was labelled with the fluorescent dye, Cy5, using a Cy5 mono-reactive
dye kit (GE Healthcare, UK). Briefly, purified Glu-plg at a concentration of 1-2 mg/mL
in PBS pH 7.4 (Section 2.2.3) was defrosted on ice. The pH of the solution was raised to
pH 9.0 to enhance labelling efficiency by the addition of a 0.1 volume of 1 M NaHCO3
pH 9.0. The Glu-plg solution was then added to one vial of Cy5 mono-reactive dye and
incubated for 16 h at 4oC in the absence of light with gentle end-over-end mixing.
Unbound Cy5 was removed by gel filtration as per section 2.2.4.1. The success of
labelling and the absence of plasmin were verified by SDS-PAGE as per section 2.2.4.1.

2.2.5

PMSF Inactivation of uPA

Inactivation of purified human uPA (Chemicon International, USA) was achieved by
incubating uPA (10 μM) with PMSF (1 mM) in PBS pH 7.4 for 16 h at 4oC. PMSF was
dissolved in isopropanol just prior use (final concentration of isopropanol in incubation:
2% (v/v)). The absence of uPA activity was confirmed by a Spectrozyme UK activity
assay (Section 2.3.11). PMSF-uPA was stored at –20oC until use for up to 2 months.

62

Chapter 2: Plasminogen binding to breast cancer cells

2.2.6

Cell Culture

The human breast cancer cell lines MDA-MB-231 and MCF-7 were routinely cultured
in RPMI-1640 (Invitrogen, USA) supplemented with 5% heat-inactivated FCS
(ThermoElectron, USA). Cells were maintained at 37oC in a humidified incubator with
5% CO2:95% air atmosphere. Fresh L-glutamine (final concentration 4 mM;
Sigma-Aldrich, USA) was added to stock media monthly. Cells were typically cultured
for 48 h prior to use in assays as per the method of Ranson et al. (1998).

2.2.7

PMA Stimulation of Cell Lines

Cells were seeded at 1 x 105 cells/mL in RPMI-1640 supplemented with 5% FCS and
cultured as per Section 2.2.6 for 32 h. Phorbol-12-myristate-13-acetate (PMA;
Sigma-Aldrich, USA) was dissolved in 100% ethanol (1.6 mM) and stored at -20oC for
up to six months. Just before use, PMA stock was diluted in culture media and added to
cells to a final concentration of 100 nM (final concentration of ethanol: 0.006% (v/v)).
Unstimulated cells were incubated with vector alone at an equivalent concentration.
Cells were then incubated for a further 16 h at 37oC without change of media, bringing
the total culture time to 48 h.

2.2.8

Preparation of Cells for Assays

Cells were passaged 48 h prior to use and were cultured as per Section 2.2.6. For all
assays except confocal analysis, sub-confluent, adherent cells were rinsed with ice-cold
PBS pH 7.4 and incubated for 5 min at 37oC with 2-5 mL pre-warmed PBS pH 7.4
containing 5 mM EDTA to detach cells. Culture vessels were then gently tapped to
dislodge cells. Cells were then swamped with 10 mL assay buffer containing 1 mM
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CaCl2 and 1 mM MgCl2 to chelate with the EDTA and pelleted at 200 x g for 5 min at
4oC. Cells were then washed twice with assay buffer, centrifuging in between washes as
above. Cells were resuspended at a concentration of 1 x 106 cells/mL in assay buffer
prior to flow cytometry assays and 1 x 105 cells/mL for activity assays.

2.2.9

Flow Cytometry

Cell surface proteins were detected by immunofluorescence flow cytometry essentially
as previously described (Ranson et al., 1998). Briefly, detached cells were washed and
resuspended in freshly prepared, ice-cold binding buffer [Hanks’ balanced salt solution
containing 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2 and 0.1% BSA (pH 7.4)] as per
Section 2.2.8. For uPA or PMSF-uPA pre-treatment, cells were incubated in binding
buffer containing 50 nM uPA or PMSF-uPA for 10 min at RT or 30 min on ice. Cells
were then washed twice with binding buffer, centrifuging at 200 x g for 5 min at 4oC
between washes. Following washes, cells were incubated in binding buffer containing
10-20 µg/mL unlabelled primary antibody or isotype control antibody for 30 min on ice.
Cells were then washed twice with binding buffer as above and incubated in binding
buffer containing 1:200 diluted FITC-labelled secondary antibody on ice in the absence
of light for 30 min. Cells were then washed twice as above in ice-cold PBS pH 7.4. Just
prior to analysis, cells were resuspended in PBS pH 7.4 containing 5 µg/mL of the vital
dye propidium iodide (PI) and analysed immediately on an LSRII flow cytometer
(BD Biosciences, USA). Cell-surface-associated FITC-fluorescence (excitation: 488
nm, emission: 520 nm) was analysed by gating for viable (i.e. PI negative) cells as per
the method in Appendix 2. Specific antibody binding was calculated by subtracting
matched isotype control fluorescence from the corresponding sample. Results are

64

Chapter 2: Plasminogen binding to breast cancer cells

expressed in the text as the average mean fluorescence intensity (MFI) of the duplicates
(minus non-specific binding) ± standard error of the mean (SEM).

Cell surface Glu-plg binding was detected essentially as previously described (Ranson
et al., 1998). Briefly, cells were prepared and resuspended in freshly prepared, ice-cold
binding buffer pH 7.4 as per Section 2.2.8 and uPA or PMSF-uPA pre-treated as above.
Following washes, cells were incubated in binding buffer containing 0.5 μM
FITC-labelled Glu-plg (Section 2.3.3) for 45 min on ice in the absence of light, in the
presence and absence of 1 mM of the lysine analogue tranexamic acid (TA). Cells were
then washed twice with ice-cold PBS pH 7.4, centrifuging at 200 x g for 5 min at 4oC
between washes. Cells were resuspended in PBS pH 7.4 containing 5 µg/mL PI and
analysed immediately on an LSRII flow cytometer (BD Biosciences, USA). Cell surface
associated FITC-fluorescence was measured as above. Lysine-dependent plg binding
was calculated by subtracting MFI in the presence of TA (lysine-independent binding)
from MFI in the absence of TA (total plg binding). Results are expressed in the text as
the average MFI of the duplicates ± SEM.

2.2.10 Confocal Microscopy
Circular glass coverslips (10 mm, No. 1 thickness) were sterilized by microwave
sterilization (2 x 10 min) or by soaking in 70% (v/v) ethanol. Cells were cultured for
48 h on sterilized coverslips in 1 mL 5% FCS/RPMI-1640 at 37oC in 24-well plates.
Coverslips were washed twice with ice-cold modified binding buffer (MBB; binding
buffer without phenol red) and fixed with freshly prepared, ice-cold 3.75%
paraformaldehyde in PBS pH 7.4 for 15 min on ice. Coverslips were then washed twice
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and incubated with MBB for 30 min on ice to block non-specific interactions with the
coverslips or plate wells. Where uPA pre-incubation was required, cells were incubated
with MBB containing 50 nM uPA for 10 min at RT. Cells were then washed twice and
incubated in MBB containing 0.5 μM Cy5-labelled Glu-plg (section 2.2.4.2) in the
absence of light for 45 min on ice, in the presence and absence of 5 mM TA. Cells were
then washed twice and incubated in MBB containing 10-20 μg/ml mouse anti-uPAR
mAb (#3936), mouse anti-uPA mAb (#394) or goat anti-annexin II (C-16) pAb
(sc-1924) for 30 min on ice in the absence of light. After two washes, samples were
incubated in MBB containing a 1:50 dilution of either FITC- or Cy3-labeled goat
anti-mouse pAb or FITC-labelled rabbit anti-goat pAb

(Sigma-Aldrich, USA) for

30 min on ice in the absence of light. Finally, samples were washed three times with
ice-cold MBB, mounted and examined as previously described (Andronicos and
Ranson, 2001) using a 40x/1.00 FLUOTAR PL oil immersion objective lens on a Leica
DM IRBE confocal microscope (Leica Microsystems, Wetzlar, Germany). Cy3
fluorescence was collected sequentially after FITC and Cy5 fluorescence to prevent
recording of FITC fluorescence in the Cy3 detector channel. All images were analysed
using Confocal Assistant V4.02 (Todd Clark Brelje, University of Minnesota, 1994).

2.2.11 uPA Activity Assay
Samples were diluted in 0.1% gelatin buffer [150 mM NaCl, 20 mM Tris-HCl pH 8.4,
0.1% gelatin] in a 96-well microtitre plate. Samples were reacted with 6 mM of the
chromogenic substrate, Spectrozyme UK® (American Diagnostica Inc., USA) at 37oC
and the absorbance at 405 nm recorded at 30 sec intervals on a SpectraMax 250 plate
reader (Molecular Devices, USA) using SoftMax Pro software V4.0 (Molecular
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Devices, USA). All samples were assayed in triplicate unless otherwise stated. Wells
containing assay buffer and Spectrozyme PL only were used as a negative control and
were subtracted from all measurements. Purified human uPA (Chemicon International,
USA) was used as a positive control.

2.2.12 Plasminogen Activation Assay
2.2.12.1 Purified protein
Samples (10 μg) and plasmin standards (0-0.5 IU/mL) were prepared in assay buffer [50
mM Tris, 0.01 % Tween-80 pH 7.5] and added to a 96-well microtitre plate in triplicate.
Plasmin standards were diluted 1:2 across the assay plate into assay buffer. Wells
containing assay buffer only were used as a negative control. Assay buffer containing
0.4 mM of the plasmin-specific chromogenic substrate Spectrozyme® PL (American
Diagnostica Inc., USA) with and without 0.5 μM Glu-plg was added to all samples and
controls. Spectrozyme containing no Glu-plg was added to the plasmin standards. Plates
were then incubated for 30 min at RT. Following incubation, absorbance of the wells
were recorded at 405 nm on a SpectraMax 250 plate reader (Molecular Devices, USA)
using SoftMax Pro software (Molecular Devices, USA). All samples were assayed in
triplicate unless otherwise stated. Plasmin specific activity was determined from the
standard curve and absorbance readings were normalised to 1 using a plasmin positive
control included on each plate prior to calculations.
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2.2.12.2 Cell surface plasminogen activation
MCF-7 cells were grown, PMA-treated and pre-incubated with uPA or PMSF-uPA
(50 nM) for 10 min at RT in modified MBB (pH 7.4) as per section 2.2.9. Cells were
then washed twice and resuspended in MBB containing 0.5 μM Glu-plg in the presence
and absence of 1.6 TIU aprotinin (to measure plasmin-dependent effects). Cells were
incubated for 10 min at room temperature before addition of 0.4 μM Spectrozyme PL.
Plg activation assays were performed in the presence of 0.25 μM α2-antiplasmin to
inhibit plasmin activity in solution and to ensure that only cell-surface plasmin activity
was assayed. Cleavage of Spectrozyme PL by plasmin was measured at 405 nm at 37ºC
using a Spectramax 250 plate reader with Softmax Pro V4.0 software (Molecular
Devices, USA).

2.2.13 Statistics
A two-tailed Student’s T-test was used to compare differences in expression of PAS
components, plg binding and plg activation between control and treatment groups where
a p value of less than 0.05 was considered statistically significant (i.e. 95% level of
significance).
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2.3

Results

2.3.1

Glu-plasminogen purification and characterisation

Glu-plg was successfully purified from human plasma by lysine-Sepharose affinity
chromatography according to the method of Deutsch and Mertz (1970) (Fig. 2.2A).
Purified Glu-plg had an apparent molecular weight of 92 kDa under non-reducing
conditions and ~100 kDa under reducing conditions (Fig. 2.2B). The disparity in
molecular weight under the two conditions is likely to result from the multiple disulfide
bonds that are present within Glu-plg. Shown also in the non-reduced sample are dual
bands of Glu-plg (Fig. 2.2B, Lane 2) likely to represent the different glycoforms of plg
that have identical amino acid sequences (Castellino, 1981). Purified Glu-plg was free
of plasmin as demonstrated by SDS-PAGE (Fig. 2.2B; Lane 3), where plasmin would
be expected to yield two bands under reducing conditions with apparent molecular
weights of 25 kDa and 63 kDa (Robbins et al., 1967). The absence of plasmin was also
demonstrated by a chromogenic plasmin activity assay (Fig.2.2C). No increase in the
absorbance at 405 nm, which would indicate cleavage of the chromogenic substrate by
plasmin, was observed in the absence of uPA. However, purified Glu-plg could be
activated to plasmin in the presence of human uPA indicating that Glu-plg was intact
and functional (Fig. 2.2C).

2.3.2

Fluorescence labelling of Glu-plasminogen

Purified Glu-plg labelled with FITC or Cy5 (Fig. 2.3A) had an apparent molecular
weight of 92 kDa and 97 kDa under non-reducing and reducing conditions respectively,
in agreement with the molecular weight of Glu-plg (Fig. 2.3B). FITC-labelled Glu-plg
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Figure 2.2. Affinity purification of Glu-plasminogen from human plasma. (A) Chromatograph of
lysine-sepharose purification of Glu-plg from human plasma showing wash steps and ε-ACA elution of
plg from the column. Relative protein concentration of the fractions was determined by BioRad protein
assay at 655 nm. (B) SDS-PAGE of purified Glu-plg fractions. Lane 1 contains broad range molecular
weight marker. Gel shows purified Glu-plg under non-reducing (Lane 2,) and reducing (Lane 3)
conditions and a commercial plasminogen preparation (Sigma-Aldrich, USA) (Lane 4). (C) Plasminspecific cleavage of the chromogenic substrate, Spectrozyme® PL (0.4 mM) was measured at 405 nm in
the presence of Glu-plg (3 μg) and/or human uPA (6 IU) for 30 min at 37oC. Negligible plasmin activity
in the absence of uPA is also shown. Commercial plasmin was included as a positive control. Values are
means ± SEM (n=3).
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Figure 2.3. Labelling of Glu-plasminogen with the fluorescent tags, FITC and Cy5. (A) Example of a
protein trace of the fractions from a PD-10 gel purification of FITC-plg to remove unconjugated FITC.
Protein concentration of the fractions was determined using the BioRad Dc Protein Assay system. (B) 12%
SDS-PAGE of FITC-plg under non-reducing (NR) and reducing (R) conditions (gels 1 and 2) and of
Cy5-plg under reducing conditions (gel 3). Gel was photographed under UV illumination to show FITC
fluorescence (Gel 2), then Coomassie stained for the presence of protein and photographed again (Gel 1).
Gel 3 (Cy5-plg) was photographed prior to Coomassie staining and shows the successful labelling of
Glu-plg with Cy5 under visible light. M, BioRad unstained broad range markers.
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also displayed fluorescent bands under short-wave UV illumination corresponding to
the bands seen in the Coomassie stained gel, indicating that plg had been successfully
labelled with FITC (Fig. 2.3B). Cy5-labelled Glu-plg bands could be seen under visible
light prior to Coomassie staining of the gel (Fig. 2.3C). In addition, no bands
corresponding to the molecular weight of plasmin (23 kDa and 63 kDa) (Robbins et al.,
1967) were seen under Coomassie staining, visible light or UV illumination indicating
the absence of labelled plasmin in the protein preparations (Fig. 2.3B and C).

2.3.3

PMSF inactivation of human uPA

PMSF was used to inactivate uPA for use in assays to determine the contribution of
uPA activity to plg binding on breast cancer cells. PMSF is an irreversible inhibitor of
serine proteases which acts by sulfonating serine residues in the active site of the protein
(Gold and Fahrney, 1964). The apparent molecular weight of PMSF-uPA was
determined to be 55 kDa for the high molecular weight form and 33 kDa for the low
molecular weight form, which is consistent with the molecular weights of active uPA
(Fig. 2.4A) and indicates that neither the process of PMSF-inactivation nor the
incubation conditions caused significant degradation of the uPA molecule.

PMSF-inactivation of uPA essentially caused complete proteolytic inactivation,
resulting in a 99 ± 2% reduction in the rate of uPA activity against the chromogenic
uPA substrate, Spectrozyme® UK (Fig. 2.4B). In comparison, PAI-2 inhibition of uPA
in a 1:1 molar reaction (a positive control) also efficiently inhibited uPA activity (95 ±
0.1%) (Fig. 2.4B). Thus, inactivation of uPA activity using the serine protease inhibitor

72

Chapter 2: Plasminogen binding to breast cancer cells

A

1

kDa
250
150
100
75

2

55 kDa
33 kDa

50
37
25
20
15

B
3.0

Active uPA
PMSF-uPA
PAI-2 inhibited uPA

2.5

A405

2.0
1.5
1.0
0.5
0.0
0

100

200

300

400

500

600

700

800

900 1000 1100 1200 1300

Time (secs)

D
150
125
100
Non PMA stimulated +uPA
PMA stimulated +uPA
Non PMA stimulated +PMSF-uPA
PMA stimulated +PMSF-uPA

75
50
25
0

0

10

20

30

40

uPA/PMSF-uPA concentration (nM)

50

A405

Relative cell surface uPA (MFI)

C

0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00

Plasmin + residual PMSF solution
Plasmin only

0

5 10 15 20 25 30 35 40 45 50
Time (min)

Figure 2.4. PMSF-inactivated uPA (PMSF-uPA). (A) 12% SDS-PAGE gel of active uPA (2 μg, Lane 1)
and PMSF-uPA (2 μg; Lane 2), which display identical molecular weight profiles under non-reducing
conditions. (B) A uPA activity assay comparing active uPA, PMSF-uPA and PAI-2-inhibited uPA (133
IU/mL). Proteins were incubated with the uPA substrate, Spectrozyme® UK (0.4 μM) at 37OC. Cleavage
of Spectrozyme® UK was followed at 405 nm. (C) Cell surface binding curve of uPA and PMSF-uPA to
PMA-stimulated (i.e. cells with increased uPAR) and unstimulated MCF-7 cells showing that uPA and
PMSF-uPA display similar cell-surface binding profiles. (D) Plasmin activity assay showing that negligible
residual (free) PMSF activity remains following incubation of PMSF for 16h at 4oC. Plasmin (1.3
mIU/mL) was incubated for 10 min at RT before addition of 0.4 μM Spectrozyme PL and incubation at
37oC. Assay was performed in the absence and presence of a 1mM PMSF solution which was incubated for
16 h at 4oC (labelling conditions) prior to the assay. Cleavage of Spectrozyme PL by plasmin was followed
at 405 nm. Values shown are means ± SEM (n=2).
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PMSF represents an effective and economical method of producing proteolytically
inactive uPA. The binding curves for PMSF-uPA to PMA-stimulated MCF-7, which
have increased uPAR, were comparable to that of active uPA (p = 0.977; Fig. 2.4C).
This was also true of PMSF-uPA binding to control cells compared to active uPA
(p = 0.982; Fig. 2.4C). Therefore, PMSF-inactivation of uPA activity did not
significantly compromise its cell surface binding properties and is therefore suitable to
use as a comparative to analyse uPA activity contribution to cell surface plg binding.

Finally, due to the small amount of uPA inactivated with PMSF at any given time
(approximately 20 μL), dialysis and gel filtration were not deemed economical for the
removal of residual PMSF as both methods result in significant loss of uPA protein
during the purification process. PMSF in aqueous solution has a short half-life
(approximately 55 min at 25oC at pH 7.5, James, 1978), therefore it was hypothesised
that after 16 h incubation at 4oC during the uPA inactivation protocol very little residual
(free) PMSF activity would remain. A PMSF solution prepared as per the inactivation
protocol (without uPA present) and incubated for 16 h at 4oC, did not inhibit the activity
of the serine protease plasmin against the chromogenic substrate Spectrozyme PL
(Fig. 2.4D). This indicates that any effects seen in the presence of PMSF-uPA are due
to a reduction in the activity of uPA and not non-specific inhibition of other serine
proteases by residual PMSF.

2.3.4

Modulation of cell-surface uPA

The MCF-7 cell line is an epithelial-like cell line derived from a human mammary gland
adenocarcinoma. This non-invasive cell line typically exhibits low expression of uPAR
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and uPA at the cell-surface and also displays low plg binding and activation
characteristics in comparison to the more “mesenchymal-like” invasive breast cancer
cell line MDA-MB-231 (Ranson et al., 1998). To study the effects that differential
cell-surface uPA expression may have on plg binding and activation (and thus invasion
and metastasis), uPA on the MCF-7 cell surface was modulated in a two-step process to
mimic the higher levels seen on MDA-MB-231 cells.

2.3.4.1 PMA stimulation to enhance uPAR
PMA stimulation of both the MCF-7 and MDA-MB-231 cell lines caused marked
changes to cellular morphology (Fig. 2.5). MCF-7 cells typically have a cuboidal cell
shape and grow in “domes”, a feature of more differentiated cells in culture. However,
following PMA stimulation these cells adopted a less differentiated morphology,
appearing more flattened and fibroblast-like. PMA stimulation also caused the cells to
grow in a monolayer and display spindle-like extensions, similar to MDA-MB-231 cells
(Fig. 2.5). Conversely, MDA-MB-231 cells typically grow in a monolayer and display
spindle-like protrusions. PMA stimulation of these cells resulted in a more rounded
morphology (Fig. 2.5). In addition, a proportion of these cells detached from the culture
vessel and may represent non-viable cells. These detached cells were not used in further
analyses. The effects on morphology are most likely due to the altered expression of a
number of genes associated with the phenotypes of these cells including those related to
hormone-receptor status and cell adhesion molecules (Lacroix et al., 2004).

Treatment of the MCF-7 cell line with 100 nM PMA for 16 h repeatedly gave a
10-15-fold increase in cell-surface uPAR levels (41.4 ± 4.2 fluorescence units)
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MCF-7

Figure 2.5. Morphological changes following PMA stimulation of MCF-7 and MDA-MB-231
cells. MCF-7 and MDA-MB-231 cells were cultured for 32 h and stimulated with 100 nM PMA or
vehicle alone (unstimulated) for a further 16 h at 37oC. Micrographs of stimulated and unstimulated
MCF-7 and MDA-MB-231 showing changes in morphology following PMA stimulation. PMA
stimulation caused MCF-7 cells to adopt a more fibroblast-like morphology, similar to that of
unstimulated MDA-MB-231. Conversely, PMA stimulation of MDA-MB-231 cells caused them to
adopt a more cuboidal morphology and detach from the culture vessel. Yellow arrows indicate
spindle-like protrusions present in both MDA-MB-231 and PMA-stimulated MCF-7. White arrow
indicates a detaching and possibly non-viable cell typically present in the PMA-stimulated MDA-MB231 populations. Scale bars represent 50 μm.
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Figure 2.6. Cell-surface PAS component expression on MCF-7 following PMA stimulation. MCF-7
cells were cultured for 32 h and stimulated with 100 nM PMA (+PMA) or vehicle alone (-PMA) for a
further 16 h at 37oC. (A) Dual colour immunofluorescence flow cytometry (in the presence of 5 μg/mL
PI) of detached cells (1x105) probed with 10 μg/mL anti-uPAR mAb. Matched isotype control
fluorescence has been subtracted. (B) Immunofluorescent confocal microscopy for uPAR on PMAstimulated and unstimulated cells. (C) Detached cells (1x105) were probed separately with 10 μg/mL
anti-uPA, tPA, PAI-1 or PAI-2 antibodies or 0.5 μM FITC-plg in the absence (total binding) and presence
(lysine-independent binding) of 1 mM TA using dual colour immunofluorescence flow cytometry in the
presence of 5 μg/mL PI. Lysine (K)-dependent plg binding was calculated as total binding minus binding
in the presence of TA. For flow cytometry data, only fluorescence associated with viable cells (PInegative) was used. Values are means ± SEM (n=2). P values were calculated using Student’s t-test and
where shown indicate a significant difference.
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compared to unstimulated cells (3.4 ± 1.2 fluorescence units) (Fig. 2.6A). This
significant increase in uPAR was specifically localised to the cell surface as visualised
by immunofluorescence confocal microscopy (Fig. 2.6B) and was not accompanied by a
significant change in cell-surface uPA level (6.19 ± 2.07 vs 14.2 ± 6.1 fluorescence
units following PMA stimulation; Fig. 2.6C). Tissue plasminogen activator (tPA) levels
were low on MCF-7 (9.5 ± 0.9 fluorescence units) and were not altered by PMA
stimulation (8.3 ± 0.7 fluorescence units following PMA stimulation; Fig. 2.6C).
Cell-surface PAI-1 and PAI-2 levels were also very low (1.1 ± 0.1 and 2.0 ± 0.3
fluorescence units respectively) and did not change significantly following PMA
stimulation (0.2 ± 0.2 and 0.7 ± 0.5 fluorescence units respectively; Fig. 2.6C),
however, previous studies have demonstrated PAI-2 to be a primarily cytosolic or
secreted protein (Liew et al., 2000) and have shown that PMA induces PAI-1 secretion
into culture media in MCF-7 (Knudsen et al., 1994).

PMA stimulation of the MDA-MB-231 cell line, which already displays high cellsurface uPAR/uPA, also resulted in an increase (3-fold) to cell-surface uPAR (563 ± 28
fluorescence units) compared to unstimulated cells (170 ± 14 fluorescence units)
(Fig. 2.7). In contrast to the MCF-7 cells however, this increase in uPAR was
accompanied by a concomitant increase in uPA (139 ± 5 vs 579 ± 9 fluorescence units
following PMA stimulation) (Fig. 2.6). It is likely that this increase in cell-surface uPA
is due to increased uPA secretion as this effect has been observed in a number of other
cell lines (e.g. endothelial, epithelial, myeloid and monocytic) following PMA
stimulation (Genton et al., 1987; Jans et al., 1987; Kobayashi, 2001; Niedbala and
Stein-Picarella, 1993).
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Figure 2.7. Cell-surface expression of uPA and uPAR on MDA-MB-231 following PMA
stimulation. MDA-MB-231 cells were cultured and PMA stimulated as in Figure 2.5. Detached cells
(1x105) were probed separately with 10 μg mL-1 anti-uPAR or anti-uPA mAb using dual colour
immunofluorescence flow cytometry in the presence of 5 μg mL-1 PI. Matched isotype control
fluorescence has been subtracted. Only fluorescence associated with viable cells was used. Values are
means ± SEM (n=2). P values were calculated using a Student’s t-test and where shown indicate a
significant increase.

2.3.4.2

Exogenous uPA treatment to enhance cell-surface uPA

Significant, dose-dependent increases in cell surface uPA were achieved on PMAstimulated MCF-7 cells by the treatment of these cells with exogenous purified human
uPA (Fig. 2.8A). Saturation of the cell surface was reached at 50 nM uPA on PMAstimulated MCF-7. Cell surface uPA on unstimulated cells was also increased by uPA
pre-incubation, indicating the presence of a proportion of unoccupied uPA receptor,
however, saturation of these cells occurred at a much lower concentration of uPA
(5 nM) possibly reflecting the relatively lower number of uPA receptors at the cell
surface (Fig. 2.8A). Incubation of PMA-stimulated MCF-7 cells with 50 nM exogenous
uPA increased cell surface uPA by ~20-fold (6.19 ± 2.09 vs 121 ± 11 MFI following
PMA stimulation and uPA treatment) compared to only a 3-fold increase on
unstimulated cells incubated with 50 nM uPA (16.9 ± 1.0 following uPA treatment)
(Fig. 2.8B).
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Figure 2.8. Modulation of cell-surface uPA on PMA-stimulated MCF-7. MCF-7 cells were
cultured and PMA stimulated as in Figure 2.5. Detached cells (1 x 105) were incubated with increasing
amounts of exogenous uPA (A) or 50 nM uPA (B) for 30 min on ice. Cells were then washed and
probed for cell surface uPA by dual colour immunofluorescent flow cytometry in the presence of
5 μg/mL PI. Matched isotype control fluorescence has been subtracted from all measurements. Values
are means ± SEM (n=2) from a representative experiment. P values were calculated using a Student’s
t-test and where shown indicate a significant increase.
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2.3.5

Effect of increased uPA on lysine-dependent plasminogen binding and

activation
The lysine-dependent binding of plg to the cell surface greatly potentiates its activation
to plasmin (Markus, 1996). The levels of lysine-dependent plg binding on
MDA-MB-231 and MCF-7 cells were determined by measuring the proportion of total
plg binding that is inhibited by the lysine analogue, tranexamic acid (TA). On
MDA-MB-231, which display increased amounts of plg activation compared to
non-invasive cells (Ranson et al., 1998), lysine-dependent plg binding accounts for
approximately 83 ± 1% (n=5) of total cell surface plg binding (Fig. 2.9). In contrast, on
MCF-7 cells, which display much lower levels of plg activation than MDA-MB-231
(Ranson et al., 1998), lysine-dependent plg binding accounts for only 58 ± 3% (n=11)
of the total binding, although total plg binding on these cells was much lower than that

Cell surface plg binding (MFI)

observed on MDA-MB-231 (Fig. 2.9).
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Figure 2.9. Cell-surface lysine-dependent plasminogen binding to MCF-7 and MDA-MB-231.
MDA-MB-231 (invasive) and MCF-7 (non-invasive) breast cancer cell lines were cultured for 48 h in 5%
FCS/RPMI. Cells were detached, washed and incubated with 0.5 μM FITC-plg in the absence (-TA) and
presence (+TA) of the lysine analogue tranexamic acid (1 mM) for 30-45 min on ice. Cells were then
washed and analysed for cell surface associated FITC-fluorescence by dual-colour flow cytometry in the
presence of 5 μg/mL PI. Values shown are means ± SEM (n=2) from representative experiments.
P values were calculated using a Student’s t-test and where shown indicate a significant difference.
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Lysine-dependent plg binding to MCF-7 (unstimulated) did not significantly change
following pre-incubation with uPA or PMSF-uPA, nor did these cells show a marked
change in cell-surface uPA (Fig. 2.10A and B). Likewise, PMA stimulation of MCF-7
cells (without uPA pre-incubation) had no significant effect on cell surface uPA
(Fig. 2.10A), but did result in an almost 2-fold increase to cell surface, lysine-dependent
plg binding (18.2 ± 2.9 vs 33.2 ± 1.7 fluorescence units following PMA stimulation;
Fig. 2.10B). This may be due to either de novo synthesis of plg binding proteins or
post-translational phosphorylation events as PMA acts to increase PKC activity and
therefore alters the expression of proteins regulated by this particular pathway (Issandou
et al., 1986; Lacroix et al., 2004; Platet et al., 1998). Pre-incubation of these cells with
uPA caused a further small but significant 1.2-fold increase in plg binding (33.2 ± 1.7 vs
40.0 ± 0.2 MFI uPA pre-treatment, p = 0.03), which was not observed following preincubation with PMSF-uPA (Fig. 2.10B). Because incubation with either uPA or
PMSF-uPA substantially increased cell surface uPA to the same extent (Fig. 2.10A), it
is reasonable to assume that the enhanced plg binding observed following uPA
pre-treatment of PMA stimulated cells was most likely due to uPA proteolytic activity.
This effect is functionally relevant as PMA stimulation alone (which significantly
increased plg binding) had no effect on plg activation, whereas additional treatment of
these stimulated cells with active uPA caused a large, 15-fold increase in plasmin
generation (0.47 ± 0.05 pmol/mg/min following PMA stimulation and uPA pretreatment) (Fig. 2.10C). In addition, the plasmin generated represents activated cell
surface bound plg as solution phase plasmin was inhibited by the presence of α2antiplasmin. The small but not significant increase in plg activation observed following
pre-treatment of unstimulated cells with active uPA (0.03 ± 0.06 pmol/mg/min; p =
0.13) reflects the small increase in active cell surface uPA (refer to Fig. 2.10A).
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Figure 2.10. Lysine-dependent plasminogen binding and activation following enhancement of cellsurface uPA on MCF-7. MCF-7 cells were cultured and PMA stimulated as in Figure 2.5. Cells were
detached, washed and treated with 50 nM uPA or PMSF-uPA for 10 min at RT. (A) Cells were washed and
probed for cell-surface uPA by dual-colour immunofluorescent flow cytometry in the presence of 5 μg/mL
PI. Fluorescence in the presence of a matched isotype control was subtracted from each value. (B) Cells
were washed and analysed for cell surface FITC-plg binding (0.5 μM) in the absence and presence of the
lysine analogue TA (1 mM) by flow cytometry as above. Lysine (K)-dependent binding was calculated as
binding in the absence of TA minus binding in the presence of TA. (C) Plg activation assay. Cells were
incubated for 30 min at 37oC with the plasmin substrate Spectrozyme® PL (0.4 μM) in the presence of
Glu-plg (0.25 μM), α2-antiplasmin (0.125 μM) to inhibit solution phase plasmin, and in the presence and
absence of a 40-molar excess of aprotinin. Plasmin-specific activity was calculated as activity in the
absence of aprotinin minus activity in the presence of aprotinin. Values are means ± SEM (n=2).
*Significant difference compared to unstimulated, non-uPA treated cells (p < 0.05). **Significantly
increased compared to PMA-stimulated cells not pre-incubated with uPA (p < 0 .05).
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Therefore, without uPA catalytic activity at the cell surface, increased plg binding alone
(such as that on PMA stimulated cells) is not sufficient for increased plg activation.
Furthermore, increased lysine-dependent plg binding has been clearly linked to
increased plg activation in the presence of uPA activity (Ranson et al., 1998).
Interestingly, although PMA stimulation enhances cell surface uPA on MDA-MB-231,
pre-treatment of these cells with exogenous uPA did not further enhance cell surface
uPA on either unstimulated or PMA stimulated cells (Fig. 2.11A). Lysine-dependent plg
binding on these cells was also not significantly altered by uPA pre-treatment, PMA
stimulation (which does increase uPA) or both (Fig. 2.11B). Since these cells already
exhibit high levels of cell-surface uPA, this result may indicate that these cells already
have maximal plg binding capacity prior to any of these treatments.
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Figure 2.11. Lysine-dependent plasminogen binding following enhancement of uPA on MDA-MB231. MDA-MB-231 cells were cultured and PMA stimulated as in Figure 2.5. Cells were detached,
washed and treated with 50 nM uPA or PMSF-uPA for 10 min at RT. (A) Cells were washed and probed
for cell surface uPA by dual-colour immunofluorescent flow cytometry in the presence of 5 μg/mL PI.
Fluorescence in the presence of a matched isotype control was subtracted from each value. (B) Cells
were washed and analysed for cell surface FITC-plg binding (0.5 μM) in the absence and presence of the
lysine analogue TA (1mM) by flow cytometry as above. Lysine (K)-dependent binding was calculated
as binding in the absence of TA minus binding in the presence of TA. Values shown are means ± SEM
(n=2) from representative experiments. P values were calculated using a Student’s t-test and where
shown indicate a significant difference.
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2.3.6

Lysine-dependent plasminogen binding is partially plasmin-dependent

Since in previous experiments increased uPA activity appeared to be linked to the
ability of the MCF-7 cells to bind increased amounts of plg in a lysine-dependent
manner (section 2.3.5) and uPA is an activator of plg, the possibility that activated plg
(plasmin) was responsible for the generation of new plg binding sites was investigated.
Experiments were performed in the presence of the plasmin inhibitor aprotinin to make
a distinction between plasmin-dependent binding (total binding minus binding in the
presence of aprotinin) and plasmin-independent binding (residual binding in the
presence of aprotinin). Lysine-dependent plg binding on unstimulated MCF-7 cells,
regardless of uPA treatment, was almost entirely plasmin-dependent as very little
residual plg binding was observed in the presence of aprotinin (17.6 ± 2.9 vs 0.5 ± 2.6
in the presence of aprotinin) (Fig. 2.12A). In contrast, PMA stimulation caused an
increase in lysine-dependent plg binding which appears to be due to a corresponding
increase in plasmin-independent binding (Fig 2.12A, red bars). This increase in
plasmin-independent plg binding may be due to the de novo expression of plg binding
moieties following PMA stimulation. Increased protease-independent plg binding has
also been observed following PMA stimulation of neutrophils (Herren et al., 2001).
Furthermore, amongst the PMA stimulated cells, the additional and significant increase
in plg binding observed following exogenous active uPA treatment was entirely
plasmin-dependent as there was no corresponding increase in residual plg binding in the
presence of aprotinin (Fig. 2.12A). A similar relationship between plasmin-dependent
and plasmin-independent binding was observed on unstimulated MDA-MB-231 cells,
which already have a high capacity for plg and uPA binding and activation (Ranson et
al., 1998), where plasmin-dependent and plasmin-independent binding accounted for
approximately

64%

and

36%

of

the

total

lysine-dependent

plg

binding,
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Figure 2.12. Plasmin-dependent plasminogen binding to breast cancer cell lines. MCF-7 cells were
cultured and PMA stimulated as in Figure 2.5. (A) Cells were detached, washed and pre-treated with 50
nM uPA or PMSF-uPA for 10 min at RT. Cells were probed for lysine (K)-dependent plg binding as in
Figure 2.10 in the presence and absence of a 40-molar excess of the plasmin inhibitor, aprotinin. Figure
shows the percentage of K-dependent binding that is plasmin-dependent (lysine-dependent binding minus
binding in the presence of aprotinin) or plasmin-independent (residual binding in the presence of
aprotinin). *Significantly different compared to non-PMA stimulated cells in the presence of aprotinin
(- uPA, + aprotinin) (p < 0.05). ** Significantly different compared to PMA stimulated cells (- uPA,
- aprotinin) (p < 0.05). (B) Shows the proportion of plasmin-independent plg binding (+Ap) to the surface
of MCF-7, PMA stimulated MCF-7 and MDA-MB-231 cells. Values shown are means ± SEM (n=2) from
representative experiments
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respectively (Fig. 2.12B). Taken together, these data indicate the importance of
increased uPA-mediated proteolytic capacity for increased cell-surface plg binding and
activation, but also suggests a role for pre-formed (unprocessed) plg receptors.

2.3.7

Plasmin-independent plasminogen binding - pre-formed plasminogen

receptors
The presence of a non-active site, direct binding determinant for plg has been shown to
exist in the C-terminal region of the uPA A-chain (Gly149-Lys158) in studies using the
monocytic cell line, U937 (Ellis et al., 1999). It has also previously been shown that
uPA and plg co-localise at the surface of breast cancer cells (Andronicos and Ranson,
2001). To determine whether this uPA:plg direct binding interaction occurs at the
surface of MDA-MB-231 breast cancer cells, plg binding experiments were performed
in the presence of antibodies directed against the A- or B-chain of uPA and under
conditions that predominantly exclude proteolytic activation of plg by uPA (i.e. on ice).
A significant decrease (34%) in cell-surface lysine-dependent plg binding was observed
only in the presence of anti-uPA A-chain mAb (141 ± 3 vs 93 ± 10 MFI in the presence
of uPA A-chain mAb; p = 0.04; Fig. 2.13), indicating the presence of a plg-binding site
within this domain of uPA. This finding is consistent with that of others (Ellis et al.,
1999; Sun et al., 2002), however, it demonstrates for the first time that this interaction
exists at the breast cancer cell surface and is responsible for a proportion of total
lysine-dependent plg binding to these cells. To confirm that the A-chain uPA antibody
used did not dissociate bound uPA, thus leading to the observed decrease in plg binding,
the blocking experiments were also performed on PMA-stimulated MCF-7 cells treated
with urine-derived uPA, which lacks the C-terminal lysine on the A-chain (Lenich et al.,
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1991). Under these conditions, plg binding was not decreased in the presence of the
A-chain antibody (data not shown), which also confirms the importance of the A-chain
C-terminal lysine for plg binding. Interestingly, uPAR-transfected T-47D cells (a
non-invasive breast cancer cell line) display concomitant but small and variable
increases in endogenous uPA (1.7 ± 0.23-fold) that is coupled with small but variable
increases in plg binding capacity (1.7 ± 0.19-fold) (Al-Ejeh, 2005; Al-Ejeh et al., 2004).

Cell-durface K-dependent
plg binding (%)
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p = 0.021

100
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40
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None

A chain

B chain Non-specific
control
Antibody

Figure 2.13. uPA-dependent plasminogen binding to MDA-MB-231. MDA-MB-231 cells were
detached, washed and pre-incubated with antibodies directed against the A-chain or B-chain of uPA (10
μg/mL anti-uPA mAb #3921 and anti-uPA mAb #394, respectively). Cells pre-incubated with an
irrelevant isotype control antibody included to account for non-specific binding of mAbs to the cellsurface. Cells were then analysed for cell surface plasminogen (plg) binding in the presence and absence
of 1 mM TA using dual-colour immunofluorescence flow cytometry in the presence of 5 μg/mL PI.
Lysine (K)-dependent plg binding was calculated as binding in the absence of TA minus binding in the
presence of TA. P value indicates a significant difference. Values are means ± SEM (n=2) from a
representative experiment.

The increase in plasmin-independent plg binding following PMA stimulation of MCF-7
(section 2.3.6) suggested that pre-formed plg receptors were up-regulated in response to
PMA stimulation. In a previous study by Andronicos and Ranson (2001), actin (but not
cytokeratin 8 or annexin II) were shown to co-localise with plg on MDA-MB-231 cells.
Therefore, the expression of these candidate plg receptors and uPA was examined at the
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surface of MCF-7 cells following PMA stimulation. Cell-surface expression of uPA,
actin and cytokeratin 8 varied from relatively low to barely detectable on MCF-7 cells
(16.9 ± 1.0, 18 ± 4.1 and 1.6 ± 0.1 respectively) and were not significantly altered
following PMA stimulation of these cells (Fig. 2.14). These proteins were therefore
unlikely to be responsible for the increase in plasmin-independent plg binding that was
associated with PMA stimulation. Detection of annexin II in its monomeric and
heterotetrameric forms at the cell surface showed that both annexin II and its
heterotetramer binding partner SA100A10 (p11), were significantly up-regulated
following PMA stimulation (1.6-fold, p = 0.02 and 6.2-fold, p = 0.01 respectively;
Fig. 2.14B). However, cell surface p11 expression remained low even after PMA
stimulation (1.74 ± 0.26 MFI vs 10.73 ± 1.04 MFI following PMA stimulation) and
could not be adequately visualised by immunofluorescence confocal microscopy (data
not shown). Due to its low expression, p11 was also therefore unlikely to act as a
significant plg receptor on this cell line on either PMA-stimulated or unstimulated cells.
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Figure 2.14. Putative plasminogen receptor expression on MCF-7 following PMA stimulation.
MCF-7 cells were cultured and PMA stimulated as in Figure 2.5, washed and detached. Cells were
analysed for cell surface expression of candidate plg receptors with and without PMA stimulation by dualcolour immunofluorescence flow cytometry in the presence of 5 μg/mL PI. Matched isotype control
fluorescence has been subtracted. P values indicate a significant difference. Values are means ± SEM
(n=2) from representative experiments
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of cell-surface annexin II are high (322 ± 9 MFI), although plg did not appear to
co-localise with annexin II on either unstimulated or PMA stimulated MCF-7 cells in
the absence of uPA activity (Fig. 2.15). This is consistent with the lack of a pre-existing
C-terminal lysine in annexin II.

2.3.8

Spatial organisation of cell-surface plasminogen binding and putative

plasminogen receptors
Plg and uPA have previously been shown to co-localise at the surface of MDA-MB-231
(Andronicos and Ranson, 2001). To investigate the spatial relationship between cell
surface bound plg and putative plg receptors co-localisation experiments were
performed using tri-colour immunofluorescence staining and confocal microscopy. In
MCF-7 cells, annexin II displays punctuate cell surface staining and diffuse intracellular
staining (Fig. 2.15). Following PMA stimulation there was both a subtle increase and a
distinct re-distribution of cell surface annexin II into clustered surface puncta (Fig.
2.15). A similar initial localisation pattern and response was observed for uPA in
response to PMA stimulation and incubation with exogenous uPA compared to
unstimulated cells, reflecting the large increase in uPAR expression (Fig 2.15).
Following PMA stimulation, there also appeared to be a small but visible increase in
cell surface bound plg, which was subtle and concentrated in specific regions (Fig.
2.15). Plg binding was lysine-dependent as binding was significantly decreased in the
presence of tranexamic acid (Fig. 2.15 inset). Importantly, clear co-localisation of uPA,
annexin II and plg was observed at the surface of these cells following PMA stimulation
and exogenous uPA pre-treatment, while very little co-localisation was observed
following exogenous uPA treatment of unstimulated cells (Fig. 2.15). This indicates that
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Figure 2.15. Putative plasminogen receptor localisation on MCF-7 following PMA stimulation and
uPA pre-treatment. MCF-7 cells were cultured and PMA stimulated as in Figure 2.5. Unstimulated and
PMA stimulated cells were treated with 50 nM uPA or buffer alone for 10 min at RT and washed. Cells
were then probed for annexin II, uPA and Cy5-plg binding in the absence and presence of 5 mM TA
(inset) using tri-colour immunofluorescence confocal microscopy. White regions indicate co-localisation
of annexin II, uPA and plg, also indicated by arrows.
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where uPA activity accumulated, annexin II and plg were co-localised, suggesting that
uPA-activated plg may cleave annexin II to reveal a plg-binding site. This process has
also been proposed to occur on endothelial cells (Hajjar et al., 1994). As urine-derived
uPA was used, which precludes the direct binding of plg to uPA, these data indirectly
show that uPA, annexin II and plg can co-localise independently of an uPA A-chain:plg
interaction.
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2.4

Discussion

Mounting evidence points to uPA being an integral facilitator of breast cancer invasion
and metastasis (Andreasen et al., 1997; Duffy, 2004; Ranson and Andronicos, 2003).
Invasive breast cancer cells that display enhanced uPA expression at the cell surface
also display increased plg binding and activation, which is known to facilitate the
invasive process (Andreasen et al., 2000; Ranson et al., 1998), yet the mechanism
linking enhanced uPA and plg binding remains unresolved. Using techniques that
maintain cell viability (and hence exclude intracellular plg binding from the analyses)
the results presented herein confirm that the majority of plg binding to breast cancer
cells is regulated by plasmin activity at the cell surface. This study also shows that
regardless of the level of plg bound, active uPA must also be present at significant
levels in order for increased plg activation to occur, and confirms that a proportion of
plg binding to the cell surface is mediated via a region in the endogenous pro-uPA/uPA
A-chain. Furthermore, this study demonstrates that annexin II is present at high levels
on the surface of MCF-7 cells and co-localises with plg and active, uPAR-bound uPA.
The AIIt subunit, p11, was also detected on these cells but at very low levels and its
involvement in plg binding could not be confirmed.

The methods used herein are distinguished from previous studies in that they
specifically focus on protein expression, ligand binding and plg activation at the cell
surface. Though previous studies have characterised plasmin-mediated plg binding
using plasmin pre-treatment, incubation with high concentrations of plasmin at 37oC has
a marked effect on cell viability in vitro, causing significant increases in membrane
permeability (Andronicos, 2000). Moreover, it has previously been shown that
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non-viable cell populations bind ~100-fold more plg than viable populations, masking
changes in cell surface binding on viable cells (Ranson et al., 1998). Thus the use of
125

I-plg (which cannot distinguish between intracellular and cell surface binding) to

measure cell surface plg binding is unsuitable, as considerable artefactual contributions
of intracellular plg binding cannot be excluded. In contrast, the use of dual-colour flow
cytometry is far superior as it allows clear distinction of cell surface from intracellular
plg binding by exclusion of non-viable cells (Ranson et al., 1998). Furthermore, the use
of aprotinin in this study to indirectly quantify the contribution of plasmin activity to
plg binding removes the inherent complication of reduced viability when utilising
plasmin treatment. These modifications therefore represent significant improvements to
previous works and allow for careful characterisation of cell surface events.

The modulation of cell-surface uPA allowed its involvement in cell surface processes to
be elucidated. Increased uPA at the cell surface was indirectly achieved through
increased expression of its receptor, uPAR. Transient transfection of the MCF-7 and
T-47D breast cancer cell lines (which both display low cell-surface uPAR, uPA and plg
binding and activation) with uPAR represents an ineffective method of achieving
controlled expression of uPA, resulting in either concomitant increases in uPA (Al-Ejeh
et al., 2004) and plg binding (Al-Ejeh, 2005) or in the case of MCF-7, yielding nonreproducible results and a significant increase in cell death (Al-Ejeh, 2005). With this in
mind, PMA was chosen to transiently increase uPAR expression in the MCF-7 cell line
via stimulation of PKC activity (Johnson et al., 1999; Ree et al., 1998), since PKC
activity is also elevated in breast tumours compared to normal breast tissue (O'Brian et
al., 1989). Treatment of MCF-7 cells with PMA for extended periods increases PKC
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activity and in vitro invasiveness, whereas the opposite is observed in MDA-MB-231
cells (Platet et al., 1998). The different and opposing effects of PMA on MCF-7 and
MDA-MB-231 invasiveness have been correlated with their opposing native PKC
activities (MCF-7 = low; MDA-MB-231 = high) and estrogen receptor (ER) status
(MCF-7 is ER+; MDA-MB-231 is ER-) (Fabbro et al., 1986; Platet et al., 1998).
Following extended treatment with 100 nM PMA, Platet et al. (1998) demonstrated that
altered invasive activity and PKC activation in MCF-7 and MDA-MB-231 were
independent of de novo synthesis and most likely due to post-transcriptional
phosphorylation events, however, in a separate study PMA treatment was also shown to
markedly alter gene expression at the RNA level in both cell lines, albeit to a greater
extent in MCF-7 (435 genes in MCF-7 vs 18 genes in MDA-MB-231) (Lacroix et al.,
2004). PMA has also been shown to have differential effects on PKCα isoform
translocation in MCF-7 and T-47D cells (Kennedy et al., 1992) possibly accounting for
the extreme effect of PMA on cell viability in the T-47D population observed following
PMA treatment (data not shown). Interestingly, a recent study identified that genes
involved in proteolysis or proteolysis inhibition, including PLAUR (uPAR), MMP1,
MMP9, MMP10, and CTSD (cathepsin D), were all up-regulated by PMA in MCF-7
(Lacroix et al., 2004). Although both uPAR and uPA were significantly increased on
MDA-MB-231 following PMA stimulation, cell-surface lysine-dependent plg binding
remained unchanged. Interestingly, PKC activity is much lower in MCF-7 than
MDA-MB-231 cells (Fabbro et al., 1986; Platet et al., 1998) and the genes which are
up- or down-regulated in MCF-7 are already expressed at high and low levels
respectively in MDA-MB-231 (Lacroix et al., 2004) suggesting that PMA does not
further alter the expression of these genes greatly in MDA-MB-231.
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As a result of low endogenous pro-uPA/uPA expression and plg binding, MCF-7 cells
possess comparatively little plg activating ability and display only minimal invasive
activity (Holst-Hansen et al., 1996; Ranson et al., 1998). By enhancing uPAR levels
and precluding direct lysine-dependent binding by using urine-derived uPA, which
lacks the A-chain C-terminal lysine residue (Lenich et al., 1991), the results presented
in this chapter indicate that uPA activity regulates plg binding and activation. Pro-uPA,
though termed an “inactive” precursor, has been shown to possess some minimal
intrinsic plg activating capability (Ellis et al., 1989). From studies on monocytic and
colon cancer cell lines, a model has been proposed in which cells with significant
amounts of pro-uPA at the cell surface are able to activate bound plg, the plasmin
formed then exposes lysine residues in nearby proteins through limited proteolysis and
also activates pro-uPA to the more efficient uPA (Behrendt et al., 2003; Burtin and
Fondaneche, 1988). Plg bound via the newly exposed C-terminal lysine residues is then
activated, thus creating a positive feedback activation loop between pro-uPA/uPA and
plg/plasmin which has the potential to generate large amounts of plasmin at the cell
surface. In the current study, aprotinin inhibited a large proportion of plg binding to
both MCF-7 and MDA-MB-231 cells. Furthermore, PMSF-uPA was not able to induce
the same increase in plg binding as active uPA on PMA-stimulated MCF-7 cells. The
results herein therefore support evidence that the feed-forward mechanism of plg
binding may occur on breast cancer cells and clearly confirm that 1) plg binding is
largely dependent on uPA activity and subsequent plasmin activity and 2) plasmin plays
a key role in the generation of new plg binding sites at the cell surface.
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A number of candidate plg receptors have been identified including actin (Lind and
Smith, 1991), amphoterin (Parkkinen and Rauvala, 1991), annexin II heterotetramer
(AIIt) (Choi et al., 2001), cytokeratin 8/18 (Hembrough et al., 1996b) and α-enolase
(Andronicos et al., 1997; Miles et al., 1991) on a number of cancer cell types including
breast, yet none of these are expressed at the cell surface at levels that can solely
account for the plg binding capacity of cancer cells (104-107 sites per cell) (Felez, 1998;
Ranson and Andronicos, 2003). This suggests the presence of multiple receptors that are
responsible for the total plg binding capacity of a cell. In addition, binding of plg to the
cell surface in a lysine-dependent manner markedly increases its activation potential
(Plow et al., 1995), localises plg proximal to a plg activator and protects the plasmin
formed from inhibition by circulating inhibitors such as α2-antiplasmin and
α2-macroglobulin (Hall et al., 1991). Since cell surface plg binding is lysine-dependent,
occurring primarily via C-terminal lysine residues of cell surface proteins and is of
relatively moderate affinity (KD 0.1-2 μM) it would be expected that many proteins can
act as plg receptors (reviewed in Ranson and Andronicos, 2003). In fact, ligand binding
studies using metastatic breast cancer cell membranes show that multiple proteins are
able to bind plg (Ranson et al., 1998).

Although the nature of cell surface plg binding and activation (i.e. moderate affinity,
high capacity and lysine-dependent) suggests a general requirement for exposed lysine
residues at the cell surface, rather than the presence of a specific receptor or suite of
receptors to promote plg binding and activation, the latter interactions may still be of
importance in the initial recruitment of plg to the cell surface. The results presented
herein indicated that a significant proportion of cell-surface lysine-dependent plg
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binding to MDA-MB-231 and PMA-stimulated MCF-7 was protease-independent.
Significant expression of actin or cytokeratin 8/18 was not observed at the MCF-7 cell
surface under any condition, although these receptors have been proposed to act as
significant plg receptors on a number of cell lines (Andronicos and Ranson, 2001;
Dudani and Ganz, 1996; Gonias et al., 2001; Hembrough et al., 1996a; Hembrough et
al., 1996b; Hembrough et al., 1995; Kralovich et al., 1998; Wang et al., 2006a). Of the
candidate plg receptors analysed, only p11, a subunit of the annexin II heterotetramer
(AIIt), displayed significant differential expression associated with the increase in plg
binding following PMA stimulation of MCF-7. Studies using surface plasmon
resonance have suggested that only AIIt or isolated p11 subunit (S100A10) are able to
bind tPA, plg and plasmin with moderate affinity, primarily via the C-terminal lysine on
the p11 subunit, whilst annexin II subunit is only able to bind plasmin (Kwon et al.,
2005; MacLeod et al., 2003). Since p11 expression was increased by PMA stimulation
and has previously been shown to co-localise with uPAR (Kwon et al., 2005), it is
possible that the small, plasmin-independent increase in plg binding described above
(section 2.3.6) may have been partially mediated by the increase in p11. However, the
overall amount of p11 was small even after PMA stimulation and p11 could not be
detected by confocal microscopy. Therefore, p11 may only account for a very small
proportion of plg binding in these cells. Conversely, the results showed that MCF-7
cells express relatively high endogenous annexin II at the cell surface, which was not
present as AIIt as evidenced by the absence of significant levels of p11. Confocal
microscopy data also showed a distinct redistribution of annexin II, and a proportion
co-localised with plg and uPA/uPAR on PMA stimulated cells. An earlier study
proposed that while native annexin II does not contain a C-terminal lysine residue,
cleavage of annexin II at the Lys307 residue by plasmin-like serine protease activity may
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expose a new plg/plasmin binding site (Hajjar et al., 1994). Further studies with purified
proteins have also demonstrated enhanced tPA-mediated plg activation in the presence
of annexin II monomer (Cesarman et al., 1994), again suggesting that plg can bind to
annexin II directly. However, proteolytically processed annexin II has not been shown
to exist either in vitro or in vivo and denatured protein has been demonstrated to
stimulate plasmin formation non-specifically, thus the significance of annexin II as a plg
receptor remains contentious (Kwon et al., 2005). Interestingly, plasmin-treated actin
has also been shown to increase plg activation (Lind and Smith, 1991). Nevertheless,
the results presented here clearly show that in the presence of increased active uPA,
annexin II and plg do co-localise at the surface of MCF-7 cells, indicating the potential
for plasmin-cleaved annexin II to act as a plg receptor. In support of this theory, a recent
study by Sharma et al. (2006) also showed that annexin II expression was associated
with invasive breast cancer but not normal or hyperplastic breast tissue and that
increased expression of endogenous annexin II was associated with the more invasive
MDA-MB-231 cell line but not the MCF-7 cell line. Though the latter result contradicts
the findings herein that MCF-7 express significant amounts of cell-surface annexin II, it
should be noted that the authors did not discriminate between viable and non-viable
cells and therefore total and cell surface annexin II expression (Sharma et al., 2006).
The presence of both protease-dependent and protease-independent plg receptors on
MDA-MB-231 and modified MCF-7 cells serve to indicate that both types of receptor
contribute to the total lysine-dependent plg binding capacity on invasive cells. This
reflects the increased suite of both uPA-localised and non-co-localised plg binding sites
on more malignant cells such as MDA-MB-231 (Andronicos and Ranson, 2001), which
the PMA stimulated, uPA pre-treated MCF-7 cells mimicked.
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The evidence presented here supports the theory that the invasive capacity of breast
cancer cells is facilitated by the presence of significant levels of active uPA, which in
concert with even a moderate amount of bound plg can generate large amounts of
plasmin at the cell surface through a positive feedback mechanism (Fig. 2.16). Plg
binding and activation have been characterised at the breast cancer cell surface using
techniques that exclude artefacts derived from intracellular proteins, contributions from
non-viable cells and the C-terminal lysine on the uPA A-chain. This study shows for
first time on breast cancer cells that several mechanisms regulate plg binding, including
direct binding of plg to uPA/pro-uPA, expression of various plg binding proteins, and
plasmin-mediated generation of plg binding sites through limited proteolysis of cell
surface proteins. Critically, cells with increased uPA and a moderate increase in plg
binding displayed dramatic increases in plasmin activity. This effect was not seen in
MCF-7 cells with moderate plg binding alone but is observed in MDA-MB-231 which
have naturally high levels of uPA, plasmin generation and invasive capacity. These data
thus support the model that increased uPA expression at the cell surface substantially
increases plasmin generation, and therefore invasive potential, via a positive feedback
mechanism. To the author’s knowledge, this mechanism has not been previously
proposed for breast cancer cells. These results also strengthen the evidence implicating
uPA as a strong therapeutic target for the treatment of metastatic breast cancer.
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Figure 2.16. Proposed mechanism for increased plasminogen (plg) binding on uPA-expressing breast cancer cells.
In the presence of elevated levels of uPA, cells are able to activate more plg, which in turn cleaves nearby proteins (latent plg recetpors) to expose Cterminal lysine residues (yellow circles) and hence new plg binding sites (plg receptors). Additional plg then binds at these sites and is activated by nearby
uPA thus starting the cycle over again and leading to increased plg binding and activation at the cell surface compared to cells with little uPAR/uPA.
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3 CHAPTER 3: A NEW IMMUNOASSAY FOR THE QUANTIFICATION
UROKINASE PLASMINOGEN ACTIVATOR IN TUMOUR HOMOGENATES

3.1

OF

Introduction

Several commercial enzyme linked immunosorbent assay (ELISA) kits exist for the
quantification of uPA in plasma samples and tissue homogenates (Table 3.1). These
assays typically use a monoclonal antibody for capture and utilise several different
secondary antibodies for detection, with assay detection limits commonly ranging from
0.03-40 ng/mL. Due to the substantial number of anticipated assays required to quantify
and compare uPA levels in tumour homogenates during a pre-clinical study (Chapter 4)
and the high cost of commercial kits, the use of these kits was not considered
economical. Therefore, a cost-effective sandwich-style antigen capture ELISA was
developed to detect and quantify uPA protein in Triton X-100 tumour homogenates
(Fig. 3.1).

The aim of this study was to generate a reliable ELISA for the quantification and
comparison of uPA in tumour homogenates based on an antigen capture approach but at
reduced cost compared to commercial kits. Affinity purified goat anti-LMW-uPA pAb
#398 (American Diagnostica Inc., USA) was used as the capture antibody. This
antibody has been shown to also detect HMW-uPA and receptor-bound uPA in human
tumour tissues (American Diagnostica Inc., USA).

Detection of bound uPA from

tumour homogenates was achieved with a murine mAb directed against an epitope on
the B-chain of uPA near the catalytic site (Anti-uPA mAb #394, American Diagnostica
Inc., USA). This antibody recognises single-chain uPA, two-chain HMW uPA and
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Table 3. 1. Product specifications of a selection of commercial uPA ELISA kits (modified from Benraad et al. (1996)).
Manufacturer
(Tradename)

a

Standard

Standard range
b
c
(LDL – HDL )

Primary antibody
(capture)

Secondary Antibody
(detection)

Tertiary antibody
(detection)

Detection
method

Recognised forms
of uPA

American
Diagnostica
(Imubind® uPA)

sc-uPA

0-1 ng/mL
(0.032 - 1 ng/mL)

Monoclonal

Biotin-strepavidinHRP-labelled
monoclonal

-

TMB
450 nm

Sc-uPA
HMW-uPA
uPA-uPAR
uPA-PAI-1
uPA-PAI-2

Biopool
(TintElize® uPA)

Pro-uPA

0-4 ng/mL
(0.277 - 4 ng/mL)

Monoclonal

HRP-labelled
polyclonal

-

OPD
490 nm

Sc-uPA
HMW-uPA
LMW-uPA

Sangtec: uPA LIA

HMW uPA

0-40 ng/mL
(0.04 - 4 ng/mL)

Monoclonal

Lumin-labelled
monoclonal

-

Luminometre

Sc-uPA
HMW-uPA
uPA-uPAR
uPA-PAI-1

Technoclone TC®
uPA

uPA standard
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a. As reported in the specification sheets supplied with the product.
b. LDL – lower detection limit as defined by and reported in Benraad et al. (1996).
c. HDL – higher detection limit as defined by and reported in Benraad et al. (1996).

104

Chapter 3: In-house ELISA for uPA quantification

Wells are coated with an anti-uPA
polyclonal antibody to “capture” uPA

uPA protein present in the tumour
homogenate is “captured” by antibody
bound to the plate

Anti-uPA monoclonal antibody is
added and binds to the captured uPA

Captured uPA with bound monoclonal
antibody is detected with peroxidaselabelled anti-mouse antibody

OPD substrate is added for colourimetric
detection. uPA is quantified using the
coloured product and a uPA standard curve.

Figure 3.1. Sandwich ELISA for in-house quantification of uPA in tumour homogenates.
Schematic representation of sandwich ELISA system for the quantification of uPA protein in tumour
homogenates. The system is based on an antigen capture style-ELISA with colourimetric detection.

105

Chapter 3: In-house ELISA for uPA quantification

LMW uPA as well as receptor bound uPA. To amplify the signal, a second detection
antibody was used: peroxidase-labelled anti-mouse IgG directed against purified mouse
IgG Fab fragment. This antibody, as supplied, had also been adsorbed with human
serum proteins to ensure minimal cross-reactivity with tissue samples or cells derived
from human sources. The ELISA design has the potential to detect variants of human
uPA including HMW uPA, LMW uPA and uPA bound to its receptor.

3.2

Materials and Methods

3.2.1

Optimisation of capture antibody concentration

An ELISA was performed to determine the concentration of goat anti-human uPA pAb
that would saturate the wells of a 96-well microtitre plate. All measurements were
performed in triplicate and all incubations were performed for 1 h at 37oC unless
otherwise specified. Polystyrene 96-well titre plates were used for all ELISAs (Greiner
Bio-One, GmbH). The wells of a 96-well plate were incubated with 100 μl/well goat
anti-human uPA pAb #398 (American Diagnostica Inc., USA) diluted 1:2 across the
plate (0 – 20 µg/mL) in 0.1 M NaHCO3 pH 8.5. As a negative control, wells were
incubated with 0.1 M NaHCO3 containing no antibody. Wells were washed three times
with PiNT buffer [50 mM Na2HPO4, 150 mM NaCl (pH 7.4), 0.05% (v/v) Tween-80]
and incubated with 100 μL per well 1% (w/v) heat-denatured casein (HDC) in PiNT
buffer to block non-specific binding to the plate. To detect anti-uPA pAb bound to the
plate, wells were incubated with 100 μL peroxidase-labelled rabbit anti-goat IgG
(Calbiochem, USA) diluted 1:200 in 1% (w/v) HDC in PiNT buffer. Wells were then
washed and the relative amount of anti-uPA pAb bound to the plate was determined
through colorimetric detection by adding 100 μL freshly prepared OPD substrate
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solution [2.2 mM OPD, 0.012% (v/v) H2O2 in 8 mM Na2HPO4 pH 5.0 (solid citric
acid)] and incubating for 2 min at RT. The reaction was stopped by the addition of
100 μL per well 10 M HCl. The absorbance of the wells was then read at 490 nm on a
SpectraMax 250 plate reader (Molecular Devices, USA) using SoftMax Pro software
(Molecular Devices, USA). A binding curve was fitted using GraphPad Prism 4 V4.00
software (GraphPad software, Inc., USA).

3.2.2

Protocol for the in-house uPA ELISA

All measurements were performed in triplicate. The wells of 96-well polystyrene
microtitre plates were coated with 100 µL per well goat anti-human uPA pAb #398
(American Diagnostica Inc., USA) at 10 µg/mL in 0.1 M NaHCO3 pH 8.5 for 1h at
37oC. Wells were washed three times with wash buffer (PiNT pH 7.4) to remove excess
antibody and incubated for 1 h at 37oC with 100 µL per well of homogenate (10-50
µg/mL) or uPA standard (Chemicon International, USA) in 1% (w/v) BSA in PiNT pH
7.4. Wells were then washed three times with wash buffer. Non-specific binding sites
on the plate were blocked with 100 μL per well 3% (w/v) BSA (Sigma-Aldrich, USA)
in PiNT buffer pH 7.4 for 1-2 h at 37oC. Wells were washed three times with wash
buffer and incubated with 100 μL per well 3 µg/mL mouse anti-human uPA B-chain
mAb #394 primary antibody (American Diagnostica Inc., USA) in 1% (w/v) BSA in
PiNT pH 7.4 for 1 h at 37oC. Wells were then washed three times with wash buffer and
incubated for 1 h at 37oC with 100 μL per well 1.4 µg/mL peroxidase-labelled goat antimouse IgG (Fab-specific; adsorbed with bovine, equine and human samples)
(Sigma-Aldrich, USA) diluted in 1% BSA in PiNT. Plates were washed three times with
wash buffer and developed with 100 µL per well OPD substrate solution at 37oC for 2 h.
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Absorbance of the wells was recorded at 450 nm (Section 1.2.1). Wells incubated with
1% BSA in PiNT only (no homogenate) were used as a negative control and were
subtracted from all measurements. Wells were incubated with 1 µg/mL purified human
tc-uPA (Chemicon International, USA) in PiNT pH 7.4 were used as a positive control.
Where multiple plates were used, data were normalised to 1 using the positive control
on each plate. The lower limit of detection (LOD) for each ELISA performed was
defined as three standard deviations above the measurement of zero analyte (Benraad et
al., 1996). Data was log transformed and a Sigmoidal dose-response curve (variable
slope; default parameters) was fitted to the data using GraphPad Prism (version 4.00 for
Windows), which was also used to determine the upper limit of detection. A test for a
linear dose-response between the lower limit of detection and the upper limit of
detection was performed using a linear regression (GraphPad Prism version 4.00 for
Windows). The amount of uPA was interpolated from a standard curve of uPA and all
interpolated values were expressed as ng uPA/mg total protein added to the well.

3.2.3

Optimisation of blocking buffer

A range of commonly used blocking solutions were investigated in order to obtain the
lowest background (non-specific) readings possible. To this end, the ELISA was
performed as per Section 2.2.2 with the omission of the antigen binding and primary
mAb steps. Non-specific binding sites on the plate were blocked with one of the
following: 100 μL per well 10% (w/v) HDC (Sigma-Aldrich, USA) in PiNT buffer pH
7.4, 1% (w/v) HDC in PiNT buffer pH 7.4, 3% (w/v) BSA Fraction V (Sigma-Aldrich,
USA) in PiNT buffer pH 7.4, 1% (w/v) BSA in PiNT buffer pH 7.4, 10% (v/v) newborn
calf serum (Sigma-Aldrich, USA) in PiNT buffer pH 7.4 or 10% (v/v) rabbit serum (NZ
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white rabbit) in PiNT buffer pH 7.4 for 2 h at 37oC. Wells were then washed three times
in PiNT buffer and incubated for 1 h at 37oC with 100 μL per well 1:1000 peroxidaselabelled goat anti-mouse (H + L chain) IgG (Calbiochem, USA) in 1% BSA in PiNT.
Plates were washed three times with PiNT pH 7 and developed with OPD solution for
10 min at 37oC. The reaction was stopped by addition of 100 μL/well 10M HCl and the
absorbances were then measured at 490 nm as described (Section 3.2.1).

3.2.4

Optimisation of primary and secondary antibody concentrations

A checkerboard-style sandwich ELISA was used to optimise primary and secondary
antibody concentrations (Fig. 3.2). The protocol in section 3.2.2 was essentially
followed with the following exceptions: 1) uPA antigen was used at 1 µg/mL tc-uPA
(Chemicon International, USA). As a negative control to determine background

Figure 3.2. Checker-board ELISA to optimise concentrations of primary and secondary antibodies.
To determine optimum concentrations of primary (mouse anti-uPA mAb) and secondary (peroxidaselabelled goat anti-mouse IgG) antibodies to use to detect uPA captured by the coating antibody, a
checkerboard style ELISA was used. On a microtitre plate coated with half uPA and half buffer only,
primary antibody was first diluted across the plate (red). Unbound antibody was washed off the plate and
the secondary antibody was then diluted down the plate (blue). Excess antibody was washed off and the
amount of secondary antibody and thus the amount of uPA bound to the plate was measured using OPD
colourimetric detection. Figure shows schematic of the checkerboard setup.
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readings (noise), half the plate was incubated with 1% BSA in PiNT pH 7.4 only;
2) primary mAb (mouse anti-human uPA B-chain #394) was diluted 1:2 across the plate
into 1% BSA in PiNT pH 7.4 at a starting concentration of 10 µg/mL (100 μL per well);
and 3) secondary pAb (peroxidase-labelled goat anti-mouse IgG) was diluted 1:3 down
the plate from a starting concentration of 4.2 µg/mL in 1% BSA in PiNT pH 7.4
(100 μL per well).

3.2.5

ELISA sensitivity

To determine the detection limits of the sandwich-style ELISA, a wide range of
dilutions of purified uPA were used within the ELISA system. The protocol in section
3.2.2 was essentially followed with purified human tc-uPA diluted 1:2 down the plate
into 1% BSA in PiNT pH 7.4 (100 μL per well) from a starting concentration of
6.6 µg/mL. The sensitivity of the ELISA was also tested by comparing the amounts of
uPA protein detected in homogenates of the MDA-MB-231 (high uPA expressing) and
MCF-7 (low uPA expressing) human breast cancer cell lines. The protocol in section
3.2.2 was followed using 10-50 µg MCF-7 and MDA-MB-231 breast cancer cell
homogenate protein per well diluted in 1% BSA/PiNT.

3.2.6

Species cross-reactivity and detection of uPA variants

The cross-reactivity of the antibodies, which were raised against human uPA protein, to
murine uPA were analysed by Western blot and also using the ELISA. Western blotting
was performed as follows using buffers and transfer solutions listed in Appendix 1.
Human HMW uPA (American Diagnostica Inc., USA; 0.5 µg) and murine HMW uPA
(Molecular Innovations, USA; 0.5 µg) were separated on a 12% SDS-PAGE gel
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(section 2.2.2). Proteins were transferred to a PVDF membrane at 30 V for 16 h at 4oC.
The membrane was washed and blocked with 10% skim milk in TBST pH 8.0. Blocked
membranes were probed with a 1:200 dilution of goat anti-human uPA pAb #398
(ELISA capture antibody) in TBST containing 2% (w/v) skim milk for 2 h at RT.
Membranes were then washed and probed with 1:5000 HRP-labelled anti-goat IgG in
TBST containing 2% (w/v) skim milk (v/v) for 1.5 h at RT. Following washing for three
5 min washes with TBST and three 5 min washes with TBS, blots were incubated with
SuperSignal West Pico ECL substrate (Pierce Biotechnology, USA) for 5 min at RT and
then exposed to ECL Hyperfilm (Amersham Biosciences, USA) for periods of up to
20 min.

To determine species cross reactivity and uPA variant detection, the ELISA was
performed as per section 3.2.2 using a dilution series of: 1) human HMW uPA
(American Diagnostica Inc., USA); 2) murine HMW uPA (Molecular Innovations,
USA); 3) HMW uPA:PAI-1 complex prepared by incubation of PAI-1 (stable mutant
14-1b; Molecular Innovations, USA) with uPA at a 1:1 ratio for 30 min at 37oC;
4) HMW uPA:PAI-2 complex prepared as per PAI-1 complex using rPAI-2 (PI-2 Ltd,
Australia); 5) human tc-uPA (HMW and LMW mixture; Chemicon International, USA);
and 6) human tPA (Actilyse®, Boehringer Ingelheim, USA); all starting at 192 nM
(equivalent to 10 μg/mL HMW uPA) and diluting 1:2 down the plate. Data were
normalised to a 0.6 nM HMW uPA positive control included on each assay plate.

3.2.7

Cost and time analysis

The cost per well of a commercial uPA ELISA, i.e. Imubind® uPA (American
Diagnostica Inc., USA), was compared to that of the in-house ELISA system as at
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February 2005. Costs per well were determined for each reagent by calculating the
amount of reagent used per well and calculating the proportion of the reagent as
supplied, and therefore the cost of that proportion used in the assay. The cost per well of
the Imubind® uPA ELISA was calculated on the basis that the kit is supplied with
96 test wells. The amount of time to perform each assay was also compared.

3.2.8

Statistics

Statistics were performed as per section 2.2.13.

3.3

Results

3.3.1

Capture antibody concentration

To determine the concentration of anti-uPA polyclonal capture antibody which would
give saturation of the well in a 96-well microtitre plate, a dilution series of the antibody
was incubated in a 96-well plate and the amount of pAb bound to the plate was detected
by ELISA (Fig. 3.3). The wells of the 96-well plate showed maximal binding of the

Average A490
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Figure 3.3. Optimisation of ELISA capture antibody concentration. Goat anti-uPA pAb #398 was
coated onto wells of a 96-well plate at increasing concentration. The amount of bound antibody was then
detected by incubation with HRP-labelled secondary antibody and subsequent colourimetric detection
with OPD substrate solution. Absorbance was measured at 490 nm. Values shown are means ± SEM
(n=2) from a representative experiment.
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goat anti-uPA pAb #398 to the plate at 10 μg/ml when used at 100 μl/well with
0.1M NaHCO3 pH 8.5 as the buffer. This concentration was selected for use in the
ELISA system.

3.3.2

Blocking buffer selection

A slight non-specific binding interaction was detected between the goat anti-uPA pAb
#398 and the peroxidase-labelled goat anti-mouse IgG as evidenced by an A490 of 0.45
in the absence of uPA antigen and mouse anti-uPA mAb. In order to minimise this
binding, a range of blocking buffers were investigated. Only the 3% BSA blocking
buffer was able to significantly reduce the non-specific binding between the capture
pAb and the secondary mAb (p = 0.002) and in fact some blocking buffers increased
non-specific background (Fig. 3.4). 3% BSA (Fraction V – 96% pure) in PiNT pH 7.4

0.8
0.7
p = 0.002

Average A490

0.6
0.5
0.4
0.3
0.2
0.1
0.0

None

10% HDC 1% HDC

3% BSA

1% BSA

10% NCS 10% NRS

Blocking Agent

Figure 3.4. Optimisation of ELISA blocking buffer. Wells were coated with capture antibody (10
mg/mL goat anti-uPA pAb #398), washed and incubated with various commonly used ELISA
blocking solutions. Wells were then probed for non-specific binding of the secondary antibody peroxidase-labelled goat anti-mouse IgG - to the capture antibody. P value indicates a significant
decrease in A490 following incubation with OPD substrate for 10 min at 37oC. None - no blocking
agent; HDC - heat denatured casein; BSA - bovine serum albumin; NCS - normal calf serum; NRS normal horse serum. Values shown are means ± SEM (n=2) from a representative experiment.
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was selected for use as a blocking solution in the ELISA system for uPA quantification.
In addition, 1% BSA in PiNT pH 7.4 was selected as an antibody/sample diluent to
reduce non-specific binding at each ELISA step.

3.3.3

Primary and secondary detection antibody concentrations

To select the concentrations of primary (mouse anti-uPA monoclonal antibody #394;
American Diagnostica Inc., USA) and secondary (peroxidase-labelled goat anti-mouse
IgG A-2304; Sigma-Aldrich, USA) antibodies that give optimal detection of uPA in the
ELISA system with minimal background interference, a checker-board style ELISA was
used. The largest signal:noise ratio was achieved with a primary antibody concentration
of 3 μg/mL mouse anti-uPA B-chain mAb #394 and a secondary antibody concentration
of 1.4 μg/mL, each in 1% BSA in PiNT pH 7.4 and each with incubation times of 1 h at
37oC (Fig. 3.5). Therefore, these concentrations were selected for use in the uPA
ELISA. OPD substrate development began to plateau after 30 min, using the optimised
conditions in the ELISA system described thus far (Fig. 3.6). Therefore
30 min was selected as the optimal development time for the antibody concentrations
used.

3.3.4

ELISA sensitivity

To discover the limitations of the ELISA system (i.e. lower and upper limits of
detection), a dilution series of purified human uPA was assayed in the optimised ELISA
system. The lower LOD was defined according to the method of Benraad et al. (1996)
as the measurement obtained with no analyte (i.e. no uPA) plus three standard
deviations. The measurement of zero analyte was determined to be 0.011 absorbance
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Figure 3.5. Optimisation of ELISA primary and secondary antibody concentration. Varying
dilutions of mouse anti-human uPA primary antibody and HRP-labelled goat anti-mouse (GaM)
secondary antibody were tested against plates coated with uPA (signal) or buffer alone (noise) in a
checker-board style ELISA. Absorbance (A405) of the plate was read 30 mins after the addition of
OPD substrate. The signal to noise ratio was calculated by dividing the absorbance at 405 nm (A405) of
the well without uPA by the corresponding A405 of the well containing uPA. The combination of
primary and secondary antibody for which there is the highest signal to noise ratio gives the least
amount of non-specific absorbance.
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Figure 3.6. Optimal ELISA substrate development time. A 96-well plate was coated with 10 mg/mL
anti-uPA pAb #398. Plates were washed, blocked with 3% BSA and incubated with 0 and 100 ng/mL
purified tc-uPA. Wells were washed and incubated with 3 mg/mL anti-uPA mAb #394. Wells were
washed again and then incubated with 1.4 mg/mL HRP-labelled anti-mouse IgG. Finally, wells were
washed and incubated with freshly prepared OPD substrate solution at 37oC and the absorbance of the
wells at 495 nm was recorded at 2 min intervals. Data shown is for the wells incubated with 100 ng/mL
uPA. Absorbances of the corresponding samples containing no uPA were subtracted before graphing.
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units at 405 nm in the optimised ELISA. Using a Sigmoidal dose-response curve fit
(variable slope; r2 = 0.9777), the lower LOD corresponded to 0.23 ng/mL uPA
(Fig. 3.7A). The upper LOD, defined as the highest concentration of uPA for which the
linear relationship of the standard curve is maintained, corresponded to 3.3 μg/mL in the
optimised ELISA system (data not shown). The detection limits of the assay using
tc-uPA were therefore defined as follows: lower LOD, 0.23 ng/ml and upper LOD, 3.3
μg/ml. Over this range, there was a linear dose-response relationship between log uPA
concentration and A405 (r2 = 0.9678, p<0.0001) indicating that this range is suitable for
use as a standard curve for the determination of unknown uPA amounts in sample
homogenates. A similar commercial assay from American Diagnostica Inc., USA,
(IMUBIND® uPA ELISA Kit) had a reported lower LOD of 0.032 ng/mL and an upper
LOD of 1 ng/mL (Benraad et al., 1996) although larger limits have been reported for
kits used for the measurement of uPA in plasma (Table 3.1). The lower LOD and
detection range of the in-house ELISA were therefore comparable to that of a
commercial kit.

To determine whether the ELISA system would successfully detect uPA differences in
TX-100 homogenates, the system was tested using homogenates of the MDA-MB-231
and MCF-7 cell lines which are known to express significantly different levels of uPA
protein (Ranson and Andronicos, 1998; Fig. 3.7B). The ELISA system successfully
detected the difference in uPA level between the MDA-MB-231 and MCF-7
homogenates, which were quantified at 141.95 ± 8.56 ng uPA/mg total protein and 0.91
± 0.03 ng uPA/mg total protein, respectively (Fig. 3.7C). The level of uPA for the
MCF-7 cell line, a non-metastatic cell line, fell within the range of expected uPA level
for a non-metastatic tumour 0.02-1.22 ng uPA/mg protein (Janicke et al., 1993), while
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Figure 3.7. ELISA sensitivity. (A) The ELISA was performed with a dilution series of uPA ranging from
0-6600 ng/mL. Absorbances were read at 405 nm, after a 30 min incubation with OPD substrate solution at
37oC. Absorbance in the absence of uPA was subtracted from all data prior to analysis. Data was log
transformed before graphing (0 ng/mL concentration value was set to 2 log units below the lowest nonzero value). A Sigmoidal dose-response (variable slope) curve was fitted using GraphPad Prism 4 software
2
with default settings (r = 0.9777). Red line represents the lower limit of detection (A405 = 0.011). Error
bars represent SEM (n = 3). (B) The difference in uPA content of the MDA-MB-231 and MCF-7 cell lines
can be visualised by Western blot technique. Equal concentrations of protein from MDA-MB-231 and
MCF-7 cell homogenates were resolved on a 12% SDS-PAGE gel and transferred to PVDF membrane.
The membrane was probed for uPA using an anti-human uPA B-chain mAb. (C) The uPA content of
MDA-MB-231 and MCF-7 cell line homogenates was determined and compared using the ELISA system.
Values shown are means ± SEM (n = 3).
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the level of uPA in the metastatic cell line MDA-MB-231 was much higher than the
range for a metastatic tumour (0.13-15.17 ng uPA/mg protein). The latter is to be
expected as the MDA-MB-231 homogenate represents a homogenous population of
cells known to express large amounts of uPA, as opposed to a tumour lysate, which
would contain a proportion of non-uPA expressing cells.

3.3.5

Species cross-reactivity

The primary sample to be analysed in the in-house ELISA were homogenates of tumour
xenografts (initiated from a human cancer cell line) isolated from a murine model (see
Chapter 4). As such, the tumour homogenates may be expected to contain uPA of
human and/or murine origin (Romer et al., 1994). To determine the specificity of the
ELISA system, various uPA variants and tPA were compared including: human HMW
uPA, human HMW/LMW uPA mixture, PAI-1 and PAI-2 inhibited human HMW uPA,
human tPA and murine HMW uPA. The ELISA was able to detect all isoforms of
human uPA with comparable sensitivity including the PAI-inhibited species (Figure
3.8). Human tPA and murine uPA were not detected in the assay. Thus, a species-
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Figure 3.8. ELISA species cross-reactivity and uPA variant detection. Dilution series of equivalent
concentrations of human tPA and variants of uPA (0-192 nM) were compared in the ELISA to
determine spectrum of detection. Values are means ± S.E. (n = 3).
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specific ELISA system that can quantify human HMW tc-uPA and LMW tc-uPA and its
PAI-inhibited forms in TX-100 tissue homogenates was successfully developed.

3.3.6

Cost and time analysis

The cost per well of a commercial uPA ELISA (Imubind® uPA; American Diagnostica
Inc., USA) was compared to that of the in-house ELISA system in order to determine
the cost effectiveness of the in-house ELISA. The Imubind® uPA ELISA was found to
be nearly 8 times more expensive on a per well basis than in-house ELISA, the latter
based on the purchase of individual reagents and plates (Table 3.2). Time also being a
factor in the analysis of cost, the two ELISAs were compared for time taken to perform
each assay. The in-house ELISA was calculated to take comparatively less time to
complete, nearly 3-fold less, than the Imubind® uPA ELISA (Table 3.3), however, it is
noted that a large proportion of the time taken to complete the Imubind® uPA ELISA is
due to an overnight (16h) incubation of the standards and samples in the pre-coated
wells. The cost-time analysis comparing these two methods (Table 3.2 and 3.3)
demonstrates that the ELISA developed herein represents are more cost-effective choice
for the quantification of uPA in tumour homogenates, in a non-clinical setting.
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Table 3.2. Cost analysis of in-house uPA ELISA vs a commercial kit (Imubind® uPA, American Diagnostica Inc., USA).
a

Cost of reagent / package size

Amount used per well

Cost per well

$ 70.00 / 100

1/9600

$ 0.01

$ 573.00 / 1 mg

1 μg

$ 0.57

$ 443.03 / 100 μg

12.5 ng

$ 0.11

Mouse anti-human uPA monoclonal antibody (American
Diagnostica Inc., USA)

$ 680.00 / 1 mg

0.3 μg

$ 0.20

Peroxidase labelled-goat anti-mouse IgG (Sigma-Aldrich,
USA)

$ 209.70 / 1 ml

0.03 μl

$ 0.01

Substrate, OPD (Sigma-Aldrich, USA)

$ 32.40 / 25 mg

24 μg

$ 0.03

Coating buffer, 0.1M NaHCO3 pH 8.5

$39.50 / 250 g

840 μg

$ 0.13

$93.10 / 1 kg

710 μg

$ 0.07

$ 59.60 / 500 g

877 μg

$ 0.10

Tween-80

$ 40.10 / 500 ml

0.05 μl

< $ 0.01

Albumin from bovine serum (BSA) (Sigma-Aldrich,
USA)

$ 343.60 / 50 g

3 mg

$ 0.02

Item
96-well plate (Interpath, Australia)
Goat anti-human uPA polyclonal antibody (American
Diagnostica Inc., USA)
Purified human tc-uPA (Chemicon, USA)

Na2HPO4
Assay buffer,
PiNT pH 7.4

NaCl

Total cost per well

$ 1.26

IMUBIND® uPA
ELISA Kit

$ 935 per
96 well plate

$ 9.74

b

Detection Range (lower LOD – upper LOD)
0.2 - 3300 ng/mL
0.03 - 1 ng/mL
a. Delivery costs to the University of Wollongong, NSW, Australia were included in the pricing of each reagent or consumable. Prices were quoted as GST exclusive for both
ELISAs.
b. Lower LOD defined as 3 standard deviations in the measurement of zero analyte (Benraad et al.,1996).
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Table 3.3. Performance time comparison: in-house uPA ELISA vs a commercial kit (Imubind® uPA ELISA (American Diagnostica Inc., USA)). Steps which were
required for both protocols were not included in the analysis therefore incubation times were used as a measure of time to complete each assay.
Step

Time taken to perform step

a

In-house ELISA

Imubind® uPA ELISA Kit

0.2 h

-

Coating of wells with capture antibody (incubation time)

1h

0 h (pre-coated)

Blocking buffer incubation

1h

0h

1–2h

overnight (~16 h)

Primary detection antibody incubation

1h

1h

Enzyme conjugate incubation

1h

1h

Enzyme substrate reaction time

0.5 h

0.2 h

Total incubation time (max)

6.7 h

18.2 h

Defrosting antibodies on ice

Sample and standard incubation

a.

The following factors were not taken into account in the calculation of time as they are either required for both protocols or were buffers which could be prepared some
time ahead of the assay itself:
- buffers for the developed ELISA may be prepared once and stored
- samples and standards for both the Imubind® uPA ELISA and the developed ELISA need to be prepared in sample buffer
- 1% BSA sample buffer needs to be freshly prepared just prior to beginning both assays
- detergent must be freshly added to the wash buffer in both assays
- antibodies and enzyme conjugates must be prepared in buffer for both assays.
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3.4

Discussion

During the design of the ELISA, the antigen capture antibody (anti-uPA pAb) and the
primary detection antibody (anti-uPA B-chain mAb) were selected to maximise the
detection of the several different species of uPA. The resultant ELISA was
demonstrated to detect several variants of uPA including HMW, HMW/LMW mixtures
and also PAI-inhibited HMW uPA, albeit to a lesser extent than uncomplexed uPA.
This is in agreement with previous studies, which show the primary detection antibody
(anti-uPA B-chain mAb) to have only a 2-fold lower affinity for PAI-1-complexed uPA
compared to uncomplexed uPA (Petersen et al., 2001). The lack of detection of tPA also
makes the assay highly specific for uPA. The detection of the variants of human uPA
makes this assay comparable to commercially available ELISAs for uPA quantification
(see Table 3.1). It was not, however, determined whether pro-uPA (sc-uPA) could be
detected in this assay system. Because the ELISA was to be used to detect differences in
uPA in tumours from a xenograft mouse model treated with a uPA-targeted therapy
based on PAI-2, it was not considered crucial that the ELISA detect pro-uPA, which has
a low rate of association with PAI-1 (Lijnen et al., 1994; Manchanda and Schwartz,
1995) and is only minimally inhibited by PAI-2 when associated with the cell surface in
non-SDS-stable complexes (Schwartz, 1994).

The lower LOD for the uPA ELISA system was determined to be 0.23 ng/mL using tcuPA. The lower LOD, as defined by Benraad et al. (1996), of 5 commercial assays and
1 well-characterised ELISA developed by the Finsen laboratory (Copenhagen,
Denmark) were determined to range from 0.002 to 0.384 ng/mL according to an
independent workshop organised within the framework of the Receptor and Biomarker
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Study Group of the EORTC and a consortium of the BIOMED-1 programme ‘Clinical
Relevance of Proteases in Tumour Invasion and Metastasis’ (Benraad et al., 1996).
While the lower LOD value of the ELISA system is deemed high according to this
study (> 0.2 ng/mL), the ELISA is to be used for comparative studies rather than
absolute determinations of uPA concentration. The ELISA also displays a much larger
detection range of up to 3300 ng/mL compared to the commercial assays, which have
upper detection limits of between 0.3 and 40 ng/mL. Although the smaller detection
limits (upper and lower) of the commercial assays allow for greater sensitivity and the
use of smaller volumes of test sample, this was not anticipated to be necessary for the
animal studies as tumour homogenates regularly yielded 40-80 mg of total protein per
gram of tumour tissue. Furthermore, a significant linear relationship (r2 = 0.9678;
p<0.0001) was observed in the dose-response curve indicating that the relationship
holds over the 0.2 – 3300 ng/mL range. A cost (time and monetary) analysis of the
developed ELISA as compared to the commercial Imubind® uPA ELISA (American
Diagnostica Inc., USA) also indicated that the developed ELISA was more costeffective in that it was significantly cheaper to perform than the commercial assay and
took less time to complete.

Species cross-reactivity studies indicated that murine uPA was not detected in the
ELISA system. It has been reported that uPA in a tumour is often expressed by host
stromal cells (Romer et al., 2004) therefore it can be expected that at least a proportion
of uPA in xenograft tumour homogenate from a murine model will be of murine origin.
In fact, this has proven to be the case with our xenograft mouse model (Stutchbury et
al., 2007) and that of others (Frandsen et al., 2001). Since the experimental therapeutic
compound is based on human PAI-2, which has been shown to interact and inhibit the
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activity of purified murine uPA (see Chapter 4), it can be assumed that the murine uPA
is targeted and therefore a reduction in tumour murine uPA levels may be seen (see
Chapter 4). However, given the species specificity of the ELISA these changes will not
be detected in this system. To overcome this shortcoming, activity assays (which do not
exhibit species specificity; see Chapter 4) could also be performed using the tumour
homogenates. The species specificity of the ELISA for human uPA would in fact allow
indirect inferences about the contribution of stromal (murine) uPA to the tumour
progression to be made when used in conjunction with a uPA activity assay.

High uPA levels have been correlated with poor disease-free and overall survival in
axillary node-negative patients (Duffy and Duggan, 2004) and a number of
experimental therapies targeting uPA with several different approaches have been
developed (Schmitt et al., 2000). In order to characterise the biological effects of a uPAtargeted therapy (e.g. 213Bi-PAI-2) in a murine model of breast cancer (see Chapter 4), a
cost-effective method of quantifying changes to the levels of uPA in the tumours was
required. The sandwich-style uPA ELISA developed here provides a relatively quick,
cost-effective and sensitive method to quantify and compare human uPA protein levels
in homogenates of tumour xenografts and is an acceptable alternative to the costly
commercial kits on offer for research in a non-clinical setting.
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4 CHAPTER 4: CHARACTERISATION OF A MURINE ORTHOTOPIC XENOGRAFT
MODEL OF HUMAN BREAST CARCINOMA FOR THE EVALUATION OF AN
ANTI-UPA TARGETED THERAPY

4.1

Introduction

Currently, treatment of Stage I-III breast cancer can be achieved with relatively high
success (more than 90% chance of survival over a 5-year period) utilising surgery and
adjuvant chemo-, hormone or radio-therapy (National Breast Cancer Foundation
Factsheet, 2006). However, the treatment success of Stage IV (metastatic) breast cancer
remains relatively low, with only a 20% chance of survival over a 5-year period
(Greenberg et al., 1996; National Breast Cancer Foundation Factsheet, 2006). Research
into targeted therapies for cancer, i.e. those that target a specific molecules that have a
role in tumour growth or progression, is expanding as knowledge about the molecular
characteristics of cancer grows (Green, 2004; Sawyers, 2004; Segota and Bukowski,
2004). The targeted nature of these therapies offer an advantage over conventional
chemotherapies, which are less specific, and offer the promise of decreased side effects
in the patient with increased selective potency toward tumour cells. Therapeutics that
target uPA/uPAR show potential for success particularly for the treatment of metastatic
breast cancer, where these molecules have already been linked to poor prognosis
(Costantini et al., 1996; Duffy and Duggan, 2004; Foekens et al., 1994; Han et al.,
2005; Harbeck et al., 2002a; Harbeck et al., 2002b; Harbeck et al., 2004b; Janicke et
al., 2001; Janicke et al., 1993; Look et al., 2002; Schmitt et al., 1991). Experimental
therapeutic strategies that target uPA/uPAR include: antisense oligonucleotides derived
from uPA, uPAR or PAI-1, antisense oligonucleotides to signalling pathway
components which regulate uPA expression, viral vectors for components of the PAS,
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soluble ruPAR to scavenge uPA, monoclonal antibodies directed against uPA to block
activity or uPA/uPAR interaction, inactive uPA to compete with active uPA for
interaction with uPAR, uPA-derived peptides to block uPA/uPAR interaction, large and
small molecule inhibitors of uPA activity (both naturally occurring and synthetic) and
toxins coupled to PAI-1, PAI-2, uPA or uPA derivatives (see Table 4.1 and Allen et al.,
2001; Muehlenweg et al., 2001; Reuning et al., 2003; Romer et al., 2004; Schmitt et al.,
2000; Sidenius and Blasi, 2003).

A promising uPA-targeted therapeutic strategy is α-PAI-2, which is composed of PAI-2
linked to an alpha emitting radionuclide such as 213Bi. PAI-2 is a serpin which displays
specific, rapid and irreversible inhibition of uPA (Al-Ejeh et al., 2004; Ellis et al.,
1990). PAI-2 represents an attractive targeting molecule for cells expressing high levels
of uPA as PAI-2 is non-toxic and circulating levels of PAI-2 in serum are very low
except during pregnancy (Astedt et al., 1998; Stegnar et al., 1993). Although PAI-2 has
also been associated with cell types such as fibroblasts and macrophages, and is also
found in gingival crevicular fluid (see review by Kruithof et al. (1995)), the majority of
PAI-2 remains intracellular and only approximately 20% of PAI-2 is secreted (Ny and
Mikus, 1997). In addition, PAI-2:uPA complexes are highly stable and are maintained
through the formation of a covalent bond in a classic serpin action (Huntington et al.,
2000). These complexes are rapidly cleared from the cell surface into lysosomes and
endosomes where PAI-2 and uPA are presumably degraded (Al-Ejeh et al., 2004). The
endocytic mechanism of PAI-2:uPA internalisation suggests that labelled PAI-2 could
be 1) rapidly delivered into the target cells; 2) removed from circulation; and 3)
degraded. Bi-213, an alpha (α) emitting radionuclide, represents an attractive cytotoxic
agent

with

which

to

label

PAI-2

in

that

it

has

a

high

energy
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Table 4.1. Examples of promising uPA/uPAR-targeted cancer therapies in pre-clinical and clinical investigations.
Name

Class of therapy and description

Target

Evidence

References

Å6
(Angstrom
Pharmaceuticals
Inc., USA)

uPAR antagonist
(uPA-derived peptide, residues 136-143;
Ac-KPSSPPEE-amide)

uPAR

Phase I clinical trials of efficacy, toxicology and pharmacokinetics in
ovarian cancer. Currently in Phase II clinical trials for ovarian cancer.
Phase I study in healthy men. In vivo studies in monkey of macular
degeneration. In vitro and in vivo efficacy studies in mouse model of
prostate cancer. Is anti-angiogenic compound.

(Berkenblit et al., 2005;
Boyd et al., 2003; Koh
et al., 2006; van
Troostenburg et al.,
2004)

DTAT

uPAR antagonist with cytotoxin
(catalytic portion of diphtheria toxin
(DT(390)), a linker, and the downstream
135-ATF portion of uPA)

uPAR

In vitro cytotoxicity studies with glioblastoma cell lines and HUVECs. In
vivo efficacy and toxicology studies in mouse model of glioblastoma.

(Rustamzadeh et al.,
2007; Vallera et al.,
2002)

PrAgU2/FP59

uPA-activatable cytotoxin
(recombinant anthrax toxin with a uPA
activation site)

Anthrax toxin
receptor/uPA/
uPARexpressing cells

In vitro studies on cell lines including non-small cell lung cancer,
pancreatic cancer, and basal-like breast cancer cell lines. In vivo efficacy
and toxicity murine studies.

(Abi-Habib et al., 2006;
Liu et al., 2003; Liu et
al., 2001; Rono et al.,
2006; Su et al., 2007)

UK122

uPA-specific inhibitor
(4-oxazolidinone analogue)

uPA

In vitro studies with pancreatic cell lines. Non-cytotoxic, potential antiinvasion/anti-metastatic therapeutic.

(Zhu et al., 2007)

WX-360 and
WX-360-Nle

Small synthetic cyclic uPA-derived
peptides

uPAR

In vivo studies in mouse model of ovarian cancer.

(Sato et al., 2002)

WXC-340

uPA inhibitor

uPA

In vivo mouse models of LPS- and surgery-induced, metastatic tumour
growth (colorectal cancer). In vitro invasion assays with murine colorectal
cancer cells.

(Killeen et al., 2007)

WX-UK1 (i.v.)/
WX-671 (oral)
(Wilex AG,
Germany)

Small molecule serine protease inhibitor
(3-amidinophenylalanine-derivative)

uPA and other
serine proteases

Currently in Phase I clinical trial - indicated for breast, gastric, pancreas,
ovarian and colorectal cancer as an anti-metastatic, non-cytotoxic agent In
vitro invasion assays with squamous cell carcinoma of the head and neck,
breast and ovarian cancer cell lines. In vivo efficacy studies in rat breast
cancer model.

(Ertongur et al., 2004;
Setyono-Han et al.,
2005; Wilex AG,
2007a; Wilex AG,
2007b)
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(8.4 MeV), a short linear path length (60 μm) thereby sparing nearby healthy tissue
from irradiation, and a short half life (45 min) allowing rapid action while not remaining
in the body in “active” state for long periods of time (Ma et al., 2001; McDevitt et al.,
1999). This radionuclide has previously been shown to be an effective cytotoxic agent
against a number of cancers in in vitro and pre-clinical targeted immunotherapy studies
(Friesen et al., 2007; McDevitt et al., 2000; Milenic et al., 2004).

213

Bi-labelled PAI-2

(α-PAI-2) produced by the method of Ranson et al. (2002) displays a high labelling
efficiency and label stability. Previous studies have demonstrated that this novel
therapeutic can kill uPA-expressing cells in vitro in a dose-dependent manner (Li et al.,
2002; Ranson et al., 2002) and is efficacious in preliminary nude mouse models of
breast and prostate cancer (Allen et al., 2003; Li et al., 2002). Furthermore, radioiodinated PAI-2 has been shown to localise in uPA-expressing tumours in a xenograft
mouse model of human colorectal cancer (Hang et al., 1998) providing proof-ofprinciple that α-PAI-2 can indeed target uPA-expressing tumours. Since the
pharmacokinetic and biodistribution properties of PAI-2 in mice have already been
obtained (Hang et al., 1998), the efficacy and toxicology of this potential therapeutic
must now be investigated in a relevant animal model in order for α-PAI-2 to progress to
Phase I clinical trials for breast cancer (Kelland, 2004).

Murine models of cancer, particularly xenograft models, must be thoroughly
characterised when used to examine the toxicity and efficacy of human therapeutics.
This is particularly important as the interaction of targeting agents against murine
targets may differ in both efficacy and toxicity from that of the human targets and
xenograft tumours often lack the heterogeneity of de novo human cancers. Several
authors suggest that the minimum characterisation of a tumour model should include an
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analysis of tumour initiation, progression and metastasis, the frequency and stability of
tumour development, and any distinct pathological features of the mouse strain
including strain specific variations (Cespedes et al., 2006; Kelland, 2004; Olive and
Tuveson, 2006; Rosenberg and Bortner, 1998). In addition, the model should also be
shown to possess molecular characteristics representative of the tumour type. To the
authors knowledge, the MDA-MB-231 orthotopic xenograft model of breast cancer in
Arc:Arc(s) nude mice has not previously been characterised to this extent. Therefore the
focus of the work presented in this chapter was 1) the characterisation of an orthotopic
murine xenograft model of breast cancer with respect to the above criteria and
assessment of its suitability as a model for testing α-PAI-2 and 2) the biological
justification of α-PAI-2 as a therapeutic modality using the orthotopic model of human
breast cancer.

4.2

Methods

4.2.1

Ethics Approval

All animal studies were approved by the Animal Ethics Committee (University of
Wollongong, NSW, Australia) (approval no. AE01/21 and AE02/11) and performed in
accordance with the NHMRC Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (6th [1997] and 7th [2004] Editions).

4.2.2

Animals

Mice used for the xenograft models were female, outbred Arc:Arc(s) nu/nu (Swiss
nude) mice (Animal Resources Centre, Canning Vale, WA, Australia). These mice are
albino,

athymic

mice

that

are

T-cell

deficient.

Because

these

mice

are
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immunocompromised they can tolerate and support xenografted human cells and tissue.
On arrival mice were housed and allowed one week to settle. During this time, mice
were handled daily to minimise stress during the subsequent treatment period. Mice
were maintained under quarantine procedures and housed under positive pressure in
isolated ventilator cabinets in autoclaved filter-top cages. Mice were fed a diet of
autoclaved feeder pellets and sterilised water.

4.2.3

Orthotopic Tumour Xenografts

MDA-MB-231 human breast carcinoma cells were maintained in 5% HI FCS/RPMI at
37oC in a humidified 5% CO2:95% air atmosphere. Cells used for xenografting were
maintained for no more than 5 passages after thawing. Cells were harvested under
sterile conditions 48 h post-seeding using sterile and endotoxin-free buffers and
reagents. Briefly, cells were rinsed with Dulbecco’s Phosphate Buffered Saline (PBS)
without CaCl2 or MgCl2 (Sigma-Aldrich, MO, USA) prepared in water (Sigma-Aldrich,
MO, USA) and detached with pre-warmed 5 mM EDTA in Dulbecco’s PBS for 5 min at
37oC. Cells were then washed once with Dulbecco’s PBS containing 1 mM CaCl2 and 1
mM MgCl2 and pelleted at 200 x g for 5 min at RT. Cells were resuspended at 10 x 106
cells/mL in Dulbecco’s PBS and 100 μL of the cell suspension (1 x 106 cells) was
injected bilaterally into the anterior-most mammary fat pads (orthotopic injection). The
site of injection was massaged gently afterward. Mice were monitored for 1 hr post
injection and then daily after that. Resultant tumours were coded as follows: Experiment
number, cohort (A-C [treatments] to D [controls]), tumour side (L [left] or R [right]),
for example 10DL is a tumour from Experiment 10, from a mouse in cohort D, on the
left hand side. In vivo tumours were measured at the longest point using Vernier
callipers.
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4.2.4

α-PAI-2 Administration and Treatment Schedules

α-PAI-2 labelling was performed by Drs. Tamantha Stutchbury and Fares Al-Ejeh as
described (Stutchbury et al., 2007). Mice were given a single intraperitoneal (i.p.)
injection of α-PAI-2 in HI/citrate/PBS buffer at either 1 or 4.5 weeks post-implantation
with tumour cells as per the dose and treatment schedules in Table 4.2. A multiple dose
schedule was also used, however, as similar results were obtained as for the single dose
schedule the results will not be discussed. Control mice were injected i.p. with an
equivalent volume of HI/citrate/PBS buffer. As [125I]-PAI-2 biodistribution is similar
following i.p., intravenous (i.v.) or subcutaneous (s.c.) administration (Hang et al.,
1998), i.p. is therefore a suitable route for administration of α-PAI-2. The radioactivity
of each injection was measured before and following injection using an Atomlab 100
Dose Calibrator (Protronic Technologies, VIC, Australia). Measured doses were
corrected for the Bi-213/Au-198 calibration factor as previously described (Allen et al.,
2005). The actual dose received by each mouse in mCi/kg was calculated based on the
total dose delivered and mouse weight at injection.
Table 4.2. α-PAI-2 treatment schedules of xenograft-bearing nude mice.
Treatment model

Chronic

Acute

10

8

Mouse age at cell line implantation

5-6 weeks

3-5 weeks

Time from implantation to α-PAI-2
treatment (tumour establishment)

1 week (early)

4.5 weeks (late)

24.0 ± 0.6 mCi/kg x 1 day
or
34.8 ± 0.3 mCi/kg x 1 day

15 ± 0.3 mCi/kg x 1 day

Number of mice per cohort

α-PAI-2 dose schedule

Endpoint
Total experimental period
(post-tumour cell implantation)

a

15 mm tumour diameter
(range: 34-74 days post-treatment)
41-82 days

3 days post-treatment

a

35 days

a. In addition to endpoints common to each experiment including distressed behaviour (i.e. hunched
posture, reduced activity, loss of appetite), ≥ 15% weight loss, impediment of movement or end of
observation period.
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4.2.5

Mouse sacrifice and Tumour Processing

Mice were sacrificed by CO2 asphyxiation at experimental endpoints, which included a
tumour diameter of 15 mm at the longest point (chronic model) or 3 days post-treatment
(acute model), distressed behaviour (i.e. hunched posture, reduced activity, loss of
appetite), ≥ 15% weight loss, impediment of movement or end of observation period.
Major internal organs (e.g. lungs, liver, spleen and kidneys) were weighed and inspected
macroscopically at dissection for colour changes and obvious signs of metastases such
as visible nodules and palpable lumps. After recording any observations these organs
were discarded. The left and right axillary lymph nodes of each mouse were located,
excised and rinsed in isotonic solution (8.5 g/L NaCl) then placed in 10% neutral
buffered formalin and fixed for 24h. Tumours were excised from the body cavity and
rinsed in cold, freshly prepared and sterile-filtered PBS pH 7.4. Tumour volume (mm3)
was calculated as per the method of Stutchbury et al. (2007) as follows:
Diameter (mm) at the longest point x Diameter (mm) at the smallest point
2

2

In the chronic model, tumours were halved, with one half placed in 10% neutralbuffered formalin for 24 h to fix for histological analysis while the other half was stored
in sterile PBS pH 7.4 on ice, drained and snap-frozen in liquid nitrogen within 1 h then
stored at –80oC until homogenisation. In the acute model, tumours were too small to cut
in half thus some were randomly selected for fixation and others for homogenisation.
After dissection, mice were disposed of as per University of Wollongong Animal House
Procedures.
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4.2.6

Histochemistry

Tumours and lymph nodes fixed in neutral-buffered formalin (see section 4.2.5) were
dehydrated in a series of increasing alcohol baths. These were then placed into paraffin
wax (halved tumours were placed cut side down) and allowed to set. Alternatively,
these tasks were performed by the Veterinary Pathology Diagnostic Services Unit
(University of New South Wales, Australia). In addition, this unit was responsible for
the production of all 4 µm sections of the paraffin-embedded tumours and lymph nodes,
which were sectioned onto silane-coated microscope slides and dried overnight at 37oC.
This unit was also responsible for hematoxylin and eosin (H&E) staining of all sections.

For immunohistochemistry, tissue slides were individually labelled and de-waxed in
SlideBriteTM clearing agent (S & S Company of Georgia, GA, USA) for 2 x 5 min.
Slides were then re-hydrated in a decreasing alcohol series: 100% ethanol for 2 x 2 min,
95% ethanol for 1 min, 70% ethanol for 1 min and finally rinsed for 1 min in dH2O. All
slides were incubated in their respective antigen retrieval solution (Table 4.3) for 20 min
in a boiling water bath. Slides were then cooled in antigen retrieval solution in a cold
water bath for 15 min. Slides were then rinsed with dH2O for 1 min to remove all traces
of antigen retrieval solution.
Table 4.3. Antigen retrieval solutions used prior to immunoperoxidase staining.
Antigen

Antigen retrieval solution

Human uPA

High pH Target Retrieval Solution
(DakoCytomation, USA)

Murine uPA

Tris-EDTA buffer
10 mM Tris, 1 mM EDTA (pH 9.0)

EMA

Tris-EDTA buffer
10 mM Tris, 1 mM EDTA (pH 9.0)
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Immunoperoxidase staining of uPA and epithelial membrane antigen (EMA) was
performed using either an autostainer (Dako® Autostainer, DakoCytomation, USA) or
manually using the Shandon Sequenza Slide System with Coverplate™ Technology
(Thermo Corporation, USA) (Table 4.4). Following staining, slides were counterstained
with Mayer’s Hematoxylin Solution (Sigma-Aldrich, USA) for 2-3 min. Slides were
then rinsed in cold tap water for 1 min to remove excess hematoxylin and then
incubated in hot tap water for 10 sec as a blueing agent. Stained tissue sections were
then dehydrated for mounting by incubating slides in 70% ethanol for 1 min, 95%
ethanol for 1 min, 100% ethanol for 2 x 2 min and finally SlideBriteTM clearing agent (S
& S Company of Georgia, USA) for 2 x 5 min. Slides were coverslipped using
BriteMount™ mounting solution (S & S Company of Georgia, GA, USA) and air-dried
for at least 2 h in a fume hood.

Immunostained slides were scored based as per the method of Yang et al. (2000): 0, no
stained cells or very weak diffuse staining; 1+, focal, weak staining; 2+, strong staining
of 25% of cells or moderate staining of <80% of cells; 3+, strong staining in 25-50% of
cells or moderate staining of >80% of cells; 4+, strong staining of >50% of cells. Slides
were blind scored by a minimum of two independent scorers without knowledge of the
stains used. Scores above 1+ were considered positive. Staining present in negative
controls, of necrotic tissue, on the edges of the tissue and around tears in the tissue was
considered as non-specific staining and was disregarded while scoring. The DAKO
Herceptest Manual for Interpretation (DAKO, 2002) was used as a general guideline for
the analysis of IHC sections including the recognition of artefact from true staining.
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Table 4.4. Immunoperoxidase staining protocols. All incubations and washes were carried out at room temperature.
ANTIGEN
Human uPA

Murine uPA

EMA

Method

Autostainer

Manual

Manual

Wash buffer

TBS solution containing 0.05% Tween 20,
pH 7.6 (DakoCytomation, USA)

PBS solution containing 0.05% Tween 20,
pH 7.2

PBS solution containing 0.05% Tween 20,
pH 7.2

Diluent

Background reducing antibody diluent
(DakoCytomation, USA)

PBS pH 7.2

PBS pH 7.2

Staining protocol
Endogenous biotin
block

3% H2O2
5 min

Performed after primary antibody incubation
(step 6).

Performed after primary antibody incubation
(step 6).

Wash

2x

2x

2x

Protein block

10% normal horse serum
(Vector Labs, USA)
10 min

1.5% normal horse serum
(Vector Laboratories, USA)
30 min

1.5% normal horse serum
(Vector Laboratories, USA)
30 min

Primary antibody
incubation

7.5 µg/mL Mouse anti-human uPA B-chain
mAb #394
(American Diagnostica Inc., USA)
45 min

10 μg/mL Rabbit anti-mouse uPA pAb
ASMUPA-GF
(Molecular Innovations, USA)
1h

4.8 μg/mL Mouse anti-EMA monoclonal
antibody M0613
(DakoCytomation, USA)
60 min

Negative control: mouse IgG1 negative control
(DakoCytomation, USA)

Negative control: rabbit IgG
(Sigma-Aldrich, USA)

Negative control: mouse IgG1 isotype control
antibody
(Centre for Animal Biotechnology, Australia)
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Table 4.4. Immunoperoxidase staining protocols continued.
ANTIGEN
Human uPA

Murine uPA

EMA

Wash

2x

2x

2x

Endogenous biotin
block

-

3% H2O2
10 min

3% H2O2
10 min

Wash

-

2x

2x

Secondary antibody

1:200 Biotinylated horse anti-mouse IgG
PK4002 (Vector Laboratories, USA)
30 min

1:200 Biotinylated goat anti-rabbit IgG
BA-1000 (Vector Laboratories, USA)
30 min

1:200 Biotinylated horse anti-mouse IgG
PK4002 (Vector Laboratories, USA)
30 min

Wash

2x

2x

2x

Immunoperoxidase
reagent

Vector ABC reagent PK4002
(Vector Laboratories, USA)
Prepared according to manufacturers
instructions
30 min

Vector ABC reagent PK4002
(Vector Laboratories, USA)
Prepared according to manufacturers
instructions
30 min

Vector ABC reagent PK4002
(Vector Laboratories, USA)
Prepared according to manufacturers
instructions
30 min

Wash

2x

2x

2x

Peroxidase substrate

Dako® Liquid DAB+ Substrate Chromogen
System Kit (DakoCytomation, USA)
5 min

Dako® Liquid DAB+ Substrate Chromogen
System Kit (DakoCytomation, USA)
5 min

Dako® Liquid DAB+ Substrate Chromogen
System Kit (DakoCytomation, USA)
5 min

Wash

3x with dH2O

3x with dH2O

3x with dH2O
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4.2.7

ELISA and Activity Assays

Excised tumours that had been snap-frozen and stored at -80oC were defrosted on ice,
blotted briefly and weighed to obtain wet weight. Tumours were homogenised into
10 mL/g tumour weight ice-cold homogenisation buffer (10 mM Tris, 0.15 M NaCl pH
7.4 containing 1% (v/v) Triton X-100) using a Dounce Homogeniser on ice (30 passes).
Tumour homogenates were incubated on ice for 30 min to allow solubilisation of cell
membranes and then centrifuged at 1000 x g for 10 min at 4oC to remove cell debris.
The supernatant was removed and centrifuged again at 1000 x g for 10 min at 4oC. The
lipid layer was then removed and discarded. The remaining supernatant (tumour
homogenate) was removed, aliquoted on ice into pre-chilled 1.5 mL microtubes and
stored at -80oC until use. No protease inhibitors were used in the homogenisation
buffers due to the potential to inhibit components of the PAS in future activity assays.
An aliquot of isolated homogenate (tumour ID 8B3L) was tested for degradation of uPA
following homogenisation, storage and thawing and verified as showing no observable
signs of degradation using a western blot technique.

The amount of uPA in the tumour homogenates was quantified using the in-house uPA
ELISA (section 3.2.2). Direct measurement of the uPA activity of the homogenates was
not possible as the salt content of the homogenates frequently caused precipitation of
the uPA chromogenic substrate. Therefore, uPA activity (by indirect measurement) and
plg activation (by direct measurement) were both determined using the Spectrozyme PL
assay (American Diagnostica Inc., USA). Briefly, tumour homogenates (10-100 μg total
protein/well) were incubated with Glu-plg (0.5 μM; section 2.3.2) and Spectrozyme PL
(0.4 mM) for 2 h at 37oC. Colour development was followed at 405 nm using a
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SpectraMax 250 plate reader (Molecular Devices, USA) with SoftMax Pro software
(Molecular Devices, USA). To determine uPA activity, plg activation in the presence of
0.5 mM uPA inhibitor (Glu-Gly-Arg-chloromethylketone; Calbiochem, USA) was also
measured and subtracted from all samples to give uPA-specific plg activation. This step
was not performed for determination of plg activation potential. Standard curves for
uPA activity were constructed using purified human high molecular weight uPA
(American Diagnostica Inc., USA) (0 – 5 IU/mL). Standard curves for plg activation
were constructed using purified human plasmin (Roche, USA) (0 – 0.5 mIU/mL) in the
absence of Glu-plg. Human uPA was used as a positive control on each plate and as a
reference to allow normalisation of the plate readings. Wells containing no homogenate
were used a negative control on each plate and were subtracted from all measurements.
Data were log transformed prior to interpolation on the standard curve using GraphPad
V4.00 (GraphPad, USA). UPA activity and plasmin activation potential were calculated
in mIU/mg total protein based on values of homogenates interpolated from the standard
curve and the total amount of protein added to each well (see Appendix 3).

4.2.8

Statistics

A two-tailed Student’s T-test was used to determine the significance of the differences
in uPA content, uPA activity and plg activation potential between control and treatment
groups. A Spearman non-parametric rank correlation (rs) was used to determine the
strength of the association between uPA and other continuous variables. Overall
survival probabilities (defined as days to reach ≤ 15mm) were calculated using the
method of Kaplan and Meier (Kaplan and Meier, 1958). Survival curves were compared
using a log-rank test. Relative hazard ratios (RHRs) were calculated and given with
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95% confidence intervals (CIs). For all statistical analyses, a two-sided P value below
0.05 was considered statistically significant (i.e. 95% level of significance). Statistical
tests were performed using GraphPad V4.00 software.

4.3

Results

4.3.1

Characterisation of an orthotopic xenograft mouse model of invasive

breast carcinoma
4.3.1.1 Tumour induction and growth
Initial studies to monitor tumour growth characteristics were performed using a cohort
of 13 mice, which were not subjected to any treatment other than cell line implantation.
In addition, 3 mice were injected with PBS only to monitor for spontaneous tumour
formation or artefacts of the implantation process. In 2/3 mice implanted bilaterally with
an MDA-MB-231 cell suspension into the anterior-most mammary fat pads (orthotopic
implantation), one or more palpable tumours per mouse were detected as early as 3 days
post-implantation, while the greatest number of mice presenting with palpable tumours
(5/13 mice) occurred at 5 days post-implantation (Fig. 4.1A). In one animal, tumours
did not become palpable until day 28, although tumours may have been present but not
yet palpable prior to this time, while 2/13 mice did not develop tumours over the 35-day
experimental period. Control mice injected with PBS buffer alone did not develop
spontaneous tumours or adverse reactions to the injections over the 35-day experimental
period. At the conclusion of the experimental period, tumours had formed in majority of
mice implanted with cancer cells (11/13 mice) (Fig 4.1B). This indicates that bilateral
implantation results in a high hit rate (at least one tumour) in nude mice using the

140

Chapter 4: Xenograft Mouse Model Characterisation

A
Initial detection of tumour/s
(# of mice/day)

6
5
4
3
2
1
0

0

1

2

3

4

5

6

7 14 21 28 31 33 35 37

Days post-implantation

C

Tumour hit rate
(Cumulative % of tumours/
total no. of injection sites)

Tumour induction
(Cumulative % of mice
bearing ≥ 1 tumours)

B

100
90
80
70
60
50
40
30
20
10
0

100
90
80
70
60
50
40
30
20
10
0

0

1

2

3

4

5 6
Day

7

14 21 28 35

0

1

2

3

4

5

7

14 21 28 35

6

Day

Figure 4.1. Tumour induction rate of MDA-MB-231 xenografts. Arc(s) nude mice (n=13) were
inoculated bilaterally with MDA-MB-231 cells (1 x 106) in 100 μl PBS into the anterior-most
mammary fat pads. Mice were monitored for the presence of palpable tumours over the experimental
period (35 days). (A) Graph showing the number of mice presenting with one or more palpable tumours
per day. Mice with one palpable tumour were not re-counted on occurrence of a second tumour. (B)
Graph showing the cumulative percentage of mice with one or more palpable tumours over the
experimental period. Mice with one palpable tumour were not re-counted on occurrence of a second
tumour. (C) Graph showing the cumulative percentage of implantations which developed into palpable
tumours over the experimental period. Maximal tumour induction and hit rate were achieved at 28 days
post implantation.
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MDA-MB-231 cell line. The efficacy of tumour induction per injection site was 70%
with 18 tumours formed from a total of 26 injection sites over the 35-day period (Fig.
4.1C). This suggests that although implantation with cancer cells will not necessarily
result in a tumour mass at each inoculation site in this mouse strain within the
experimental timeframe, inoculation at 2 sites will most likely ensure at least one
tumour per animal. Furthermore, as only 2/13 mice did not develop tumours this
suggests that this method is effective in generating xenograft tumours using this cell
line.

In a separate cohort (n=10) with a longer experimental period (up to 74 days), tumours
were palpable 6 days post-implantation on average (Fig. 4.2A). Tumours reached 5 mm
in diameter (at the longest point) between 19 and 49 days (mean 34 ± 4 days) and the
experimental endpoint of 15 mm between 29 and 70 days (mean 47 ± 5 days). The
tumours exhibited a mean doubling time of 9.8 ± 0.9 days (Fig 4.2A). Within this cohort
there appeared to be a propensity to develop only one tumour even though mice were
implanted with cancer cells at two sites (Fig. 4.2B). This may be due to the increased
energy requirements of any single tumour which prevents establishment of a second
tumour mass, as in a separate study mice injected with MDA-MB-231 cells in an
identical manner and in the same strain of mouse (n = 10) but at only one site, a 100%
hit rate was observed for the development of tumours from implanted cells (K. Vine,
personal communication). In this study, there did not appear to be a preference for
tumour development to either the left or right mammary fat pad following bilateral
implantation (Fig. 4.2C).
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Figure 4.2. Tumour growth rate and take pattern of MDA-MB-231 xenografts. Arc(s) nude mice
were injected bilaterally into the anterior-most pair of mammary fat pads with 1x106 MDA-MB-231
cells in 100 μL PBS. (A) Average tumour diameter over the experimental period measured at the
longest point is shown for each tumour. Averages were calculated at each timepoint including zero
growth for tumours which eventually developed but excluding tumours from mice from the time of
sacrifice due to tumour endpoint being reached (≥ 15 mm diameter), therefore n varied from 1 to 9.
Error bars indicate SEM. (B) Number of mice bearing 0, 1 or 2 tumours at end of experimental period
(74 days). (C) Number of mice with tumour mass present in either the left or right MFP (mammary fat
pad) by the end of the experimental period (74 days).
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There was a significant association between increased tumour size and tumour necrosis
(Correlation coefficient [rs] = 0.82, p = 0.006) (Fig. 4.3A). The necrotic centres in larger
tumours, particularly those that grew to 15 mm in diameter, were typically localised to
the centre of the tumour mass (Fig. 4.3B). This is likely to be related to the decreased
nutrient availability to the tumour at this location and in this respect, the larger
xenograft tumours mimicked solid human tumours (Minchinton and Tannock, 2006). In
addition, the smaller tumours appeared to be less dense in tumour cells, were more
interspersed with stromal matter and were more highly vascularised (Fig. 4.3C). The
necrotic centres inherent of the larger xenogenic tumours can make determinations of
the necrotic/apoptotic power of a trial therapeutic difficult to assess and this should be
taken into consideration when designing such experiments.

4.3.1.2

Local invasion and metastasis

The MDA-MB-231 cell line is derived from the metastatic pleural effusion of a
mammary gland adenocarcinoma (Cailleau et al., 1978) and has been demonstrated to
be highly invasive in both in vitro and in vivo assays (Ranson et al., 1998). The tumours
formed following orthotopic implantation of these cells into nude mice maintained this
invasive characteristic, spreading into surrounding muscle tissue and sometimes
glandular tissue, which was apparent 5 weeks post-implantation (Fig. 4.4). Tumours
were often interspersed with stromal cells, which in the absence of mature Tlymphocytes are most likely macrophages (Dirkx et al., 2006), which can comprise
more than 50% of a solid tumour mass (Leek et al., 1996). Infiltration of a solid tumour
by immune cells is often seen in invasive tumours in both humans and mice (Bucana et
al., 1992; Dirkx et al., 2006; Normann, 1985; Ohtani, 2007; Vukanovic and Isaacs,
1995).
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Figure 4.3. Variation in
tumour characteristics with
increasing tumour volume.
Arc(s) nude mice were
injected bilaterally into the
anterior-most
pair
of
mammary fat pads with 1x106
MDA-MB-231
cells.
Tumours were removed at
various
timepoints
at
dissection. 4 μm sections of
the tumours were H&E
stained. (A) Tumour size and
area
of
necrosis
are
correlated. Sections were
evaluated under low power
magnification (40x) for the
proportion of necrotic tissue
present in each tumour. Twotailed P value and Spearman
correlation coefficient (rs) are
shown. (B) Large tumours
(for example this tumour
measuring
723
mm3)
exhibited necrotic centres (N),
were densely packed with
tumour cells (T) and often did
not have a clear border,
invading into surrounding
tissue such as muscle (M).
(C) In contrast, smaller
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connective tissue (CT) also
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Figure 4.4. Invasive characteristics of MDA-MB-231 xenograft tumours after 5 weeks of growth.
Tumours were sectioned (4 μm) and H&E stained. (A) Tumour tissue often showed infiltration (I) of
tumour cells (T) into surrounding normal muscle tissue (M). Stromal cells were also present at regions
of invasion, and were most likely immune cells. This tumour was approximately 118 mm3 at
dissection. (B) In some cases tumours invaded into nearby glandular tissue (G). This tumour was
approximately 170 mm3 at dissection. Invasion into adjacent healthy tissue indicates that these
tumours are highly invasive. Photos were taken of 2 separate tumours at 400x magnification.
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Organs were macroscopically evaluated for metastases at dissection. Some of the
common human organs that display breast cancer metastases include lungs, liver, bone,
pancreas, spleen and kidneys (Weigelt et al., 2005). Evaluation of these organs, except
bone, did not detect the presence of obvious metastases, which would have been
expected to manifest as discolouration, small lesions or palpable lumps within or on the
organ (Welch, 1997). Average kidney weights were within the normal range (Table 4.5)
whether sacrificed 5 weeks post-implantation (early tumours), or up to 12 weeks postimplantation (later tumours). Average liver weights were approximately 1.5 times
greater than that of a non-immunocompromised female mouse of comparable age in
both models (p < 0.0001; Table 4.5). In mice sacrificed after 41-82 days of tumour
growth, the spleen weight was also nearly 3 times greater than that of a nonimmunocompromised female mouse (p < 0.0001; Table 4.5).
Table 4.5. Phenotypic properties of the orthotopic xenograft mouse model. Female Arc(s) mice were
implanted bilaterally with MDA-MB-231 cells (1x106 cells/site x 2 sites) at the anterior-most mammary
fat pads to form human xenograft tumours. Organs were removed, weighed and macroscopically analysed
at dissection. *Significantly increased compared to corresponding organ from a nonimmunocompromised female outbred laboratory mice of comparable age.
1

“Normal” mouse

Later tumour
model

“Normal” mouse

8-10 weeks

10 weeks

12 – 17 weeks

18 weeks

35 days

NA

41-82 days

NA

1.65 ± 0.15*

1.12 ± 0.09

1.82 ± 0.19*

1.40 ± 0.15

Kidney

0.37 ± 0.05
(combined)

0.18 ± 0.02 (R)/
0.17 ± 0.02 (L)

0.41 ± 0.05
(combined)

0.22 ± 0.03 (R)/
0.21 ± 0.03 (L)

Spleen

0.11 ± 0.05

0.10 ± 0.02

0.36 ± 0.12*

0.13 ± 0.03

8

10

10

10

Mouse age at
dissection
Tumour growth
period
Organ weight (g)
(mean ± SD)
Liver

n

1

Early tumour
model

2

Macroscopic
None
NA
None
NA
evidence of
metastases
1. Data for Japanese outbred ICR and ddY laboratory mice (female) of comparable age from Takamasa
et al. (2001). ICR and ddY strains are often used for toxicological and pharmacological studies.
2. Not applicable.
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4.3.1.3 Axillary lymph node involvement
Axillary lymph node involvement (regional invasion) is associated with a poor
prognosis in breast cancer (Carter et al., 1989; Rosen et al., 1989; Weigelt et al., 2005).
In mice implanted bilaterally with MDA-MB-231 cells, 80% of mice displayed one or
more enlarged axillary lymph nodes (Table 4.5; Fig. 4.5A), with approximately 67% of
mice having both lymph nodes enlarged. Enlarged axillary lymph nodes typically
displayed sinus histiocytosis (Fig. 4.5B), an expansion of the medullary sinus
histiocytes (macrophages) that is characteristic of lymph nodes with an adjacent
metastatic cancer or infection (Asano et al., 2003). This lymph node morphology may
progress to sinus catarrh (Hartveit, 1982), the latter being associated with metastasis in
breast cancer patients (Hartveit, 1982; Thoresen et al., 1983; Urdiales-Viedma et al.,
1986). The large cysts which were present on some of the enlarged lymph nodes did not
contain any cells and were therefore not likely to be metastases but rather an artefact of
the nude mouse phenotype (Sainte-Marie and Peng, 1983). Lymph nodes were also
stained for the presence of epithelial membrane antigen (EMA), a generic protein found
on most cell types of normal and neoplastic epithelial origin, which would show the
presence of micrometastases of the MDA-MB-231 cells. This antibody does not react
with lymphoid tissue with the exception of B lymphocytes (Cordell et al., 1985). Faint
diffuse staining of B lymphocytes could be seen in sections of the lymph node but the
intensity of other stained cells was much greater (Fig. 4.6). In addition, isotype control
staining of the lymph node sections gave weak, diffuse staining but no evidence of
strong focal staining, indicating that this type of stronger staining observed in the EMA
stained sections was not due to artefactual binding of the murine monoclonal antibody
by lymphoid cells (Fig 4.6). Definite positive staining for EMA (> 1+ score) was
observed

in

axillary
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nodes

from

4/9

mice
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and

was
148

Chapter 4: Xenograft Mouse Model Characterisation

A

B
1

2

3

4
S
S

Figure 4.5. Axillary lymph node
morphology in the xenograft mouse
model. Arc(s) nude mice were injected
bilaterally into the anterior-most pair of
mammary fat pads with 1x106 MDA-MB231 cells in 100 μL PBS. Mice were
euthanised when tumours were ≥ 15 mm
in diameter at the longest point. Lymph
nodes were excised at dissection.
(A) Gross morphology. Lymph nodes
shown are representative of the typical
morphologies observed at dissection.
These included normal (1), enlarged (2),
enlarged with fluid filled cysts indicated
by a yellow arrow (3) and very large and
distorted with multiple fluid filled cysts
(4). The white arrow indicates fatty tissue
attached to the lymph node. Enlarged
lymph nodes typically displayed a more
translucent character compared to normal
sized lymph nodes. Scale bar represents
5 mm. (B-D) H&E staining of 4 μm
sections of normal sized and enlarged
lymph nodes. Shown is the medullary
cortex of (B) a normal sized lymph node,
(C) an enlarged lymph node and (D)
enlarged lymph node with cyst. The
normal and enlarged nodes show both Blymphocytes and histiocytes in the sinus
where as the enlarged lymph node with
cysts shows histiocytosis. M – medullary
cords,
S
–
medullary
sinus,
CY – cystic region. Scale bar represents
100 μm.
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Figure 4.6. Micrometastases
of tumour cells to the axillary
lymph nodes. Lymph nodes
were removed at dissection
when tumours reached ≥15 mm
in diameter. Axillary lymph
nodes were formalin-fixed,
paraffin-embedded
and
sectioned (4 μm). (A) Sections
were stained for epithelial
membrane antigen, which is
specific to epithelial cells. The
majority of positive staining
was localised in the sinuses (S)
and not in the medullary cords
(MC), which is composed
primarily of B-lymphocytes
(which stain weakly, indicated
by arrows) and macrophages.
Micrometastases of MDA-MB231 cells (M) stain highly
positive for EMA. (B) A
sequential section was H&E
stained to allow visualisation of
positively stained cell types.
(C) Weak, diffuse non-specific
staining of a lymph node tissue.
(D) Cytospin of MDA-MB-231
cells showing strong positive
cytoplasmic staining for EMA.
Photos
taken
at
600x
magnification.

MC

C

D

150

Chapter 4: Xenograft Mouse Model Characterisation

generally localised to the sinuses of the axillary lymph nodes. This staining pattern is
strongly suggestive of the positively stained cells being micrometastases, as this effect
has been observed in several cancers including breast cancer (Morgagni et al., 2001;
Mukai et al., 2004).

4.3.1.4 Distribution of uPA in xenograft tumours
The

distribution

of

both

human

and

murine

uPA

were

analysed

by

immunohistochemistry (IHC). Tumours xenografts expressed both human and murine
uPA, indicating that uPA was secreted by both tumour and stromal cells, respectively
(Fig. 4.7). The antibody used to detect human uPA did not react with murine uPA as
confirmed by Western blotting (Fig 4.8) and ELISA (section 3.3.5), therefore it was
likely that only human uPA, presumably secreted by the tumour cells, was detected
when this antibody was used for IHC. Human uPA was apparent in some of the tumour
tissue sections ranging from weak (1+) to intense staining (3+) and was localised to the
membrane and cytoplasm of the tumour cells (Fig. 4.7A). In contrast, the antibody used
to detect murine uPA was somewhat cross-reactive with human uPA (Fig. 4.8),
therefore the uPA detected using this antibody could be either human (tumour) or
murine (stromal) in origin. The majority of tumours, however, appeared to express
mainly stromal cell associated uPA (Fig. 4.7B), which is consistent with evidence that
suggests that this is an important source of tumour uPA in both human cancer and
mouse models of human cancer (Frandsen et al., 2001; Nielsen et al., 1996; Romer et
al., 1994; Tetu et al., 1999).
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Figure 4.7. Localisation of uPA in xenograft tumours. Tumours were removed when they reached
≥15 mm in diameter at the longest point. (A) Human uPA is expressed mainly in the membrane and
cytoplasm of the tumour cells (T). (B) Murine uPA is localised in the cytoplasm of stromal cells (S).
Tumour cells may also appear positive for murine uPA due to cross-reactivity of the antibody used
with human uPA. Tissues were counterstained with hematoxylin to allow visualisation of cell nuclei.
Insets – negative controls showing weak, diffuse, non-specific staining. Photos taken at 600x
magnification.
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2 min exposure

Anti-murine uPA pAb

Figure 4.8. Species cross-reactivity of anti-uPA antibodies used for immunostaining. Western blots
of human uPA (huPA; 0.5 μg) and murine uPA (muPA; 0.5 μg) fractionated by 12% SDS-PAGE under
non-reducing conditions. The same blot was sequentially probed with either (A) murine anti-human
uPA mAb for 20 min or (B) rabbit anti-murine uPA pAb for 5 sec or 2 min. The blot was stripped and
extensively washed prior to re-probing. Blots show species cross-reactivity for the anti-murine uPA
antibody but not for the anti-human uPA antibody.

153

Chapter 4: Xenograft Mouse Model Characterisation

4.3.1.5 uPA levels in tumour homogenates
Quantification of uPA in the tumour homogenates was performed using an ELISA
system developed in-house (see Chapter 3). The assay used only detects human uPA
and not murine uPA or human tPA (see section 3.3.5), thus the quantification of uPA
shown here represents uPA produced by the tumour cells and not stromal cells. The
human uPA content in the tumour homogenates ranged from 45.3 to 258.3 ng uPA/mg
total protein with an average content of 106.4 ± 23.2 ng uPA/mg protein (median, 81.65
ng uPA/mg protein) (Fig. 4.9A), thus there was a wide range of human uPA expression
within the tumours, which reflects the range seen by IHC staining. The overall high uPA
expression in the tumours is consistent with the high uPA-expressing nature of MDAMB-231 cells in culture (Ranson et al., 1998) and is also consistent with an aggressive
primary breast tumour with a predicted poor outcome, which generally displays uPA
content of greater than 2.97 ng uPA/mg protein (Janicke et al., 1993). There appeared to
be no significant correlation between tumour volume and human uPA content
(Fig. 4.9B; Spearman correlation coefficient [rs] = -0.21, two-tailed, 95% confidence
limit, p = 0.62) indicating that there was not a significant relationship between tumour
size and human uPA expression.

4.3.1.6 uPA proteolytic activity of tumour homogenates
Direct measurement of uPA activity was not possible as the salt content of the
homogenates caused precipitation of the uPA-specific chromogenic substrate
Spectrozyme UK (American Diagnostica Inc., USA). To address this, uPA activity was
indirectly measured by determining the ability of the homogenates to activate human
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Figure 4.9. Quantification of human uPA in xenograft tumour homogenates. Tumours were
removed when they reached ≥ 15 mm in diameter at the longest point and homogenised into TX-100
buffer. (A) The uPA content of the homogenates was quantified in triplicate using an in-house ELISA for
uPA. (B) Spearman (non-parametric) correlation of uPA content as a function of tumour volume. Line
indicates a linear regression. Shown are the P value and Spearman correlation coefficient (rs). One
tumour with volume of 1734 mm3 was excluded from the analyses as an outlier.

155

Chapter 4: Xenograft Mouse Model Characterisation

Glu-plg in the presence and absence of the uPA inhibitor, GGACK. This indirect
activity assay was therefore able to detect uPA activity from both human (tumour cells)
and murine (stromal cells) sources, which can both activate human plg (Fig. 4.10A),
while excluding activity from tPA, which is not inhibited by GGACK. In fact, there was
no correlation between human uPA content and uPA activity in the tumour
homogenates (Fig. 4.10B) possibly due to this incongruity in the species specificity of
the two assays.

The uPA activity of tumour homogenates ranged from 10.96 to 22.93 mIU activity/mg
total protein, with an average activity of 17.15 ± 1.5 mIU/mg total protein (median,
16.96 mIU/mg total protein) (Fig. 4.11A). There was no significant correlation between
uPA activity in the homogenates and tumour volume (rs = 0.14, p = 0.75) (Fig. 4.11B)
indicating that there was no significant relationship between active uPA expression by
the tumours and tumour size. Although uPA activity of the tumour homogenates was
not significantly related to the presence of micrometastases in the lymph nodes as
determined by staining for EMA (p = 0.88, two-tailed t-test), it appeared that tumours
from mice with positive EMA staining of the lymph nodes had generally higher uPA
activity (Fig. 4.11D).

4.3.1.7 Plasminogen activation potential of tumour homogenates
The plg activation assay used measures the ability of the homogenates to activate Gluplg, regardless of the pathway of activation (e.g. uPA, tPA, kallikreins etc.), which may
provide an indication of the total invasive potential of the original tumour. Plg
activation by homogenates of the tumour xenografts ranged from 3.71 to 14.74 mIU
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Figure 4.10. Indirect uPA activity assay: species specificity. (A) Human uPA and murine uPA
display different rates of human plasminogen activation. Human plg (0.5 μM) was reacted at 37oC with
human or murine uPA (10 nM) in the absence and presence of 0.4 μM GGACK (uPA inhibitor) or
50 μM aprotinin (Ap, plasmin inhibitor). uPA-dependent plasmin formation was monitored through
cleavage of the plasmin substrate, Spectrozyme PL (0.4 μM), at 405 nm. (B) Correlation between uPA
content and uPA activity (determined in plg activation assay) in tumour homogenates. P value was
calculated using a Spearman (nonparametric) correlation, also shown is the Spearman r value (rs).

157

Chapter 4: Xenograft Mouse Model Characterisation

A
uPA activity
(mIU/mg total protein)

25
20
15
10
5
0
R
10
D
10 R
8
D
10 L
7
D
10 L
6
D
10 R
5
D
10 L
4
D
10 L
3
D
10 R
2
D
10 L
1
D

10

Tumour ID

B
uPA activity
(mIU/mg protein)

25

20

15

10

P = 0.75
r s = 0.14
0

200

400

600

800

1000

Tumour vol (mm3)

C
uPA activity
(mIU/mg total protein)

26
24
22
20
18
16
14
12
10

EMA negative

EMA positive

Micrometastases

Figure 4.11. Human/murine uPA activity of xenograft tumour homogenates. Arc(s) nude mice
were injected bilaterally into the anterior-most pair of mammary fat pads with 1x106 MDA-MB-231
cells in 100 μL PBS. Tumours were removed when they reached ≥ 15 mm in diameter at the longest
point and were homogenised. (A) The uPA activity of TX-100 homogenates of each of the tumours
was measured in triplicate using an indirect assay (plasminogen activation assay). (B) Spearman (nonparametric) correlation of uPA activity as a function of tumour volume at dissection. A tumour with
volume of 1734 mm3 was excluded from the analyses as an outlier. (C) Box and whisker plot of uPA
activity relation to the presence of micrometastases in the lymph nodes as measured by histological
staining of paraffin-embedded lymph node sections for EMA antigen. Although not statistically
significant, the presence of micrometastases appears to be associated with a higher uPA activity.
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plasmin generated/mg total protein, with an average of 7.28 ± 1.5 mIU/mg total protein
(median, 5.32 mIU/mg total protein) (Fig. 4.12A). As with uPA activity of the
homogenates, there was no significant correlation between the ability to activate plg and
tumour volume (Spearman rs = 0.43, p = 0.30) (Fig. 4.12B). There was no significant
relationship between the relative ability to activate plg and the presence of
micrometastases in the lymph nodes (p = 0.89, two-tailed t-test; Fig. 4.12C).

4.3.2

Model suitability for the evaluation of α-PAI-2 in a pre-clinical

investigations.
The xenograft mouse model appears suitable as a model of metastatic human breast
carcinoma for the evaluation of a uPA-targeted therapy as the tumours express both
human (tumour) and murine (stromal) uPA and display invasive characteristics (section
4.3.1). As part the characterisation of the model, the effects of α-PAI-2 treatment on the
xenograft tumours were also characterised with respect to effects on uPA protein
expression, uPA proteolytic activity and plg activation. These analyses were carried out
as part of a larger pre-clinical investigation into the efficacy and toxicology of α-PAI-2
for use as an anti-cancer therapeutic. Several treatment schedules were analysed,
however, two are presented for comparison. These two treatment schedules were used to
evaluate the chronic effects (up to 74 days post-treatment) of α-PAI-2 under a singledose regimen (24.0 and 34.8 mCi/kg) on 1-week post-implantation tumours and the
acute effects (3 days post-treatment) on tumour biology in a single-dose regimen
(15 mCi/kg) on established tumours (4.5-weeks post-implantation) (refer Table 4.2).
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Figure 4.12. Plasminogen activation potential of xenograft tumour homogenates. Arc(s) nude mice
were injected bilaterally into the anterior-most pair of mammary fat pads with 1x106 MDA-MB-231
cells in 100 μL PBS. Tumours were removed when they reached ≥ 15 mm in diameter at the longest
point. (A) The ability of TX-100 homogenates of each of the tumours to activate human plg was
measured in triplicate using a plg activation assay. (B) Correlation graph showing plg activation as a
function of the number of days taken for the tumour to reach ≥ 15 mm in diameter. Line indicates a
linear regression. A tumour with volume of 1734 mm3 was excluded from the analyses as an outlier.
(C) Box and whisker plot of plg activation in relation to the presence of micrometastases in the lymph
nodes, as measured by histological staining of paraffin-embedded lymph node sections for EMA
antigen (p = 0.89).
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4.3.2.1 Toxicological effects and efficacy of α-PAI-2 treatment
As these results were not the focus of this particular study, only a brief summary is
presented. For a detailed account the reader is directed to Stutchbury et al. (2007).
Maximum tolerated dose was not reached, even with a single dose of 34.8 mCi/kg
α-PAI-2. Macroscopically, there were no significant differences in the appearance of the
major organs in control and treatment groups with the following exceptions: 1/10 mice
treated with 34.8 mCi/kg α-PAI-2 presented with pale coloured kidneys, 1/10 mice
presented with a mottled spleen and 1/10 control mice presented with a large spleen.
There was no significant difference in kidney weight between the treatment and control
groups in either the acute or the chronic model, however, α-PAI-2 treated groups
displayed significantly smaller spleens in the chronic treatment model (two-tailed
T-tests, p < 0.001) and significantly larger spleens (1.7-fold) in the acute model (twotailed T-test, p = 0.034) (Fig. 4.13). However, it should be noted that the spleens of
untreated mice were larger on average than that of a normal mouse of approximately the
same age (see Table 4.5). Both these regimens were otherwise associated with little or
no toxicity in the mice (Table 4.6). In contrast, treatment of the mice with an equivalent
dose (36 mCi/kg) of free 213Bi resulted in moderate toxic effects including failing renal
function, liver dysfunction and liver and kidney damage (Stutchbury et al., 2007).

Decreased tumour growth rates were observed following treatment with either 24 or
34.8 mCi/kg α-PAI-2 in the chronic effects model, though this was not significant at all
time points or dose-dependent (Fig. 4.14A). Compared to controls, administration of
34.8 mCi/kg α-PAI-2 conferred a significant survival advantage (p = 0.0269) and
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Figure 4.13. Major organ weight following treatment with α-PAI-2. Arc(s) nude mice were injected
bilaterally into the anterior-most pair of mammary fat pads with 1x106 MDA-MB-231 cells. Mice were
given a single dose of α-PAI-2 and were sacrificed when (A) tumours reached ≥ 15 mm in diameter at
the longest point or (B) 3 days post-treatment with α-PAI-2. Organs were removed at dissection and
weighed to give an indication of organ size. P values obtained from a two-tailed Student’s T-test are
shown for measurements which were significantly different.
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Table 4.6 Toxicological effects of α-PAI-2 treatment. Female Arc(s) mice were implanted with bilateral
orthotopic injections of MDA-MB-231 cells (1x106 cells/site) to form human xenogenic tumours. Mice
were then treated under various schedules with 213Bi -PAI-2. Toxicity was analysed at different time
points. Blood biochemistry, haematology, and histopathology of animal organs and analyses were
undertaken by an accredited animal pathology laboratory (ICP Firefly Pty. Ltd., Sydney, Australia or
IDEXX Laboratories, Sydney, Australia). Toxicology studies were carried out by Tamantha Stutchbury,
data used with permission. Adapted from Stutchbury et al. (2007).
Treatment model
α-PAI-2 dose schedule

Chronic

Acute

24.0 ± 0.6 mCi/kg x 1 day

15 ± 0.3 mCi/kg x 1 day

or
34.8 ± 0.3 mCi/kg x 1 day
1

15 mm tumour diameter

3 days post-treatment

Liver

None

None

Kidney

None

ND

Spleen

None

ND

3 days post-treatment

ND

3.5-fold increase

7 days post-treatment

ND

1.8-fold increase

Normal

NA

Endpoint

2

Acute organ toxicity

3

White Blood cell count

33-74 days post-treatment

4

1. In addition to endpoints common to each experiment including distressed behaviour (i.e. hunched
posture, reduced activity, loss of appetite), ≥ 15% weight loss, impediment of movement or end of
observation period.
2. Organs were removed 3 and 7 days post-treatment from the cohort treated with 24 mCi/kg α-PAI-2.
Acute organ toxicity was determined by histopathologic analysis of the liver, kidneys and spleen.
3. Not determined
4. Not applicable
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although this effect was not significant after 74 days following treatment with the lower
dose of 24 mCi/kg α-PAI-2 (p = 0.1113), the trend was still apparent (Fig. 4.14B).

4.3.2.2 Effect of α-PAI-2 on invasion and metastasis
Gross anatomical inspection of mouse organs at dissection did not detect any
macroscopic indications of metastasis to the lungs or liver in either treated (24 or 34.8
mCi/kg α-PAI-2) or control mice. However, several of the mice developed enlarged
lymph nodes in both the control and the treated groups (Table 4.7). There was no
significant difference in the number of EMA-positive axillary lymph nodes (Table 4.7),
the latter indicating the presence of micrometastases.
Table 4.7. Chronic effects of α-PAI-2 treatment on lymph node morphology and metastases. Arc(s)
nude mice were injected bilaterally into the anterior-most pair of mammary fat pads with MDA-MB-231
cells (1x106/site). Mice were treated with a single-dose of α-PAI-2 (either 24 or 34.8 mCi/kg) and were
sacrificed when tumours reached ≥ 15 mm in diameter at the longest point. In all cases, this was between
34-75 days post-treatment. Lymph nodes were removed at dissection and examined macroscopically.
α-PAI-2 dose
0 mCi/kg

24.0 mCi/kg

34.8 mCi/kg

Enlarged lymph nodes

4/10

2/10

3/10

Fluid-filled cysts present

1/10

1/10

0/10

Positive EMA staining

6/9

9/10

7/9

4.3.2.3 Biological effects of α-PAI-2 treatment
In the chronic model (34-75 days post-treatment), where tumours were removed when
they reached 15 mm in diameter or at the end of the 75-day observation period, no
significant difference in the uPA content of tumours was observed between mice treated
with 24 mCi/kg α-PAI-2 (67.5 ± 13.3 ng/mg total protein) or 34.8 mCi/kg α-PAI-2 (69.1
± 12.9 ng/mg total protein) compared to untreated control mice (106.4 ± 23.2 ng/mg
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total protein) (Fig. 4.15A). The uPA activity of the tumours was not significantly
different in mice treated with 24 mCi/kg (17.9 ± 1.5 mIU/mg total protein) or 34.8
mCi/kg (16.1 ± 1.1 mIU/mg total protein) α-PAI-2 compared to control mice (17.2 ± 1.5
mIU/mg total protein) (Fig. 4.15B). No significant difference in plg activation potential
was observed between 24 mCi/kg (7.18 ± 1.0 mIU/mg total protein) or 34.8 mCi/kg
(6.6 ± 1.9 mIU/mg total protein) α-PAI-2 treated mice compared to control mice (7.28 ±
1.5 mIU/mg total protein) (Fig. 4.15C).

In the acute model (3 days post-treatment), generally smaller tumours meant that there
was the limited sample to work with. For this reason, the data presented can be
considered as a pilot study only as there was limited homogenate and thus limited
sample to analyse. These tumours, removed at 5 weeks post-implantation, expressed
approximately 6.0 ± 1.2 ng uPA/mg total protein (n = 2) and ranged in size from 1 to
723 mm3, with an average size of 179 ± 66 mm3 (n=10). While there were too few
samples to perform a meaningful statistical comparison, the tumours appeared to
express less uPA 3-days after treatment with 15 mCi/kg α-PAI-2 compared to tumours
from control mice (6.03 ± 1.22 vs 4.45 ± 0.28 ng/mg protein following treatment) (Fig.
4.16A). Using a semi-quantitative method (i.e. immunoblotting), parallel results were
seen for uncomplexed uPA. By this method, homogenates from tumours post-treatment
with α-PAI-2 had much less uncomplexed uPA (apparent molecular weight: 55 kDa)
compared to tumours from mice not treated with α-PAI-2 (Fig. 4.16B). This indicates
that at this time point (3 days post-treatment), a reduction in tumoural uPA as a result of
α-PAI-2 treatment can be witnessed, however, the ELISA system is more quantitative.
There was, however, no obvious difference in uPA activity (which takes into account
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Figure 4.15 Chronic effects of α-PAI-2 treatment on uPA, uPA activity and plasminogen
activation potential of tumour xenografts. Arc(s) nude mice implanted bilaterally with MDA-MB231 cells in the mammary fat pads 1 week prior, were treated with a single dose of either 24 or 34.8
mCi/kg α-PAI-2. Tumours were removed at dissection when tumours reached 15 mm in diameter (3475 days post-treatment) and homogenised into TX-100 buffer. Homogenates were analysed for (A) uPA
content, (B) uPA activity and (C) plg activation. Bars indicate median values. No significant
differences were observed for uPA content, uPA activity or plg activation following treatment with
either 24 or 34.8 mCi/kg α-PAI-2 (p>0.05).
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Figure 4.16 Acute effects of α-PAI-2 treatment on uPA, uPA activity
and plasminogen activation potential of tumour xenografts. Female
Arc(s) nude mice implanted with MDA-MB-231 cells in the mammary
fat pads 4.5 weeks prior, were treated with a single dose of 15 mCi/kg αPAI-2. Tumours were removed at dissection 3 days post-treatment and
homogenised into TX-100 buffer. Homogenates were analysed for uPA
content in an ELISA for uPA antigen (A) and a Western blot
immunostained for uPA (B), uPA activity (C) and plg activation (D).
The small sample size precludes statistical comparison, however, the
reduction in tumour uPA observed following α-PAI-2 treatment (A) was
also apparent in a western blot of the same homogenates probed for uPA
(B). Western blot was performed by Tamantha Stutchbury, University of
Wollongong. There was no apparent difference in the comparative uPA
activity and plasminogen activation of the homogenates. Bars indicate
median values.
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tumour and stromal uPA), between mice treated with 15 mCi/kg α-PAI-2 (2.9 ± 0.43
IU/mg total protein) and control mice (3.36 ± 0.08 IU/mg total protein) (Fig. 4.16C) nor
was there a difference in the ability of the homogenates to activate plg between control
and treated mice (6.32 ± 0.08 vs 6.21 ± 0.18 following treatment) (Fig. 4.16D).
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4.4

Discussion

The uPA system has been linked in numerous experimental and clinical studies to
metastasis and poor patient outcome (Dano et al., 2005; Duffy, 2004; Ranson and
Andronicos, 2003). The tumour model used in this study has been characterised with
respect to tumour induction, growth rate, lymph node behaviour and expression/activity
of the target molecule, uPA. Xenograft tumours induced from orthotopic implantation
of the MDA-MB-231 cell line were similar to human invasive breast tumours in that
they were interspersed with host stromal cells, were vascularised at smaller sizes but
less so at larger sizes, displayed invasion into surrounding tissue, expressed significant
levels of uPA and were able to efficiently activate plg to plasmin. This characterisation
is particularly important for determining the suitability of this model for use in preclinical trials of human anti-cancer/anti-metastatic therapeutics for use in humans.

Several types of animal model are commonly used for the study of human cancer in
mice. These include transgenic mice which develop spontaneous tumours, allografts of
tumours from one strain of mouse to another (syngeneic transplants) or implantation of
human cancer cell lines or tumours into immunocompromised mice (xenografts). In the
case of the last two models, cells or tissue may be implanted ectopically
(e.g. subcutaneous) or orthotopically. Orthotopic implantation of MDA-MB-231 cells
was used in the current study as orthotopic tumours are more likely to be regulated by
similar local host factors to their human counterparts compared with ectopically
implanted tumours (Cespedes et al., 2006; Kelland, 2004). Stromal cells are critical for
the support and progression of human cancers (Alberti, 2006; Bilalovic et al., 2006;
Dolle et al., 2006; Proia and Kuperwasser, 2005; Ronnov-Jessen et al., 1996; Zalatnai,
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2006). Stromal cells effect such processes as angiogenesis and tumour cell growth
through secretion of factors which stimulate these processes (e.g. prostate carcinoma
cells co-implanted with prostate stromal cell lines in nude mice exhibit increased
tumorigenesis and vascularisation compared to carcinoma cells in the absence of
stromal cell lines (Tuxhorn et al., 2002)), or through secretion of intermediates which
effect cancer growth and metastasis (e.g. expression of the proteases Cathepsin D,
stromelysin-A and uPA by stromal cells in breast tumours is associated with poor
outcome but expression of these by the tumour cells themselves is not (Tetu et al.,
1999)). Cells of the immune system including leukocytes, macrophages and dendritic
cells are also important components of this stroma (Mareel and Leroy, 2003) and are
often seen infiltrating solid tumours in invasive cancers in both humans and mice
(Bucana et al., 1992; Dirkx et al., 2006; Normann, 1985; Ohtani, 2007; Vukanovic and
Isaacs, 1995). In this study, both the smaller (38 days post-implantation) and larger (4182 days post-implantation) xenograft tumours were interspersed with stromal cells.
Furthermore, tumours showed expression of both murine (stromal) and human (tumour)
uPA. In human breast tumours, uPA is produced by tumour-associated macrophages but
has also been localised to fibroblasts and mast cells (Dirkx et al., 2006; Nielsen et al.,
1996; Normann, 1985), suggesting that these cells may be responsible for production of
uPA in the xenograft tumours. In this respect, the tumours appear to mimic solid
tumours in humans in that the stromal cells appear to be responsible for a large
proportion of uPA production.

Investigation anti-metastatic agents is problematic and each model should be carefully
characterised under the conditions used (discussed in Welch, 1997). The interaction of
tumour cells with the stroma also contributes to the ability of tumour cells to
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metastasise (Baglole et al., 2006; De Wever and Mareel, 2003). Xenografted tumours
display differential responses to stroma compared to spontaneous tumours from
transgenic mouse models (Fantozzi and Christofori, 2006), however, the latter do not
typically spontaneously metastasise and so do not mimic advanced disease (Cespedes et
al., 2006; Kerbel, 1998; Rosenberg and Bortner, 1998). It should be noted that some
transgenic models do exist which have achieved this goal (see Derksen et al., 2006). In
contrast, orthotopic xenograft models tend to reproduce the pattern of metastasis seen in
human tumours, suggesting sufficient interaction with the stroma (Cespedes et al.,
2006; Welch, 1997). Moreover, localised breast cancer is commonly treated with
surgery or localised radiation therapy with most therapeutics developed for systemic
therapy (National Cancer Institute, 2007). Therefore, given the lack of metastasis
observed in many spontaneous models these models do not seem appropriate for
evaluating potential anti-metastatics, even though these tumours are more likely to
represent the histological and immunological properties of human tumours (Rosenberg
and Bortner, 1998). Metastases were not detected macroscopically in the orthotopic
model used in this study, however, EMA-positivity was present in the majority of
axillary lymph nodes indicating regional invasion, which is predictive of metastasis
(Weigelt et al., 2005). The capacity of MDA-MB-231 to metastasise to the lymph
nodes, lungs, liver, bone and kidneys, has previously been observed following
orthotopic implantation of this cell line in SCID mice (Man et al., 2002; Muller et al.,
2001). The lack of macrometastases observed in the current study, suggest that the
model may in fact represent microscopic, low-volume metastatic disease but not high
volume advanced metastatic disease. It is possible, however, that the presence of the
primary tumour in the mouse model may have suppressed the growth and
vascularisation of metastases once seeded (O'Reilly et al., 1994) and it is also noted that
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the MDA-MB-231 cell line, while classed an invasive cell line in in vitro studies (Farina
et al., 2002; Holst-Hansen et al., 1996; Magee et al., 2004; Ranson et al., 1998), has
been shown to have a modified protein expression profile as a result of the host stromal
environment in female immunodeficient C.B-17 SCID mice (Jessani et al., 2004). This
particular study, which also utilised orthotopically implanted MDA-MB-231 cells,
showed that uPA mRNA was significantly down-regulated in the implanted parental
cells whereas the opposite was seen when MDA-MB-231 cells were passaged once
through the mouse mammary fat pad prior to implantation. Though human uPA
expression was still observed in the xenograft tumours in this study and stromal cell
uPA has also been shown to be a highly important source of tumour uPA (Frandsen et
al., 2001; Romer et al., 1994), passaging the cell line through mice before use to obtain
a more highly metastatic subpopulation may give enhanced results with regard to
tumour metastasis and α-PAI-2 efficacy. However, it would not be expected to affect
the toxicology results already obtained as PAI-2 is still able to form complexes with
murine uPA and has been shown to internalise via uPA/uPAR in the murine cell line
L929 (Stutchbury et al., 2007).

Excision at different time points i.e. 38 days post-implantation (“early”) or 41-82 days
post-implantation (“later”) yielded control tumours of comparatively different size.
“Later” tumours were generally much larger and therefore gave ample material to work
with for both histological and biological assays on matched sample. These tumours
were also more likely to be invasive at tumour endpoints and had higher levels of uPA,
whereas some of the early tumours were still mostly encapsulated. In fact, in the early
tumours, the level of uPA was still approximately 2x the threshold of expression for a
highly invasive tumour in humans, compared to 35x the threshold of expression in the
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“later” tumours (Janicke et al., 1993). In addition, the large tumours, while lacking the
extensive stromal involvement of the small tumours, displayed a lack of vascularisation
and had large necrotic centres, a result of hypoxia that is highly characteristic of solid
tumours in humans (Minchinton and Tannock, 2006). It can be seen that different
tumour biology is observed at these time points and thus time-to-treat in a model must
be taken into consideration for several reasons: 1) larger tumours mimic the compact
vascularisation in human tumours; 2) delivery of drugs into these tumours via the
vascular system will be compromised as a result of reduced vascularisation and 3) the
microenvironment (e.g. stromal cells) varies with tumour size (Jain, 1994; Minchinton
and Tannock, 2006). As α-PAI-2 would be considered for clinical application as an antimetastatic, time to onset of metastases should be taken into account in future studies
(e.g. adjuvant therapy is more likely to be effective against smaller metastases than
larger more established metastases). Therefore in future studies, tumour size, growth
rate and time to onset of metastasis should be considered when deciding when treatment
should be initiated in the pre-clinical model (Kelland, 2004).

It has been suggested that xenograft mouse models of human cancer are not appropriate
to assess the efficacy and toxicology of uPA/uPAR targeting therapeutics as significant
species specificity exists in the uPA/uPAR interaction (Romer et al., 2004). This is
especially relevant for uPA antagonists. However, it has been demonstrated that the
murine fibroblastic cell line L929 is able to internalise rPAI-2 inhibited murine uPA via
an LRP/uPAR-mediated mechanism that is analogous to its internalisation by human
cancer cell lines (Stutchbury et al., 2007). This suggests that the model described herein
is suitable for analysing therapeutics based on rPAI-2. The effective targeting of this
molecule in the murine model was also demonstrated by the decreased toxicity of
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α-PAI-2 compared to an equivalent dose of free

213

Bi. In addition, although the second

order association rate constant for PAI-2:uPA interaction is approximately 70 times
higher for murine uPA compared to human uPA (Stutchbury et al., 2007), delivery of
even a few molecules of

213

Bi via α-PAI-2 may exert a cytotoxic effect due to the high

toxicity of 213Bi.

Analysis of the biological effects of α-PAI-2 treatment showed that in tumours removed
at 15 mm diameter there was no apparent difference in human uPA expression, uPA
activity or the ability to effectively activate plg between control and treatment groups.
α-PAI-2 was administered as a single dose and though it inhibited tumour growth it did
not completely stop it. Given that these larger tumours were mostly composed of
tumour (MDA-MB-231) cells with little stroma and that uPA content and activity
calculations were standardised to the total amount of protein, it is therefore not
surprising that large differences were not observed. Conversely, in the acute model,
which typically had a much larger stromal cell component, an observable and
convincing difference in human uPA level was observed 3 days post-treatment even
with a slightly lower dose of α-PAI-2, albeit in a pilot experiment. In the acute model,
overall tumour uPA activity and the ability to activate plg were not different in α-PAI-2
treated mice compared to control mice, possibly indicating the involvement of stromal
mouse uPA and tPA, though again these were only preliminary observations. Therefore,
the chronic model was more appropriate for assessing efficacy of the uPA-targeted
therapeutic in this system, however, the acute model appeared more appropriate for
understanding the biological basis for the action of the uPA-targeted therapeutic.
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A single dose of α-PAI-2 (34.8 mCi/kg) significantly slowed tumour growth, increased
survival in mice bearing tumours and was associated with little to no toxicity
(Stutchbury et al., 2007). This therapeutic has also had similar success in pre-clinical
studies for uPA-expressing prostate cancer and pancreatic cancer in nude mouse models
of these diseases (Abbas Rizvi et al., 2006; Qu et al., 2005) and has yielded promising
results in in vitro toxicity experiments for ovarian cancer (Song et al., 2006). However,
the use of xenograft models is still questioned (Cespedes et al., 2006; Dennis, 2006;
Kelland, 2004; Kerbel, 2003). Contradictions in the clinical response to therapies by
xenograft-bearing mice and humans have been observed, for example endostatin (an
antiangiogenic compound) which caused total regression of transplanted tumours in
mice (Boehm et al., 1997), did not exhibit this effect in Phase I clinical trials (Twombly,
2002). Nevertheless, while a retrospective study of the clinical response to some
chemotherapeutics in over 60 cancer cell lines in xenograft mouse models has shown
that the MTD of mice is markedly different to that of humans (approx 4-5 times lower),
the clinically relevant dose in humans still stimulated the same clinical pathway in the
mice, indicating that these models are still useful in providing clinically relevant
efficacy data (Inaba et al., 1989; Kerbel, 2003). It should also be noted that in that
particular study, orthotopic injections of the cell lines were not used. That being said,
studies with multiple cancers comparing xenograft models in immunocompromised
mice to the clinical response in humans for the relevant cancer have shown that some of
these models give similar overall response rates for a range of clinically active drugs
(Kelland, 2004; Steel et al., 1983). It is important to note that xenograft nude mouse
models are still the model of choice for anti-cancer screening and in vivo testing of
therapeutics by the Developmental Therapeutics Program at the National Cancer
Institute/National Institute of Health (MD, USA), although compounds are first tested in
176

Chapter 4: Xenograft Mouse Model Characterisation

a hollow fibre assay for in vivo cytotoxicity against 12 cancer cell lines implanted at
2 sites (i.p. and s.c.) (Hollingshead et al., 1995; National Cancer Institute and National
Institute of Health, 2007). Furthermore, though not targeted therapies, a panel of 5 drugs
in clinical use: paclitaxel [indicated for breast cancer]; gemcitabine [indicated for
ovarian, breast, non-small cell lung cancer, pancreatic cancer]; docetaxel [indicated for
breast, prostate and non small lung cell cancer]; vindesine [indicated for leukaemia,
breast, colorectal, renal and lung cancer]; and topotecan [indicated for ovarian, cervical
and small lung cell cancer], showed similar overall response rates in human tumour
xenograft mouse models as in clinical trials using the same drugs (reviewed in Kelland,
2004). Discrepancies in the pre-clinical versus clinical response may be due to the more
advanced and possibly drug resistant nature of tumours in humans which are not
adequately replicated in early tumour models (Kerbel, 2003). Although the tumour size
at treatment (~0.5 mm diameter) in the current study would be considered representative
of an “early stage” strategy (Kelland, 2004), it is appropriate given the fast growing
nature of the MDA-MB-231 xenografts, which if left longer would exceed the diameter
approved by the AEC before the end of the experimental period. It is also important to
note that in the nude mouse model, which is T-cell depleted, toxicological effects and
pharmacokinetic properties may be understated since the uPA system is also expressed
by cells of the immune system (Dano et al., 1999; Estreicher et al., 1990; Plesner et al.,
1994) and may be important for T-cell mediated responses (Gyetko et al., 2004). Thus,
it is envisaged that α-PAI-2 toxicology and pharmacokinetics would be assessed in at
least one other animal model (e.g. rabbit). Preliminary experiments carried out with
α-PAI-2 in rabbits to this end appear promising (M. Ranson, personal communication).
Conversely, the use of the athymic nude mouse in a pre-clinical model is advantageous
as it lessens the complication of certain host-mediated immune responses against the
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tumour, especially cytotoxic T-cell mediated responses, which would not normally be
observed in human cancers (Kerbel, 1998).

In conclusion, this study has shown that the orthotopic xenograft mouse model can be
utilised to determine both efficacy (with extended time post-treatment) and biological
action (in an acute version of the model) of uPA-targeted therapies such as α-PAI-2.
This orthotopic model maintains to a large extent the characteristics of the original
tumour cells and mimics the development and histology of human breast tumours
including uPA expression by stromal cells. This is important as current opinion suggests
that targeting stromal cells as well as tumour cells may be a more successful therapeutic
strategy (De Wever and Mareel, 2003; Dolle et al., 2006; Zigrino et al., 2005).
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5 CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
Deregulated expression of components of the uPA PAS, which leads to increased
plasmin generation, has been linked to the metastatic phenotype (Andreasen et al.,
2000; Han et al., 2005; Ranson and Andronicos, 2003). Combined expression of the
PAS components uPA and PAI-1 have also been correlated to adverse prognosis in
breast cancer patients and are the only biological molecules to have been validated as a
biomarker for breast cancer in two Level 1 Evidence studies (Duffy and Duggan, 2004).
The aims of this thesis were to provide a physiologically relevant model for the
enhanced plg binding observed in uPA-overexpressing breast cancer cell lines in vitro,
to characterise a murine model of uPA-expressing breast cancer for use as a model to
test potential uPA-targeting therapeutics, and to develop an in-house assay for
quantification of uPA in homogenates of tumours derived from that model.

5.1

Enhanced cell-surface plasminogen binding is largely dependent on

plasmin activity
Numerous studies detail the existence of a diverse range of plg receptors on cancer cells
in vitro and several studies have shown that plasmin pre-treatment can enhance plg
binding to cells (reviewed in Ranson and Andronicos, 2003). The results presented in
Chapter 2 indicate that a large proportion of enhanced plg binding is due to plasmin
proteolysis of cell surface proteins, which leads to the generation of C-terminal residues
and hence new plg binding sites. However, it was also noted that a significant
proportion (approximately 30%) of plg binding was plasmin-independent, possibly
binding to pre-formed plg receptors. This may comprise an important fraction of cell
surface plg binding in that it could be responsible for initial localization of plg to the
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surface of uPA-expressing cells, thus facilitating initiation of the plg activation positive
feedback loop. The expression of several putative plg receptors (i.e. actin, annexin II,
p11, cytokeratin 8/18, uPA) and their possible contribution to plg binding was also
analysed in the modified MCF-7 cell line, however, the entirety of plasmin-independent
binding was not accounted for. Future identification of these proteins on this and the
MDA-MB-231 cell surface is therefore necessary and may be achieved through the use
of the tri-functional cross-linker Sulfo-SBED (Pierce, USA). This molecule contains an
NHS arm with which to label the targeting molecule e.g. plg; a photoactivatable arylazide arm which may be used to covalently cross-link the labelled molecule to its
binding partner; a reducible disulfide bond to allow release of the targeting molecule
from its cross-linked partner e.g. a plg receptor; and finally a biotin moiety which
remains on the cross-linked protein after reduction and may be utilized to detect or to
isolate the unknown protein by strepavidin affinity chromatography. Once isolated, the
newly biotinylated proteins may then be identified by tryptic peptide digest and
MALDI-TOF mass spectrometry. The Sulfo-SBED system affords advantages over
other labelling protocols in that the Sulfo-SBED-labelled plg would be membraneimpermeable, allowing for identification of cell surface proteins. Second, this represents
a significant improvement on other common methods of plg binding protein
identification e.g. ligand binding to isolated proteins from membrane-purified fractions,
in that the labelled plg will only bind proteins that in the correct orientation at the cell
surface. Using the Sulfo-SBED method, there is also the potential to isolate nonproteinaceous moieties to which plg may also bind e.g. fatty acids. The Sulfo-SBED
method has recently been used to identify AIIt as the receptor for plasmin-induced
signalling on monocytes (Laumonnier et al., 2006).
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PMA was used to up-regulate cell-surface uPAR, thus creating an avenue to increase
cell-surface uPA, however, the expression of multiple proteins in the MCF-7 cell line
would also have been altered (Lacroix et al., 2004). Because the experiments performed
focussed on plg binding in the presence and absence of increased uPA both following
PMA stimulation, the use of PMA was an acceptable and quick method to modulate
uPAR. However, for further analysis it may be prudent to look at other methods which
effect only uPA expression. As discussed in Chapter 2, acid elution to remove uPA
from its receptor at the cell surface has effects on cell viability, likewise, transfection
with uPAR had similar effects on viability in this cell line, was not reproducible and in
other cell lines resulted in concomitant increases to uPA. One possibility for future
investigations may be the use of small interfering RNA (siRNA) to down-regulate
expression of uPA (or uPAR) in MDA-MB-231 cells, to study uPA contribution to plg
binding in these naturally high uPA-expressing cells. However, it should be noted that
complete knock-down of uPA/uPAR expression would not allow a distinction to be
made between direct uPA plg-binding and uPA-dependent activation of plg, which both
appear to facilitate enhanced plg binding on these cells. siRNA has been successfully
used to down-regulate expression of the uPA activator, matriptase, in THP-1 monocytic
cells, demonstrating that matriptase is an important initiator of the plg activation
cascade on THP-1 monocytes (Kilpatrick et al., 2006). siRNA knockdown has also been
used to down-regulate the plg receptor, p11, in Colo 222 colon cancer cells to show
decreased plasmin generation and invasion of these cells in the absence of p11 (Zhang
et al., 2004). It is important to note that as uPA/uPAR participate in a number of other
pathways involved in cell adhesion and cell signalling, this approach may also have
widespread effects on the cell that are not directly related to plg binding and activation.
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5.2

A cost-effective ELISA system for in-house quantification of uPA in

tumour homogenates
The ELISA developed in Chapter 3 was useful for the quantification and comparison of
uPA levels in TX-100 tumour homogenates (Chapter 4). The ELISA allowed a certain
degree of species specificity to be attained which was important given that stromal uPA
(in this case of murine origin) has been linked to increased invasiveness in in vivo
models of breast cancer (Frandsen et al., 2001; Romer et al., 1994). Quantitative PCR
could also be used to quantify uPA expression in tumour tissues. While increased
species specificity may be obtained using this method and the quantification of both
mouse and human uPA could be obtained (or both if a total uPA quantification is
required), this method is not without its drawbacks. While the amount of uPA mRNA
can be quantified and can give an indication of the potential changes to gene expression,
it does not necessarily give a direct indication of the amount of uPA protein actually
being expressed in the tumour tissue and may therefore give misleading results. This is
of particular concern when studying the effect on uPA-expression following uPAtargeted therapy in murine tumour models. This method has, however, been used to
quantify and compare uPA and PAI-1 in human cancer biopsies where a relationship
between mRNA expression and protein expression and also mRNA expression and
cancer progression was shown (Castello et al., 2007; Gilabert-Estelles et al., 2003).

5.3

A murine model for the study of potential uPA-targeted therapies

An orthotopic xenograft mouse model of human breast cancer was characterised for
tumour induction, growth rate, tumour necrosis, uPA expression, uPA activity, plg
activation, the presence of micrometastases and correlation of uPA expression and
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activity to micrometastases. The model was shown to be useful for analysing the
efficacy and action of the uPA-targeted therapy, α-PAI-2. However, some drawbacks to
this model were also identified. Due to the cost and lifespan of the

213

Bi generator and

the limited schedule for the efficacy and toxicity studies, the following modifications
could be not pursued during the course of the research but are presented here for
reference during future studies.

Though micrometastases to the lymph nodes were detected by EMA immunostaining,
there was a small possibility of cross-reactivity of the anti-EMA antibody with Blymphocyte cells, though it was not believed that this was a significant issue in the
current study. However, MDA-MB-231-BAG (which express β-galactosidase) or
MDA-MB-231-GFP cells (which express green fluorescent protein) could be used in
future studies to establish xenograft tumours and allow easy visual identification of
metastatic cells in tissue sections. The use of these cells also allows for the possibility of
double staining for uPA expression and cell-surface binding by metastatic tumour cells
to provide information as to the effectiveness of α-PAI-2 as a uPA-targeting, antimetastatic agent.

The murine model used fell into the category of microscopic, low volume metastatic
disease that is unlikely to mimic the clinical situation of Phase I-III trials, which
generally present as advanced metastatic disease (discussed in Kerbel, 2003). To obtain
a more highly metastatic, high volume disease in future studies, MDA-MB-231 cells
may be passaged through the mammary fat pad first before inoculation into test mice,
which has been shown to yield a higher uPA-expressing, faster growing, more
metastatic MDA-MB-231 derivative (Jessani et al., 2004). Alternatively, MDA-MB184
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231 cells that have metastasised to various organs may also be isolated and expanded to
obtain a more metastatic subpopulation, which can then be used to establish xenograft
in future mouse models. Further to these two strategies, the primary tumour may also be
surgically removed prior to treatment, as the presence of a primary tumour in mouse
models has been suggested to retard the growth of metastases (Welch, 1997). There are
several aspects to this method to consider, however, 1) the size at which the primary
tumour should be removed would need to be determined empirically for each cell line
and mouse strain; 2) the time of primary tumour removal should be carefully
determined as there is balance between occurrence of metastasis and size of tumour at
which removal will detrimentally affect the health and recovery of the animal (Welch,
1997); 3) removal of the primary tumour may necessitate the services of a qualified
veterinarian as in the experience of our laboratory, palpable MDA-MB-231 tumours
often had significant vasculature. Initial enquiries to locate a local veterinarian willing
to perform this surgery on multiple mice were unsuccessful. Phase I-III clinical trials are
often also performed on patients presenting with drug-resistant cancers. It would be
interesting to assess the efficacy of α-PAI-2 on xenografts established from uPAexpressing but anti-cancer drug resistant cancer cell lines, which may need to be
established in-house. The tumour xenografts in the studies detailed in Chapter 4 were
solid tumours. Recent opinion suggests that co-administration of anti-adhesive drugs
may serve to “open-up” solid tumours to therapeutics (Minhinton 2006). This
therapeutic strategy could also be investigated in future studies.
It is also acknowledged that while human and murine uPA both interact efficiently with
PAI-2 (Stutchbury et al., 2007), murine uPA has a slower reaction rate with human
PAI-2 than human uPA, therefore future studies may include the use of a syngeneic
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mouse model of uPA-expressing breast cancer to assess the toxicological effects of uPA
in the absence of human uPA. This would also nullify the use of an
immunocompromised (nude) mouse and provide additional information regarding any
targeted effects on the immune system, particularly since uPA/uPAR have been shown
to be functional in this system (Gyetko et al., 1999; Gyetko et al., 1994).

5.4

Concluding remarks

In conclusion, the studies detailed within this thesis provide evidence of a possible
mechanism for the enhanced plg binding and activation (which has been linked to
invasion and metastasis) in uPA-expressing breast cancers in vitro. This evidence
indicates that uPA is a pivotal molecule in that it is not only responsible for the direct
activation of plg leading to enhanced proteolytic activity, but through this action is also
indirectly responsible for the ability of cells to recruit increased levels of plg at the cell
surface. The results also support the work of others suggesting increased plg binding
may not be seen unless a base level of uPA expression is exceeded, which may be
influenced by the expression of the PAIs (Behrendt 2003). In an in vivo setting, this
thesis also contains a detailed characterisation of a murine model of breast cancer,
which may be utilised for the study of uPA contribution to tumour progression or for the
pre-clinical study potential uPA-targeted therapies such as 213Bi-PAI-2.
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7 APPENDICES
7.1

Appendix 1 - Media and Buffers

General Buffers
PBS (10x, pH 7.4)
NaCl ..........................................................................................................................80 g/L
KCl ..............................................................................................................................2 g/L
Na2HPO4 ................................................................................................................14.4 g/L
KH2PO4 ....................................................................................................................2.4 g/L
TBS (10x, pH 8.0)
Tris-HCl .....................................................................................................................0.5 M
NaCl ...........................................................................................................................1.5 M

Media
RPMI Media (pH 7.4)
RPMI-1640 medium ..............................................................................................10.4 g/L
NaHCO3 ....................................................................................................................20 g/L
Fetal calf serum .................................................................................................... 5 % (v/v)

Immunofluorescence and Ligand Binding Assay Reagents
Binding Buffer (pH 7.4)
Hanks’ Buffered Salts ............................................................................................... 0.97 g
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)................................ 0.48 g
CaCl2 (500 mM) ...................................................................................................... 200 μL
MgCl2 (500 mM) ..................................................................................................... 200 μL
BSA ............................................................................................................................. 0.1 g
Distilled H2O...................................................................................................... to 100 mL
Modified Binding Buffer (pH 7.4)
Hanks’ Buffered Salts (no phenol red) ..................................................................... 0.97 g
HEPES ...................................................................................................................... 0.48 g
CaCl2 ......................................................................................................................... 1 mM
MgCl2 ........................................................................................................................ 1 mM
BSA ............................................................................................................................. 0.1 g
Distilled H2O...................................................................................................... to 100 mL
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Activity Assay Reagents
Plasmin Activity Assay Buffer (pH 7.5)
Tris-HCl .................................................................................................................. 50 mM
Tween 80.......................................................................................................... 0.01% (v/v)
uPA Activity Assay (pH 8.4)
Tris-HCl .................................................................................................................. 20 mM
NaCl ...................................................................................................................... 150 mM
Gelatin ............................................................................................................... 0.1% (w/v)

Cell Lysis Reagents
RIPA Cell Lysis Buffer
Tris-HCl (pH 7.4).................................................................................................... 50 mM
NaCl ...................................................................................................................... 150 mM
SDS .................................................................................................................... 0.1% (v/v)
Triton X-100 ......................................................................................................... 1% (v/v)
Sodium deoxycholate ........................................................................................... 1% (w/v)
EDTA ........................................................................................................................ 1 mM
PMSF ........................................................................................................................ 1 mM

Homogenisation Reagents
1 % TX-100 Homogenisation Buffer (pH 7.4)
Tris-HCl .................................................................................................................. 10 mM
NaCl ...................................................................................................................... 150 mM
Triton X-100 ......................................................................................................... 1% (v/v)

ELISA reagents
PiNT (pH 7.5)
Na2HPO4 ................................................................................................................. 50 mM
NaCl ...................................................................................................................... 150 mM
Tween 80.......................................................................................................... 0.05% (v/v)
OPD substrate buffer (pH 5.0)
Na2HPO4 ................................................................................................................... 8 mM
Solid citric acid .................................................................................................... to pH 5.0

OPD substrate solution
O-phenylenediamine dihydrochloride (OPD) ........................................................... 12 mg
30 % (v/v) H2O2 ........................................................................................................ 30 μL
OPD substrate buffer........................................................................................... to 50 mL
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Immunohistochemistry Reagents
Tris-EDTA antigen retrieval buffer (pH 9.0)
Tris-HCl .................................................................................................................. 10 mM
EDTA ........................................................................................................................ 1 mM
PBS Wash Buffer (pH 7.2)
1x PBS (pH 7.2)
Tween-20 ......................................................................................................... 0.05% (v/v)
TBS Wash Buffer (pH 7.6)
1x TBS (pH 7.6)
Tween-20 ......................................................................................................... 0.05% (v/v)
3% H2O2 Peroxidase Blocking Solution
1x PBS (pH 7.2)
30% H2O2 ....................................................................................................................1 mL

Plasminogen Purification Reagents
Salt Wash Buffer (pH 7.5)
Na2HPO4 ..................................................................................................................0.05 M
NaCl ...........................................................................................................................0.5 M
EDTA ........................................................................................................................ 5 mM
PMSF ........................................................................................................................ 1 mM
EACA Elution Buffer (pH 7.5)
1x PBS (pH 7.5)
ε-ACA ................................................................................................................... 200 mM

SDS-PAGE reagents
12% Resolving gel (per gel)
40% Bis Acrylamide ..............................................................................................1.55 mL
1.5 M Tris-HCl (pH 8.8) ........................................................................................1.25 mL
10% SDS ................................................................................................................... 50 μL
Distilled H2O............................................................................................................2.4 mL
10 % (w/v) APS ........................................................................................................ 25 μL
N,N,N’,N’-tetramethylethylenediamine (TEMED) ............................................... 0.25 μL
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4% Stacking gel (per gel)
40% Bis Acrylamide ............................................................................................... 225 μL
0.5 M Tris-HCl (pH 6.8) ......................................................................................... 600 μL
10% SDS ................................................................................................................... 25 μL
Distilled H2O............................................................................................................1.6 mL
10 % (w/v) APS ..................................................................................................... 12.5 μL
N,N,N’,N’-tetramethylethylenediamine (TEMED) ............................................... 0.13 μL
Non-Reducing Sample Buffer
Tris-HCl (pH 6.8).................................................................................................... 60 mM
Glycerol............................................................................................................... 10% (v/v)
SDS ....................................................................................................................... 1% (v/v)
Bromophenol blue........................................................................................... 0.01% (w/v)
Reducing Sample Buffer
Dithiothreitol ......................................................................................................... 100 mM
Non-reducing sample buffer (5 x)
SDS-PAGE Running Buffer (10 x)
Tris base ....................................................................................................................30 g/L
Glycine ....................................................................................................................144 g/L
Sodium dodecyl sulfate .............................................................................................10 g/L
Rapid Coomassie Blue Stain
Coomassie Blue R-250................................................................................................... 1 g
Methanol .................................................................................................................400 mL
Glacial acetic acid ...................................................................................................100 mL
Distilled H2O..............................................................................................................to 1 L
Rapid Destain
Methanol .................................................................................................................400 mL
Glacial acetic acid ...................................................................................................100 mL
Distilled H2O..............................................................................................................to 1 L
Final Destain
Glacial acetic acid ...................................................................................................100 mL
Glycerol.....................................................................................................................40 mL
Distilled H2O..............................................................................................................to 1 L

Western and Ligand Blotting Reagents
Transfer Buffer
Tris Base ................................................................................................................3.03 g/L
Glycine ...................................................................................................................14.4 g/L
Methanol ............................................................................................................. 20% (v/v)
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TBST
TBS (1 x)
Tween 20.......................................................................................................... 0.05% (v/v)
10 % Blocking Solution
TBS (1 x)
Skim milk powder .............................................................................................. 10% (w/v)
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7.2

Appendix 2 - Measuring cell-surface-associated FITC

fluorescence
1. Compensation settings on the flow cytometer were optimised before use and saved
for each fluorochrome, combination of fluorochromes and cell line to ensure
fluorescence of one fluorochrome was not detected in an inappropriate channel. For
example, using cells double-stained positive for PI and FITC, the PMT voltages were
adjusted such that PI-fluorescence was not detected in the channel for FITCfluorescence and vice versa.
2. To establish a viability gate, a viable cell sample stained with PI only was used. A
dot plot of FSC (size) versus FL-3 (PI) fluorescence of this sample was made and a
gate (shown in pink) was established around the PI-negative (viable) population e.g:
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3. A histogram of FL-1 (FITC) fluorescence was made using only the fluorescence
associated with the gated population and was used to establish autofluorescence. The
PMT voltage was adjusted such that this sample fluorescence read in the 0-10
fluorescence units range.

4. All other samples were then subsequently read without further altering the PMT
voltages. The geometric mean of FL-1 fluorescence for each gated population was
taken as the cell-surface-associated FITC-fluorescence for that sample. If a clear
histogram peak was not observed, the cells were considered mostly non-viable and
the sample was not considered as valid.
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7.3

Appendix 3 - uPA activity assay calculations

Representative standard curve

1.00

A405

0.80
0.60
0.40
0.20
0.00
0.0

0.5
1.0
1.5
uPA activity (mIU)

2.0

Example of a standard curve of purified uPA activity using an indirect uPA activity assay.
A dilution series of uPA of known activity was incubated in triplicate with 0.5 μM human
plasminogen and the plasmin-specific substrate, Spectrozyme PL. The formation of plasmin
through the activation of plasminogen by uPA was measured by recording the absorbance at 405
nm (A405).

Calculations
1. Normalise all absorbance values (A405) to 1 using positive control (50 mIU
plasmin) on each plate as reference.
2. Subtract the absorbance of wells containing only plasminogen and no uPA or
homogenate on each plate from all samples.
3. Interpolate uPA activity (mIU) of the tumour homogenates from the standard curve
using the triplicate absorbance values (A405).
4. Divide the calculated uPA activity (mIU) by the total protein content of the tumour
homogenate (mg) present in the well to obtain activity as a function of protein
concentration (mIU/mg protein).

224

Appendix 4

7.4

Appendix 4 - uPA ELISA calculations

A490

Representative standard curve

-1

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1

R2 = 0.9906
0

1

2

uPA (ng)

Example of a standard curve of purified uPA using the in-house uPA ELISA. A dilution
series of uPA known concentration was measured in triplicate.

Calculations
1. All absorbance values (A405) were normalised to 1 using a positive control (uPA)
on each plate as reference.
2. The absorbance of wells containing negative control (50 ng BSA) on each plate was
subtracted from each sample.
3. The uPA content (ng) of the tumour homogenate was interpolated from the standard
curve using the triplicate absorbance values (A405).
4. The relative uPA content (ng/mg total protein) was calculated by dividing uPA
amount per well (ng) (from step 3) by the total protein of the tumour homogenate
(mg) present in the well.
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7.5

Appendix 5 – Criteria for scoring criteria of

immunohistochemistry slides

1.

Negative and positive controls were observed to define a 0 and a 3+ score
respectively.

2.

The intensity of the stain on each tissue section as a whole was scored, ignoring
non-specific staining (see figure below). For example, staining of non-lymph node
tissue when scoring lymph nodes and staining around the edges of tissue and tears
in the tissues. Slides were compared to negative controls to determine if weak
staining was indeed significant. Non-specific staining generally manifested as a
non-localised, weak staining of the connective tissue particularly.

3.

The percentage of the tissue which was stained positive was also scored e.g. 0-25,
25-50, 50-75 or 75-100%. This was taken into account when giving a final score
(see methods section).
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Excerpts from a guide created to assist persons in blind
scoring IHC sections of the mouse tumours and lymph
nodes. Non-lymphoid tissue includes (A) myoepithelial tissue,
and (B-C) glandular tissue. Non-specific staining includes (D)
weak, diffuse staining, particularly at the edges of tissue or
tears in the tissue.
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Abstract
Introduction The regulation of extracellular proteolytic activity
via the plasminogen activation system is complex, involving
numerous activators, inhibitors, and receptors. Previous studies
on monocytic and colon cell lines suggest that plasmin pretreatment can increase plasminogen binding, allowing the active
enzyme to generate binding sites for its precursor. Other studies
have shown the importance of pre-formed receptors such as
annexin II heterotetramer. However, few studies have used
techniques that exclusively characterise cell-surface events and
these mechanisms have not been investigated at the breast
cancer cell surface.

Results Cell-surface plasminogen binding was significantly
enhanced in the presence of elevated levels of uPA in an activitydependent manner and was greatly attenuated in the presence
of the plasmin inhibitor aprotinin. Pre-formed receptors were
also found to contribute to increased plasminogen binding after
PMA stimulation and to co-localise with uPA/uPAR and
plasminogen. Nevertheless, a relatively modest increase in
plasminogen-binding capacity coupled with an increase in uPA
led to a dramatic increase in the proteolytic capacity of these
cells.

Methods We have studied plasminogen binding to MCF-7 in
which urokinase plasminogen activator receptor (uPAR) levels
were upregulated by PMA (12-O-tetradecanoylphorbol-13acetate) stimulation, allowing flexible and transient modulation of
cell-surface uPA. Similar experiments were also performed
using MDA-MB-231 cells, which overexpress uPAR/uPA
endogenously. Using techniques that preserve cell integrity, we
characterise the role of uPA as both a plasminogen receptor and
activator and quantify the relative contribution of pre-formed and
cryptic plasminogen receptors to plasminogen binding.

Conclusion We show that the majority of lysine-dependent
plasminogen binding to breast cancer cells is ultimately
regulated by plasmin activity and is dependent on the presence
of significant levels of active uPA. The existence of a proteolytic
positive feedback loop in plasminogen activation has profound
implications for the ability of breast cancer cells expressing high
amounts of uPA to accumulate a large proteolytic capacity at the
cell surface, thereby conferring invasive potential.

Introduction

late plg binding and activation (kringles 1, 4, and 5), and a Cterminal protease domain [3]. Plg may be activated to the
broad-spectrum protease plasmin (pln) by a number of proteases, including tissue-type plg activator (tPA), factor XIa,
factor XIIa, and kallikrein, via cleavage of the Arg561-Val562
peptide bond [4]. However, the urokinase plg activator (uPA)
is widely accepted as the most significant activator of plg during tissue degradation [5,6]. This serine protease is secreted

The components of the plasminogen activation system (PAS)
are important determinants of metastatic capacity, participating in both proteolytic and non-proteolytic pathways during
cancer progression [1,2]. Plasminogen (plg), the central
zymogen in the PAS, is secreted as a single-chain glycosylated protein with an N-terminal glutamic acid (Glu) residue,
five kringle regions containing lysine-binding sites that regu-

AIIt = annexin II heterotetramer; Cy = cyanine; FCS = foetal calf serum; FITC = fluorescein isothiocyanate; Glu = glutamic acid; IgG = immunoglobulin
G; Kd = dissociation constant; mAb = monoclonal antibody; MBB = modified (no phenol red) binding buffer; MFI = mean fluorescence intensity; pAb
= polyclonal antibody; PAI-1 = plasminogen activator inhibitor type-1; PAI-2 = plasminogen activator inhibitor type-2; PAS = plasminogen activation
system; PBS = phosphate-buffered saline; PI = propidium iodide; plg = plasminogen; pln = plasmin; PMA = 12-O-tetradecanoylphorbol-13-acetate;
PMSF = alpha-toluenesulfonyl fluoride; PMSFuPA = alpha-toluenesulfonyl fluorideinactivated urokinase plasminogen activator; TIU = trypsin inhibitor
units; tPA = tissue-type plasminogen activator; uPA = urokinase plasminogen activator; uPAR = urokinase plasminogen activator receptor.
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as the 53-kDa zymogen pro-uPA and is present at the cell surface bound to its GPI (glycosylphosphatidylinositol)-anchored
receptor, uPAR [5]. Receptor-bound pro-uPA is activated by
pln and a number of other proteases in vitro through cleavage
of the Lys158-Ile159 peptide bond to form the active two-chain
protease uPA. The uPA A-chain contains a growth factor-like
domain (amino acids 1 to 48) and a kringle domain (amino
acids 50 to 131), whereas the B-chain contains the protease
domain [7]. The reciprocal activation of pro-uPA by pln and of
plg by uPA is an important mechanism in the regulation of pln
activity [8].
Receptor-mediated cell-surface localisation of the various
components of the PAS (for example, uPA, plg, and plg activator inhibitor type 1 [PAI-1] and type 2 [PAI-2]) is critical for the
spatial and temporal regulation of proteolysis. Proteins, gangliosides, and free fatty acids are among the mediators that
regulate cell-surface plg binding [9,10]. Several heterogeneous candidate receptors have been identified, including actin
[11], amphoterin [12], annexin II heterotetramer (AIIt) [13],
cytokeratin 8/18 [14], and α-enolase [15,16], with dissociation constant (Kd) values ranging from 0.1 to 2 μM. Receptor
candidates can be grouped into three classes: (a) those that
possess a pre-existing C-terminal lysine residue (pre-formed),
(b) those that are cleaved to expose a lysine residue (cryptic),
and (c) those that bind plg through a lysine-independent
mechanism [1]. Initial binding of Glu-plg to exposed internal or
C-terminal lysine residues results in a rapid conformational
change, whereas binding at a second lysine residue stabilises
the more open, activation-susceptible γ-conformation [17-19].
In addition, treatment of cells with basic caboxypeptidases significantly reduces plg binding [20]. The lysine-dependent
binding of plg via cell-surface receptors therefore both
anchors plg to the cell surface and facilitates its activation to
pln. The high plg-binding capacity (104 to 107 binding sites per
cell) and relatively low affinity (Kd 0.1 to 2 μM) of cell-surface
plg binding suggest the presence of multiple plg receptors
that are responsible for the total plg-binding capacity of a cell
[1]. Furthermore, several studies have shown that limited proteolysis of the cell surface with trypsin or pln to reveal C-terminal lysyl residues results in enhanced plg binding in various
cell types [21-23]. Together, these observations point to a
general mechanism of cell-surface plg binding in which total
binding is determined by the collective expression of a spectrum of heterogeneous receptors and proteolytic activity.
Mounting evidence implicates uPA as a key regulator of breast
cancer metastasis and demonstrates a role for uPA in a
number of processes that facilitate tumour progression,
including extracellular matrix degradation, cell proliferation,
migration, and adhesion [24,25]. Furthermore, high levels of
uPA and its inhibitor PAI-1 in primary breast tumours are correlated with shortened disease-free interval and poor overall
survival, independent of other predictors such as tumour
grade, tumour size, and hormone receptor status [2,26]. Sig-
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nificantly higher levels of uPA and uPAR are expressed at the
cell surface of metastatic breast cancer cells in vitro and these
cells are capable of binding larger amounts of Glu-plg at the
cell surface than non-metastatic breast cancer cells [27].
Moreover, although plg displays widespread cell-surface binding to a range of putative receptors, it is the uPA-co-localised
fraction of plg that is readily activated to pln [28]. This highlights uPA as an important regulator of cellular plg activation.
A direct, non-active-site interaction between the uPA A-chain
and plg has been shown to exist at the cell surface of the
monocytic cell line, U937 [29]. In addition, the amino-terminal
fragment of uPA (specifically the Lys135 residue) has been
shown to mediate the activation of plg by uPA and the reciprocal activation of pro-uPA by pln [30]. Thus, the accrual of
active uPA may be a key step in tumour invasion and metastasis by controlling not only the levels of plg activated at the cell
surface but also the levels of plg bound. This mechanism has
not been definitively shown in situ (that is, at the cell surface)
on breast cancer cells. Using techniques that preserve cell
integrity and exclude the contribution of intracellular plg-binding moieties [28], we characterise the relative contribution of
uPA, pln, and several candidate plg receptors to cell-surface
plg binding on breast cancer cells.

Materials and methods
Specific proteins and antibodies
Active human urine-derived uPA (40% high molecular weight,
50% low molecular weight, 10% transitory forms; A-chain Cterminal residue: Phe158) and mouse anti-cytokeratin 8/18
monoclonal antibody (mAb) (CBL195) were purchased from
Chemicon International (Temecula, CA, USA). Bovine aprotinin, rabbit anti-actin C-11 polyclonal antibody (pAb)
(A2066), rabbit immunoglobulin G (IgG) (I5006), goat IgG
(I9140), fluorescein isothiocyanate (FITC)-labelled goat antimouse Fab-specific pAb (F4018), FITC-labelled rabbit antigoat pAb (F7367), FITC-labelled goat anti-rabbit pAb
(F6005), and cyanine (Cy) 3-labelled goat anti-mouse pAb
(C2181) were purchased from Sigma-Aldrich Pty. Ltd. (St.
Louis, MO, USA). Spectrozyme PL, mouse anti-uPAR mAb
(no. 3936), mouse anti-uPA A-chain mAb (no. 3921), and
mouse anti-uPA B-chain mAb (no. 394) were purchased from
American Diagnostica Inc. (Stamford, CT, USA). Goat antiS100A10 (p11) mAb (AF1698) was purchased from R&D
Systems, Inc. (Minneapolis, MN, USA). Human α2-antiplasmin
was purchased from Molecular Innovations, Inc. (Southfield,
MI, USA). Goat anti-annexin II (C-16) pAb (sc-1924) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). Irrelevant isotype-matched control antibodies mouse
anti-sheep lymphocyte antigen IgG1 mAb (SBU-T6) and IgG2α
mAb (SBU-LCA) were obtained from the Centre for Animal
Biotechnology (Parkville, Victoria, Australia).
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Cell culture
MCF-7 (low uPAR/uPA-expressing, low plg-binding) and
MDA-MB-231 (high uPAR/uPA-expressing, high plg-binding)
cell lines were maintained in RPMI-1640 medium (Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with 5%
heat-inactivated foetal calf serum (FCS) (Thermo Electron
Corporation, Waltham, MA, USA) at 37°C in a humidified incubator with 5% CO2.
Purification and modification of Glu-plg
Human Glu-plg was affinity-purified from plasma using Lysine
Sepharose™ 4B (GE Healthcare, Little Chalfont, Buckinghamshire, UK) as described [16]. Glu-plg was either FITC- or Cy5conjugated as described [28,31].
Inactivation of uPA
Purified human uPA (0.5 mg/ml) was inactivated by incubation
overnight with alpha-toluenesulfonyl fluoride (PMSF) (1 mM) in
phosphate-buffered saline (PBS) (pH 7.4) at 4°C (final concentration of isopropanol 2%). PMSF inactivation of uPA was
maintained for the duration of the assays (data not shown). Pln
activity assays confirmed that residual excess PMSF in the
preparation was negligible after overnight incubation and dilution for use in the assays (data not shown).
PMA treatment to enhance cell-surface uPA
MCF-7 cells were cultured for 32 hours in 5% FCS/RPMI1640 and then incubated with PMA (12-O-tetradecanoylphorbol-13-acetate) (100 nM; concentration of ethanol 0.006%
vol/vol) without change of media at 37°C for a further 16 hours
as previously described [32]. Control cells were treated with
an equivalent volume of ethanol in 5% FCS/RPMI-1640. Cells
were characterised for plg binding and activation and PAS
component expression as described below. Ethanol has been
shown to increase uPAR expression in certain cell types [33],
but this effect was not observed in MCF-7 at the low concentration used (data not shown).
Cell-surface plg binding assays
Throughout this study, only the lysine-dependent proportion of
total plg binding is shown because this represents the pool of
cell-bound plg which is readily activatable [28]. Subconfluent,
adherent cells were prepared and analysed for lysine-dependent plg binding essentially as described [27]. However, prior
to incubation with antibodies or plg, cells were pre-incubated
with either uPA or PMSF-inactivated uPA (PMSF-uPA) (50
nM) in binding buffer (Hanks' balanced salt solution containing
1 mM calcium chloride, 1 mM magnesium chloride, 20 mM
HEPES
[N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic
acid)], and 0.1% bovine serum albumin) (pH 7.4) for 10 minutes at room temperature (21°C to 25°C) (allowing limited proteolytic activity) and then washed prior to further analysis on
ice with all incubations performed in the absence or presence
of aprotinin (1.6 trypsin inhibitor units [TIU]). Lysine-dependent plg binding was calculated as total plg binding minus bind-

ing in the presence of 1 mM tranexamic acid. Lysinedependent binding was typically 58% ± 3% of total cell-surface binding in the MCF-7 cell line and 83% ± 1% in the MDAMB-231 cell line. For antibody inhibition experiments, cells
were pre-incubated for 30 minutes with 20 μg/ml anti-uPA Achain (mAb no. 3921), anti-uPA B-chain (mAb no. 394), or an
irrelevant isotype control on ice prior to the plg binding step.
Cells were then washed and analysed for cell-surface lysinedependent plg binding as described [27].
Plg binding assays were performed using dual-colour flow
cytometry with propidium iodide (PI) to distinguish between
viable and non-viable cells as previously described [27]. Only
cells that excluded PI (that is, viable cells with intact membranes) were included in further analyses. Cell-surface-associated fluorescence was measured on an LSR II flow cytometer
(BD Biosciences, San Jose, CA, USA). All data were analysed
using WinMDI version 2.8 (The Scripps Research Institute, La
Jolla, CA, USA) [34].
Plg activation assays
MCF-7 cells were grown, PMA-treated, and pre-incubated
with uPA or PMSF-uPA (50 nM) for 10 minutes at room temperature as per plg binding assays in modified (no phenol red)
binding buffer (MBB) (pH 7.4). Cells were then washed twice
and resuspended in MBB containing 0.5 μM Glu-plg in the
presence and absence of 1.6 TIU aprotinin (to measure plndependent effects). Cells were incubated for 10 minutes at
room temperature before addition of 0.4 μM of the colorimetric
pln substrate Spectrozyme PL. Plg activation assays were performed in the presence of 0.25 μM α2-antiplasmin to inhibit pln
activity in solution and to ensure that only cell-surface pln activity was assayed. Pln activity was measured at 405 nm at 37°C
using a Spectramax 250 plate reader with Softmax Pro version
4.0 software (Molecular Devices Corporation, Sunnyvale, CA,
USA).
Cell-surface pre-formed receptor characterisation by
flow cytometry and confocal microscopy
Cell-surface uPAR, uPA, cytokeratin 8/18, actin, annexin II,
and S100A10 (p11) expression was analysed by indirect
immunofluorescence staining as previously described [27].
Only cells that excluded PI (that is, viable cells with intact
membranes) were included in further analyses. Isotype control
fluorescence was subtracted from all measurements. These
antibodies have previously been shown to detect their respective antigens on positive controls [28].

For confocal microscopy, MCF7 cells (2 × 105 cells per millilitre) were cultured onto sterile glass coverslips in 24-well tissue culture plates in 1 ml of 5% FCS/RPMI-1640 for 32 hours
and PMA treated as above. Coverslips were washed twice
with ice-cold MBB and fixed by incubation with freshly prepared, ice-cold 3.75% paraformaldehyde in PBS (pH 7.4) for
15 minutes on ice. Coverslips were washed twice and blocked

Page 3 of 11
(page number not for citation purposes)

Breast Cancer Research

Vol 9 No 1

Stillfried et al.

for 30 minutes with MBB on ice. Samples were incubated for
10 minutes at room temperature with MBB containing 50 nM
uPA. Cells were washed and incubated for 45 minutes with
Cy5-labelled Glu-plg (0.5 μM) in the presence and absence of
5 mM tranexamic acid in MBB on ice in the absence of light.
Cells were washed and incubated for 30 minutes with 10 to
20 μg/ml mouse anti-uPAR mAb (no. 3936), mouse anti-uPA
mAb (no. 394), or goat anti-annexin II (C-16) pAb (sc-1924) in
MBB on ice in the absence of light. After two washes, samples
were incubated for 30 minutes either with 1:50 FITC- or Cy3labelled goat anti-mouse pAb or with FITC-labelled rabbit antigoat pAb in MBB on ice in the absence of light and washed
three times with ice-cold MBB. Samples were mounted and
examined as previously described [28] using a × 40/1.00
FLUOTAR PL oil immersion objective lens on a Leica DM IRBE
confocal microscope (Leica Microsystems GmbH, Wetzlar,
Germany). All images were analysed using Confocal Assistant
version 4.02 (Todd Clark Brelje, University of Minnesota, Minneapolis, MN, USA).
Statistics
Graphs shown represent mean ± standard error (performed in
duplicate) and are representative of experiments performed on
multiple days. The means of the data were compared statistically using Student's t test (assuming equal variances). Where
variances differed significantly, data were log-transformed
prior to analysis by t test.

Results
Plg binds directly to endogenous (pro)-uPA
The presence of a non-active site, direct binding determinant
for plg in the C-terminal region (Gly149-Lys158) of the uPA Achain has been shown to exist on U937, a monocytic cell line
[29], and we have previously shown that uPA and plg co-localise at the surface of breast cancer cells [28]. To determine
whether this interaction occurs at the surface of MDA-MB-231
cells (a breast cancer cell line that has high endogenous uPA
expression [27]), binding experiments using antibodies
directed against the A- or B-chain of uPA were performed
under conditions that predominantly exclude proteolytic activation of plg by uPA. A significant decrease (34%) in cell-surface lysine-dependent plg binding was observed only in the
presence of anti-uPA A-chain mAb (Figure 1), indicating the
presence of a plg-binding site within this domain of uPA. To
confirm that the A-chain uPA antibody used did not dissociate
bound uPA, thus leading to the observed decrease in plg binding, we performed these blocking experiments using stimulated MCF-7 cells with significant levels of cell-surface urinederived uPA, which lacks the C-terminal lysine (see below).
Under these conditions, plg binding was not decreased (data
not shown), which also confirms the importance of the C-terminal lysine for binding. Interestingly, under similar conditions,
uPAR-transfected T-47D cells [35], which display concomitant but small and variable increases in endogenous uPA (1.7
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Figure 1

cells
Cell-surface
plasminogen (plg) binding via (pro)-uPA on MDA-MB-231
cells. MDA-MB-231 cells were detached, washed, and pre-incubated
on ice for 30 minutes with antibodies against the uPA A-chain, the uPA
B-chain, or an irrelevant isotype control antibody. Cells were then
washed and incubated for 45 minutes on ice in the dark with fluorescein isothiocyanate-labelled Glu-plg in the absence (total binding) and
presence (lysine-independent binding) of 1 mM tranexamic acid. Cells
were then washed and analysed for cell-surface plg binding in the presence of 5 μg/ml of the vital stain, propidium iodide, using dual-colour
flow cytometry. Lysine-dependent plg binding was calculated by subtracting lysine-independent binding from total binding. Glu, glutamic
acid; uPA, urokinase plasminogen activator.

± 0.23-fold), also displayed small but variable increases in plgbinding capacity (1.7 ± 0.19-fold).
Modulation of cell-surface uPA on MCF-7 cells
High levels of uPA on breast cancer cell lines are linked to
increased plg binding [27,28]. We and others [36] have found
that acid stripping of the cell surface to remove uPA markedly
compromises membrane integrity, making cell-surface measurements difficult and increasing the likelihood of introducing
artifacts. In addition, upregulation of uPAR using transfection
techniques [35] did not allow sufficient control of uPA levels
between experiments (data not shown). Therefore, to directly
assess the effect of altered cell-surface uPA on plg-binding
capacity, we used a model breast cancer cell line (MCF-7) that
has very low constitutive cell-surface uPAR and modulated its
expression by PMA stimulation [32]. After 16 hours of stimulation with 100 nM PMA, a large enhancement (approximately
12-fold; mean fluorescence intensity [MFI] of 3.4 ± 1.2 versus
41.4 ± 4.2 fluorescence units after PMA stimulation) of cellsurface uPAR was observed on MCF-7 cells (Figure 2a,b).
Enhancement of uPAR expression was observed without significant changes to endogenous cell-surface expression of
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Figure 2

Figure 3

Cell-surface urokinase plasminogen activator (uPA) binding on PMAstimulated cells. MCF-7 cells were cultured for 16 hours in 5% foetal
calf serum/RPMI containing 100 nM PMA (open symbols) or vehicle
control (closed symbols). Cells were detached, washed, and pre-incubated for 30 minutes on ice with increasing concentrations of active
uPA or PMSF-inactivated uPA. Cells were then washed and analysed
for cell-surface uPA level as in Figure 2. Curves were fitted using a onesite binding equation in GraphPad Prism version 4.00 (GraphPad Software, Inc., San Diego, CA, USA). MFI, mean fluorescence intensity;
PMA, 12-O-tetradecanoylphorbol 13-acetate; PMSF, alpha-toluenesulfonyl fluoride.
Plasminogen
MCF-7 cells activation system component changes on PMA-treated
MCF-7 cells. MCF-7 cells were cultured for 16 hours in 5% foetal calf
serum/RPMI containing 100 nM PMA. (a) Cells were washed and incubated for 30 minutes on ice with 10 to 20 μg/ml of anti-uPAR monoclonal antibody (mAb), anti-uPA mAb, anti-tPA mAb, anti-annexin II (Ann
II) C-16 polyclonal antibody (pAb), anti-S100A10 (p11) pAb, or a
matched isotype control antibody. Cells were then washed and incubated for 45 minutes on ice in the dark with a 1:200 dilution of appropriate secondary antibody labelled with fluorescein isothiocyanate
(FITC). All cells were then washed and analysed for cell-surface-associated FITC fluorescence in the presence of 5 μg/ml propidium iodide
using dual-colour flow cytometry. Specific antibody binding was calculated by subtracting control antibody fluorescence. Solid line indicates
a fold increase of 1 (equivalent to no change). P values indicate a significant increase compared to the corresponding untreated control. (b)
Confocal microscopy on attached cells was also used to verify
enhancement of cell-surface uPAR by PMA treatment. PMA, 12-O-tetradecanoylphorbol 13-acetate; tPA, tissue-type plasminogen activator;
uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen
activator receptor.

tPA (Figure 2a), actin, or cytokeratin 8/18 (data not shown),
which had low to non-detectable expression. Neither PAI-1
nor PAI-2 was detectable at significant levels at the cell surface under any condition (data not shown). Increases in
endogenous uPA after PMA stimulation were small (twofold;
MFI of 6.19 ± 2.07 versus 14.2 ± 6.0 fluorescence units after
PMA stimulation) but not statistically significant. Although the
increase in annexin II (1.4-fold) was also relatively small, this
observation is significant because basal annexin II expression
was high (MFI of 782 ± 5 versus 895 ± 17 after PMA stimula-

tion). Interestingly, a substantial (6.1-fold) increase in
S100A10 (p11) expression was also observed after PMA
stimulation (Figure 2a). However, it should be noted that overall expression levels of p11 were still low (MFI of 1.74 ± 0.26
versus 10.73 ± 1.04 fluorescence units after PMA
stimulation).
Dose-dependent cell-surface binding of exogenous uPA was
observed on PMA-stimulated MCF-7 cells. Saturation of
enhanced uPAR was observed at 50 nM uPA (Figure 3), representing an approximately eightfold increase in cell-surface
uPA compared to untreated controls. PMSF-uPA displayed
identical cell-surface binding properties to active uPA (Figure
3), indicating that inactivation did not affect the binding characteristics of uPA. Several studies have suggested that uPA
may cleave cell-surface uPAR, rendering it incapable of binding uPA and its other binding partners [37-39]. However, we
observed no change in the level of cell-surface uPAR subsequent to incubation with uPA (data not shown). Thus, stimulation of MCF-7 cells with PMA for 16 hours followed by
incubation with 50 nM uPA provides appropriate flexibility in
transient modulation of cell-surface uPA. Furthermore, the use
of urine-derived uPA eliminates significant A-chain Lys158 residue contribution to plg binding and thus this model is highly
useful for investigating the role of uPA activity in cell-surface
plg binding and activation.
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Figure 4

PMA stimulation
Cell-surface
urokinase
prior toplasminogen
urokinase plasminogen
activator (uPA)
activator
binding
(uPA)
on PMAincubation mediates increased plasminogen (plg) binding at the MCF-7 cell
surface. Confocal microscopy images of control and PMA-stimulated
(100 nM, 16 hours) MCF-7 cells both incubated with 50 nM uPA for 10
minutes at room temperature, washed, and probed for annexin II (AnnII),
uPA, and Glu-plg binding. Areas of co-localisation of annexin II, uPA,
and Glu-plg are shown in white in the merged image. Arrows indicate
areas of concentrated expression. Inset shows non-lysine-dependent
plg binding (that is, plg binding in the presence of 5 mM tranexamic
acid). Glu, glutamic acid; PAS, plasminogen activation system; PMA,
12-O-tetradecanoylphorbol 13-acetate.

Spatial organisation of cell-surface plg binding and
putative plg receptors
To investigate the spatial relationship between cell-surfacebound plg and putative plg receptors, we performed co-localisation experiments using immunofluorescence staining and
confocal microscopy. Results for both control and PMA-stimulated MCF-7 cells pre-incubated with exogenous uPA are
shown (Figure 4). In the absence of exogenous uPA, regardless of PMA stimulation, very little uPA staining was observed
(data not shown).

In MCF-7 cells, annexin II displays punctuate cell-surface and
diffuse intracellular staining. After PMA stimulation, there was
both a subtle increase and a distinct redistribution of cell-surface annexin II into clustered surface puncta (Figure 4). A similar localisation pattern was observed for exogenous uPA in
response to PMA stimulation, reflecting the large increase in
uPAR expression compared to control cells (Figure 4). After
PMA stimulation, there also appeared to be a visible increase
in cell-surface-bound plg, which was subtle and concentrated
in specific regions (Figure 4). Plg binding was lysine-dependent given that binding was significantly decreased in the presence of tranexamic acid (Figure 4, inset). Importantly, clear colocalisation of uPA, annexin II, and plg was observed at the surface of these cells after PMA stimulation and exogenous uPA
treatment (Figure 4). Very little co-localisation was observed in
uPA-treated unstimulated control cells. Because urine-derived
uPA was used, these data indirectly show that uPA, annexin II,
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and plg can co-localise independently of an uPA A-chain/plg
interaction after PMA stimulation.
uPA proteolytic capacity is the critical determinant of plg
binding and activation
Several studies in other cell types have shown that limited proteolysis of the cell surface by pln can reveal cryptic plg-binding
sites [21,22,40]. To assess the effect of cell-surface proteolytic activity on plg binding, a number of experiments were performed on MCF-7 cells with modulated active and inactive
exogenous uPA levels. No significant difference in lysinedependent plg binding was observed in control cells pre-incubated with either uPA or PMSF-uPA (data not shown). However, lysine-dependent plg binding on MCF-7 cells after PMA
stimulation increased to approximately 183% compared to
control cells (Figure 5a). Subsequent addition of exogenous
uPA caused a further approximately 37% increase in plg binding, which was not observed with the addition of PMSF-uPA
(Figure 5a). Given that the direct, non-active-site-dependent
interaction of plg with uPA was precluded through the use of
urine-derived uPA, this clearly demonstrates that the additional
plg binding observed after uPA treatment of PMA-stimulated
cells is entirely dependent on uPA catalytic activity. This effect
is functionally important because PMA stimulation alone
(which increased plg binding) had no effect on plg activation,
whereas uPA treatment of these cells caused a very large (15fold) increase in cell-surface pln generation (Figure 5b). In
addition, the pln generated represents activated cell-surfacebound plg as solution-phase pln was inhibited by the presence
of α2-antiplasmin. Hence, without uPA catalytic activity at the
cell surface, increased plg binding alone is not sufficient for
increased plg activation. Nevertheless, increased lysinedependent plg binding has been clearly linked to increased
plg activation in the presence of uPA activity [27].

To further dissect lysine-dependent plg binding mechanisms
in our experimental model, experiments were performed in the
presence of the pln inhibitor aprotinin to allow a distinction to
be made between pln-dependent binding (total binding minus
binding in the presence of aprotinin) and pln-independent
binding (residual binding in the presence of aprotinin). Plg
binding on control (unstimulated) cells, regardless of uPA
treatment, was entirely pln-dependent as very little residual plg
binding was observed in the presence of aprotinin (Figure 5c).
In contrast, PMA stimulation caused an increase in plg binding, which appears to be due to a corresponding increase in
pln-independent binding (denoted by the hatched bars in Figure 5c). This pln-independent increase in plg binding may be
due to the de novo expression of plg-binding moieties after
PMA stimulation. Furthermore, amongst the PMA-stimulated
cells, the additional and significant increase in plg binding
observed after exogenous active uPA treatment was entirely
pln-dependent given that there was no corresponding
increase in residual plg binding in the presence of aprotinin
(Figure 5c). A similar binding relationship was observed on
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Figure 5

Plasminogen binding and activation on MCF-7 cells.
cells After culture for 16 hours in 5% foetal calf serum/RPMI containing 100 nM PMA (PMA-stimulated) or vehicle alone (control), cells were detached and pre-incubated for 10 minutes at room temperature in the absence or presence of 50 nM
active urokinase plasminogen activator (uPA) or PMSF-inactivated uPA (PMSF-uPA), washed, and then analysed for cell-surface plg binding or activation. (a) Cell-surface, lysine-dependent plg binding to PMA-stimulated MCF-7 cells is shown as a percentage increase compared to unstimulated
MCF-7 cells in the absence of uPA. (b) Cell-surface plasmin (pln) generation. Pln activity assays were performed using Spectrozyme PL in the presence of α2-antiplasmin to inhibit any solution-phase pln generation. Activity in the presence of aprotinin (pln inhibitor) was also measured and subtracted from all values to determine pln-dependent activity. (c) Cell-surface lysine-dependent fluorescein isothiocyanate-plg binding was measured
in the presence or absence of aprotinin. Percentages show the proportion of binding due to pln activity at the cell surface (that is, pln-dependent
binding calculated as total binding minus binding in the presence of aprotinin; open bars) and the proportion that is independent of pln activity (that
is, pln-independent binding calculated as residual binding in the presence of aprotinin; hatched bars), which together constitute total lysine-dependent plg binding. *Significant increase compared to unstimulated control cells not pre-incubated with uPA or PMSF-uPA (p < 0.05). **Significant
increase compared to PMA-stimulated cells not pre-incubated with uPA or PMSF-uPA. MFI, mean fluorescence intensity; PMA, 12-O-tetradecanoylphorbol-13-acetate; PMSF, alpha-toluenesulfonyl fluoride.

unstimulated MDA-MB-231 cells (which already have a high
capacity for plg and uPA binding and activation [27]), where
pln-dependent binding accounted for approximately 64% and
pln-independent binding for 36% of the total lysine-dependent
plg binding. Taken together, these data indicate the importance of increased uPA proteolytic capacity for increased cellsurface plg binding and activation but also suggest a role for
pre-formed receptors.

Discussion
A number of clinical and functional studies have shown that
uPA-mediated plg activation is integral to the processes of
cancer cell invasion and metastasis [1,2,6]. We have used
techniques that maintain cell viability (and hence exclude intracellular plg binding from the analyses) to confirm that the
majority of plg binding on breast cancer cells is regulated by
pln activity at the cell surface. We show that regardless of the
level of plg bound, active uPA must be present at significant
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levels in order for increased plg activation to occur, and we
confirm that a proportion of plg binding to the cell surface is
mediated via a region in the endogenous (pro)-uPA A-chain.
Furthermore, we demonstrate that annexin II is present at high
levels on the surface of MCF-7 cells and co-localises with plg
and uPA/uPAR under conditions of increased cell-surface plg
binding.
Progression to the metastatic phenotype is clearly associated
with deregulation of the uPA system [1,24,41,42], which also
appears to be coupled with an increase in pre-formed plg
receptors [28]. Plg bound at the cell surface may then be activated to pln by cell-surface or possibly stromal cell-derived
[43-46] uPA. The increased uPA expression associated with
metastatic cancer increases pln activity, catalysing extracellular matrix degradation and promoting migration [47]. We have
previously shown that metastatic breast cancer cells (for
example, MDA-MB-231) have increased uPA at the cell surface and have the potential to bind and activate relatively large
amounts of plg compared to nonmetastatic cells (for example,
MCF-7 and T-47D) [27]. In a clinical setting, strong immunohistochemical staining of uPA has been significantly correlated
to more invasive tumours [48,49] and uPA constitutes a
strong, statistically significant independent prognostic marker
for shorter disease-free survival [50-52]. Together, these
results suggest that uPA has a key role in regulating metastatic
potential by modulating cell-surface plg binding and activating
capacity and hence proteolytic activity.
Pro-uPA, though termed an 'inactive' precursor, has been
shown to possess some minimal intrinsic plg activating capability [53]. In a proposed model based on studies of monocytic
and colon cancer cell lines, cells with significant amounts of
pro-uPA at the cell surface are able to activate bound plg, the
pln formed then exposes lysine residues through limited proteolysis of nearby proteins and in addition activates pro-uPA to
the more efficient uPA [40,54]. The newly bound plg is then
activated, creating a positive feedback activation loop
between (pro)-uPA and plg/pln which has the potential to generate large amounts of pln at the cell surface. Our results
provide further support for this mechanism of action on breast
cancer cells. MCF-7 cells possess low endogenous cell-surface (pro)-uPA levels and bind small amounts of cell-surface
plg [27]. As a result, they possess comparatively little plg activating ability and display only minimal invasive activity [27]. By
enhancing uPAR levels and using urine-derived uPA to
preclude direct lysine-dependent binding, we clearly confirm
that plg binding is largely dependent on uPA activity and subsequent pln activity and that pln does play a key role in the generation of new plg-binding sites at the cell surface (Figure 5).
The ability of pln to generate its own plg-binding sites in a positive feedback loop (independent of de novo synthesis) has
been demonstrated on neutrophils and monocytic and colon
cancer cell lines by pretreatment of cells with pln [21-23].
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Additionally, carboxypeptidase treatment to remove C-terminal
lysine residues from proteins has been shown to cause
marked decreases in plg binding in a number of cell types
[20,22,55]. In our experience, however, pre-treatment with
high concentrations of pln at 37°C devastates cell viability in
vitro. Moreover, we have previously shown that non-viable cell
populations bind approximately 100 times more plg, masking
changes in cell-surface binding on viable cells [27]. Thus, the
use of 125I-plg (which cannot distinguish between intracellular
and cell-surface binding) to measure cell-surface plg binding
is unsuitable because considerable artifactual contributions of
intracellular plg binding cannot be excluded. In contrast, the
use of dual-colour flow cytometry is far superior because it
allows clear distinction of cell-surface from intracellular plg
binding by exclusion of non-viable cells. Furthermore, the use
of aprotinin in this study to quantify the contribution of pln
activity to plg binding removes the inherent complicating effect
of pln treatment on cell viability. These modifications therefore
represent significant improvements to previous works and
allow careful characterisation of cell-surface events.
A number of proteins, including actin, AIIt (consisting of two
molecules of annexin II [p36 subunit] and two molecules of
S100A10 [p11 subunit]), cytokeratin 8, and α-enolase, have
been shown to both bind and enhance the activation of plg to
pln on a number of cell types [1]. The nature of cell-surface plg
binding and activation (that is, low-affinity, lysine-dependent)
suggests a general requirement for exposed lysine residues at
the cell surface rather than the presence of a specific receptor
or suite of receptors to promote plg binding and activation.
We did not observe significant expression of actin or cytokeratin 8/18 at the MCF-7 cell surface under any condition. However, MCF-7 cells have relatively high endogenous levels of
annexin II at the cell surface (Figures 2 and 4). Annexin II has
been shown to exist in monomeric, heterodimeric, and heterotetrameric forms [56] and associates with the cell surface in
a calcium-dependent manner [57]. Initially, it was reported that
annexin II on endothelial cells bound tPA, plg, and pln [58],
suggesting that although native annexin II does not contain a
C-terminal lysine residue, cleavage of annexin II at the Lys307
residue by pln-like serine protease activity may expose a new
plg/pln binding site. Further studies with purified proteins have
demonstrated enhanced tPA-mediated plg activation in the
presence of annexin II monomer [59], again suggesting that
plg can bind to annexin II directly. However, proteolytically
processed annexin II has not been shown to exist either in vitro
or in vivo and denatured protein has been demonstrated to
stimulate pln formation non-specifically [60].
Surface plasmon resonance studies have demonstrated that
only AIIt or isolated p11 subunit (S100A10) is able to bind
tPA, plg, and pln with moderate affinity, whereas annexin II
subunit is able to bind only pln [60,61]. P11 expression is regulated by annexin II via a post-translational mechanism in various epithelial cell lines and it has been suggested that plg
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binding to AIIt occurs primarily via the Cterminal lysine on the
p11 subunit [61-63]. We observed pln-independent
upregulation of the p11 subunit after PMA stimulation (Figure
2), associated with an increase in plg binding. Our confocal
microscopy data showed a distinct redistribution of annexin II,
and a proportion co-localised with plg and uPA/uPAR in PMAstimulated cells (Figure 3). Because p11 expression is
increased by PMA stimulation and has been shown to colocalise with uPAR [60], it is possible that the pln-independent
increase in plg binding may be partially mediated by the
increase in p11. However, the overall amount of p11 was
small, even after PMA stimulation, and we could not detect
p11 by confocal microscopy. Therefore, p11 may account for
only a very small proportion of plg binding in these cells. Thus,
the presence of both protease-dependent and -independent
plg receptors on modified MCF-7 and MDA-MB-231 cells
serves to indicate that both types of receptor contribute to the
total lysine-dependent plg-binding capacity on invasive cells.
This reflects the increased suite of both uPA-localised and
non-co-localised plg-binding sites on more malignant cells
such as MDA-MB-231 [28], which the PMA-stimulated and
uPA-treated MCF-7 cells mimicked.
The invasive capacity of breast cancer cells may be linked to
the presence of significant levels of active uPA, which in concert with even a moderate amount of bound plg can generate
large amounts of pln at the cell surface through a positive feedback mechanism. Mounting evidence points to uPA as an integral facilitator of breast cancer progression. Recent studies
have indicated that uPA deficiency in a breast cancer mouse
model significantly reduces lung and lymph node metastases
[64], and recent findings by our group indicate that targeting
of uPA (of either tumour or stromal cell origin) with a radiolabelled ligand significantly retards the growth of MDA-MB-231
xenografts in nude mice [65]. These studies and others indicate the importance of targeting uPA in anti-invasive tumour
strategies.

Conclusion
This study characterises plg binding and activation at the
breast cancer cell surface using techniques that exclude artifacts derived from intracellular proteins, contributions from
non-viable cells, and the C-terminal lysine from the uPA Achain. We show for the first time that several mechanisms regulate breast cancer cell plg binding, including direct binding of
plg to uPA/pro-uPA, expression of various plg binding proteins, and pln-mediated generation of plg-binding sites
through limited proteolysis of cell-surface proteins. Critically,
cells with increased uPA and a moderate increase in plg binding displayed dramatic increases in pln activity. This effect was
not observed in MCF-7 cells with moderate plg binding alone
but was observed in MDA-MB-231 cells, which have naturally
high levels of uPA, pln generation, and invasive capacity. Our
data thus support the model that increased uPA expression at
the cell surface substantially increases pln generation, and

therefore invasive potential, via a positive feedback mechanism. These results also strengthen the evidence implicating
uPA as a strong therapeutic target for the treatment of metastatic breast cancer.
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